[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 23311
1. Pereira SB, Thiel Rdo R, Riccetto C, Silva JM, Pereira LC, Herrmann V, Palma P: [Validation of the International Consultation on Incontinence Questionnaire Overactive Bladder (ICIQ-OAB) for Portuguese]. Rev Bras Ginecol Obstet; 2010 Jun;32(6):273-8
MedlinePlus Health Information. consumer health - Urinary Incontinence.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Validation of the International Consultation on Incontinence Questionnaire Overactive Bladder (ICIQ-OAB) for Portuguese].
  • [Transliterated title] Validação do International Consultation on Incontinence Questionnaire Overactive Bladder (ICIQ-OAB) para a língua portuguesa.
  • PURPOSE: To translate, culturally adapt and validate the questionnaire "International Consultation on Incontinence Questionnaire Overactive Bladder" (ICIQ-OAB) for the Portuguese Language.
  • The final version of the ICIQ-OAB was applied together with the previously translated and tested version of the International Consultation on Incontinence Questionnaire - Short Form (ICIQ-SF) in 142 male and female patients with irritative urinary symptoms.
  • CONCLUSION: The culturally adapted version of the ICIQ-OAB translated into Brazilian Portuguese presented satisfactory reliability and survey validity and was considered valid for the evaluation of irritative urinary symptoms of Brazilian patients of both genders.
  • [MeSH-major] Surveys and Questionnaires. Urinary Bladder, Overactive / diagnosis. Urinary Incontinence / diagnosis

  • Genetic Alliance. consumer health - Incontinence.
  • MedlinePlus Health Information. consumer health - Overactive Bladder.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20945012.001).
  • [ISSN] 1806-9339
  • [Journal-full-title] Revista brasileira de ginecologia e obstetrícia : revista da Federação Brasileira das Sociedades de Ginecologia e Obstetrícia
  • [ISO-abbreviation] Rev Bras Ginecol Obstet
  • [Language] por
  • [Publication-type] English Abstract; Journal Article; Validation Studies
  • [Publication-country] Brazil
  •  go-up   go-down


2. Yagnik V, Chadha A, Chaudhari S, Patel K: Inflammatory myofibroblastic tumor of the urinary bladder. Urol Ann; 2010 May;2(2):78-9

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Inflammatory myofibroblastic tumor of the urinary bladder.
  • Inflammatory myofibroblastic tumor (IMT) of bladder is an uncommon benign tumor of bladder, which is of unknown neoplastic potential, characterized by spindle cell proliferation with characteristic fibroinflammatory and pseudosarcomatous appearance.
  • Essential criteria for the diagnosis of IMT are: spindle myoepithelial cell proliferation and lymphocytic infiltrate.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20882160.001).
  • [ISSN] 0974-7834
  • [Journal-full-title] Urology annals
  • [ISO-abbreviation] Urol Ann
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] India
  • [Other-IDs] NLM/ PMC2943686
  • [Keywords] NOTNLM ; Immunohistochemical staining / inflammatory myofibroblastic tumor / spindle myoepithelial cell proliferation
  •  go-up   go-down


3. Lopez-Beltran A, Requena MJ, Cheng L, Montironi R: Pathological variants of invasive bladder cancer according to their suggested clinical significance. BJU Int; 2008 Feb;101(3):275-81
MedlinePlus Health Information. consumer health - Bladder Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pathological variants of invasive bladder cancer according to their suggested clinical significance.
  • Several pathological variants of bladder cancer, reflecting tumour heterogeneity in urothelial carcinoma, have been recently recognized.
  • It is important for both pathologists and urologists to be aware of the diverse morphological patterns in invasive bladder cancer, as they might be relevant in patient management and prognosis, mainly because they can mimic benign lesions, secondary tumours or might require a specific therapeutic approach.
  • [MeSH-major] Carcinoma / pathology. Urinary Bladder Neoplasms / pathology
  • [MeSH-minor] Diagnosis, Differential. Diagnostic Errors. Female. Humans. Male. Neoplasm Invasiveness / pathology

  • Genetic Alliance. consumer health - Bladder cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17986288.001).
  • [ISSN] 1464-410X
  • [Journal-full-title] BJU international
  • [ISO-abbreviation] BJU Int.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Number-of-references] 71
  •  go-up   go-down


Advertisement
4. Abbas F, Memon A, Siddiqui T, Kayani N, Ahmad NA: Granular cell tumors of the urinary bladder. World J Surg Oncol; 2007;5:33
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Granular cell tumors of the urinary bladder.
  • BACKGROUND: Granular cell tumors (GCTs) are extremely rare lesions of the urinary bladder with only nine cases being reported in world literature of which one was malignant.
  • Generally believed to be of neural origin based on histochemical, immunohistochemical, and ultrastructural studies; they mostly follow a clinically benign course but are commonly mistaken for malignant tumors since they are solid looking, ulcerated tumors with ill-defined margins.
  • MATERIALS AND METHODS: We herein report two cases of GCTs, one benign and one malignant, presenting with gross hematuria in a 14- and a 47-year-old female, respectively.
  • The benign tumor was successfully managed conservatively with transurethral resection alone while for the malignant tumor, radical cystectomy, hysterectomy with bilateral salpingo-oophorectomy, anterior vaginectomy, plus lymph node dissection was done.
  • CONCLUSION: We recommend careful pathologic assessment for establishing the appropriate diagnosis and either a conservative or aggressive surgical treatment for benign or localized malignant GCT of the urinary bladder, respectively.
  • [MeSH-major] Cystoscopy / methods. Granular Cell Tumor / pathology. Granular Cell Tumor / surgery. Neoplasm Invasiveness / pathology. Urinary Bladder Neoplasms / pathology
  • [MeSH-minor] Adolescent. Biopsy, Needle. Emergency Service, Hospital. Female. Follow-Up Studies. Hematuria / diagnosis. Hematuria / etiology. Humans. Immunohistochemistry. Middle Aged. Neoplasm Staging. Nephrostomy, Percutaneous / methods. Risk Assessment. Tomography, X-Ray Computed. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Pathol. 1973 Feb;109(2):101-11 [4124410.001]
  • [Cites] Oral Surg Oral Med Oral Pathol. 1963 Oct;16:1202-13 [14079990.001]
  • [Cites] Br J Urol. 1961 Mar;33:76-9 [13683165.001]
  • [Cites] J Laryngol Otol. 1998 Apr;112(4):373-6 [9659502.001]
  • [Cites] Am J Surg Pathol. 1991 Jan;15(1):48-58 [1985501.001]
  • [Cites] Br J Urol. 1985 Feb;57(1):109-10 [2982445.001]
  • [Cites] J Pathol. 1984 Mar;142(3):221-9 [6323661.001]
  • [Cites] Am J Pathol. 1983 Aug;112(2):139-46 [6192721.001]
  • [Cites] Cancer. 1982 Apr 15;49(8):1624-8 [6175391.001]
  • [Cites] Virchows Arch A Pathol Anat Histol. 1980;386(2):239-48 [7189308.001]
  • [Cites] J Urol. 1974 Sep;112(3):343-5 [4368755.001]
  • [Cites] Cancer. 1962 Sep-Oct;15:936-54 [13893237.001]
  • [Cites] Am J Clin Pathol. 1971 Dec;56(6):736-49 [4108241.001]
  • [Cites] Cancer. 1971 Apr;27(4):948-55 [4102365.001]
  • [Cites] Hinyokika Kiyo. 1969 Jul;15(7):505-13 [4310526.001]
  • [Cites] J Urol. 1968 Dec;100(6):735-7 [4301412.001]
  • [Cites] Int J Urol. 2001 Jan;8(1):29-31 [11168695.001]
  • [Cites] BJU Int. 1999 Nov;84(7):871-2 [10532990.001]
  • (PMID = 17355632.001).
  • [ISSN] 1477-7819
  • [Journal-full-title] World journal of surgical oncology
  • [ISO-abbreviation] World J Surg Oncol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC1828733
  • [General-notes] NLM/ Original DateCompleted: 20070810
  •  go-up   go-down


5. Schwalenberg T, Neuhaus J, Horn LC, Alexander H, Zimmermann G, Ho Thi P, Mallock T, Stolzenburg JU: [New insights in the differential diagnosis of bladder pain syndrome]. Aktuelle Urol; 2010 Mar;41(2):107-18
MedlinePlus Health Information. consumer health - Interstitial Cystitis.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [New insights in the differential diagnosis of bladder pain syndrome].
  • [Transliterated title] Neue Erkenntnisse zur Differenzialdiagnostik des Bladder-Pain-Syndroms.
  • The diagnosis of bladder pain syndrome/interstitial cystitis (BPS/IC) is challenging, since pathogenetic mechanisms and the definition of clinical relevant parameters are still under lively discussion.
  • The criteria recently proposed by the European Society for the Study of Interstitial Cystitis (ESSIC) define a collective of patients based on the cardinal symptom of bladder pain which is heterogeneous, and therefore cannot receive standardised consistent therapy.
  • Thus an extended diagnosis based on molecular markers seems to be indicated to render individual pharmacotherapy possible, and to contribute to elucidation of BPS/IC pathogenesis.
  • For this purpose we feel the vital need for taking a bladder biopsy.
  • The diagnosis of BPS/IC should rely on 3 "columns":.
  • Since a significant contribution of the 3 functional units of the bladder to the pathophysiology is most evident, the examinations should ideally include urothelium, lamina propria, and detrusor musculature.
  • [MeSH-major] Cystitis, Interstitial / diagnosis
  • [MeSH-minor] Biopsy. Capillaries / pathology. Capillaries / physiopathology. Chorionic Gonadotropin, beta Subunit, Human / genetics. Cystoscopy. Diagnosis, Differential. Gene Expression / physiology. Humans. Mast Cells / pathology. Mast Cells / physiology. Mucous Membrane / pathology. Mucous Membrane / physiopathology. Nerve Fibers / pathology. Nerve Fibers / physiology. Practice Guidelines as Topic. Receptors, G-Protein-Coupled / genetics. Risk Factors. Urinary Bladder / pathology. Urinary Bladder / physiopathology. Urinary Bladder, Overactive / classification. Urinary Bladder, Overactive / pathology. Urinary Bladder, Overactive / physiopathology. Urothelium / pathology. Urothelium / physiopathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Georg Thieme Verlag Stuttgart New York.
  • (PMID = 20309783.001).
  • [ISSN] 1438-8820
  • [Journal-full-title] Aktuelle Urologie
  • [ISO-abbreviation] Aktuelle Urol
  • [Language] ger
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Chorionic Gonadotropin, beta Subunit, Human; 0 / Receptors, G-Protein-Coupled
  • [Number-of-references] 52
  •  go-up   go-down


6. Margulis V, Shariat SF, Ashfaq R, Sagalowsky AI, Lotan Y: Ki-67 is an independent predictor of bladder cancer outcome in patients treated with radical cystectomy for organ-confined disease. Clin Cancer Res; 2006 Dec 15;12(24):7369-73
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Ki-67 is an independent predictor of bladder cancer outcome in patients treated with radical cystectomy for organ-confined disease.
  • PURPOSE: To determine the association of the cell proliferative marker Ki-67 with pathologic features and disease prognosis in patients with transitional cell carcinoma (TCC) of the urinary bladder.
  • METHODS: Immunohistochemical staining for Ki-67 was done on serial cuts from tissue microarrays containing cystectomy specimens from 9 patients without bladder cancer and 226 consecutive patients with bladder TCC.
  • In contrast, it was absent in all nine benign cystectomy specimens.
  • In multivariate analyses, pathologic stage and lymph node metastases were independent predictors of disease recurrence and bladder cancer-specific mortality.
  • In the subgroup of patients with organ-confined disease (<pT(3) N(0); n = 91), excluding patients who received neoadjuvant or adjuvant chemotherapy, Ki-67 status was an independent predictor of both disease recurrence (risk ratio, 7.591; P = 0.001) and bladder cancer-specific mortality (risk ratio, 4.045; P = 0.041).
  • CONCLUSIONS: Ki-67 overexpression is associated with features of aggressive bladder TCC and adds independent prognostic information to standard pathologic features for prediction of clinical outcome after radical cystectomy.
  • [MeSH-major] Carcinoma, Transitional Cell / diagnosis. Carcinoma, Transitional Cell / surgery. Ki-67 Antigen / physiology. Urinary Bladder Neoplasms / diagnosis. Urinary Bladder Neoplasms / surgery
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Biomarkers, Tumor / physiology. Cystectomy / statistics & numerical data. Disease-Free Survival. Female. Gene Expression Regulation, Neoplastic. Humans. Lymphatic Metastasis / diagnosis. Lymphatic Metastasis / pathology. Male. Middle Aged. Multivariate Analysis. Neoplasm Recurrence, Local / diagnosis. Neoplasm Recurrence, Local / mortality. Neoplasm Staging. Prognosis. Survival Analysis. Treatment Outcome

  • Genetic Alliance. consumer health - Bladder cancer.
  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17189409.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Ki-67 Antigen
  •  go-up   go-down


7. Haferkamp A, Hohenfellner M: [Intravesical treatment of overactive bladder syndrome]. Urologe A; 2006 Oct;45(10):1283-8
Hazardous Substances Data Bank. OXYBUTYNIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Intravesical treatment of overactive bladder syndrome].
  • [Transliterated title] Intravesikale Therapie des Overactive-bladder-Syndroms.
  • Overactive bladder and urgency incontinence are common conditions generally treated with oral anticholinergic medication.
  • Botulinum toxin type A injections into the detrusor have been shown to increase bladder capacity and to decrease detrusor overactivity for 6 or more months.
  • Intravesical local anesthetics such as lidocaine and bupivacaine block the conduction of unmyelinated C fibers which results in an increase of functional bladder capacity.
  • Intravesical capsaicin and resiniferatoxin also affect the afferent C fiber innervation of the bladder, leading to a decrease in detrusor overactivity and also an increased bladder capacity.
  • In conclusion, intravesical therapies can provide an alternative treatment for the management of overactive bladder.
  • [MeSH-major] Administration, Intravesical. Cholinergic Antagonists / administration & dosage. Muscarinic Antagonists / administration & dosage. Urinary Bladder, Overactive / drug therapy. Urinary Incontinence / drug therapy

  • MedlinePlus Health Information. consumer health - Overactive Bladder.
  • MedlinePlus Health Information. consumer health - Urinary Incontinence.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Br J Obstet Gynaecol. 1995 Nov;102(11):929-30 [8534633.001]
  • [Cites] Urology. 2000 May;55(5A Suppl):60-4; discussion 66 [10767456.001]
  • [Cites] J Urol. 1992 Aug;148(2 Pt 2):595-7 [1640530.001]
  • [Cites] J Urol. 1989 Jun;141(6):1350-2 [2724432.001]
  • [Cites] J Urol. 2002 Nov;168(5):1897-913 [12394674.001]
  • [Cites] J Urol. 2000 Sep;164(3 Pt 1):692-7 [10953127.001]
  • [Cites] Geburtshilfe Frauenheilkd. 1991 Jan;51(1):54-7 [2026301.001]
  • [Cites] Int Braz J Urol. 2004 Jan-Feb;30(1):53-8 [15707518.001]
  • [Cites] Lancet. 1992 May 16;339(8803):1239 [1349978.001]
  • [Cites] Curr Urol Rep. 2005 Nov;6(6):429-33 [16238916.001]
  • [Cites] Neurourol Urodyn. 2005;24(3):231-6 [15747344.001]
  • [Cites] J Urol. 2003 May;169(5):1892-5 [12686868.001]
  • [Cites] Arzneimittelforschung. 1998 May;48(5):486-91 [9638316.001]
  • [Cites] BJU Int. 2005 May;95(7):1023-7 [15839924.001]
  • [Cites] J Urol. 2005 Sep;174(3):984-9 [16094019.001]
  • [Cites] Am J Obstet Gynecol. 2005 May;192(5):1735-40 [15902187.001]
  • [Cites] Eur Urol. 2004 Jul;46(1):88-93; discussion 93-4 [15183552.001]
  • [Cites] J Urol. 2005 Sep;174(3):977-82; discussion 982-3 [16094018.001]
  • [Cites] J Med Assoc Thai. 2003 Sep;86(9):861-7 [14649971.001]
  • [Cites] Urology. 2005 Jul;66(1):82-7 [15992872.001]
  • [Cites] J Urol. 2000 Aug;164(2):340-3 [10893580.001]
  • [Cites] Urology. 2000 May;55(5A Suppl):33-46; discussion 50 [10767450.001]
  • [Cites] J Obstet Gynaecol. 2006 Feb;26(2):141-3 [16483973.001]
  • [Cites] Neurourol Urodyn. 1999;18(5):447-53 [10494116.001]
  • [Cites] Geburtshilfe Frauenheilkd. 1988 Aug;48(8):562-6 [3215450.001]
  • (PMID = 16972089.001).
  • [ISSN] 0340-2592
  • [Journal-full-title] Der Urologe. Ausg. A
  • [ISO-abbreviation] Urologe A
  • [Language] ger
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Anesthetics, Local; 0 / Cholinergic Antagonists; 0 / Mandelic Acids; 0 / Muscarinic Antagonists; 0 / Neuromuscular Agents; EC 3.4.24.69 / Botulinum Toxins, Type A; K9P6MC7092 / oxybutynin
  • [Number-of-references] 26
  •  go-up   go-down


8. Herr H, Donat M, Dalbagni G, Taylor J: Narrow-band imaging cystoscopy to evaluate bladder tumours--individual surgeon variability. BJU Int; 2010 Jul;106(1):53-5
MedlinePlus Health Information. consumer health - Bladder Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Narrow-band imaging cystoscopy to evaluate bladder tumours--individual surgeon variability.
  • STUDY TYPE: Diagnosis (exploratory cohort) Level of Evidence 2b.
  • OBJECTIVE: To assess individual urologist variability using narrow-band imaging (NBI) cystoscopy to evaluate bladder tumours.
  • PATIENTS AND METHODS: In all, 50 patients underwent white-light and NBI cystoscopy to evaluate for recurrent bladder tumours.
  • Endoscopic images in each patient were independently viewed by four urologists assessing presence or absence of tumour.
  • RESULTS: In all, 26 patients had recurrent tumour and 24 had benign histology.
  • There were no significant differences among urologists detecting recurrent tumour or in determining final pathology.
  • CONCLUSIONS: There does not appear to be a 'learning curve' for adapting to NBI-surveillance cystoscopy in patients with bladder cancer.
  • [MeSH-major] Cystoscopy / methods. Image Enhancement / methods. Neoplasm Recurrence, Local / diagnosis. Urinary Bladder Neoplasms / diagnosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] BJU Int. 2008 Nov;102(9):1111-4 [18778359.001]
  • [Cites] BJU Int. 2008 Mar;101(6):702-5; discussion 705-6 [18005206.001]
  • (PMID = 20002669.001).
  • [ISSN] 1464-410X
  • [Journal-full-title] BJU international
  • [ISO-abbreviation] BJU Int.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / T32 CA082088; United States / NCI NIH HHS / CA / T32 CA082088-12
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ NIHMS297487; NLM/ PMC3137239
  •  go-up   go-down


9. Bensalah K, Patard JJ: [Management of T1G3 tumours of the bladder]. Ann Urol (Paris); 2006 Apr;40(2):93-100
MedlinePlus Health Information. consumer health - Bladder Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Management of T1G3 tumours of the bladder].
  • [Transliterated title] Prise en charge des tumeurs de vessie T1G3 management of T1G3 tumours of the bladder.
  • T1G3 tumours are the most aggressive superficial tumours of the bladder, with a high risk of recurrence and progression.
  • Complete endoscopic resection of the tumour is the first diagnostic and therapeutic step in T1G3 management.
  • A second resection should be done at 1 month to avoid residual tumour and misdiagnosis of a muscle infiltrative cancer.
  • As a result of treatment by instillations of Calmette and Guérin bacillus following endoscopic resection, a 5-year survival rate of 80% has been reported, with 50 to 60% of bladder preservation.
  • BCG is the only conservative treatment that has proven effectiveness on both tumour recurrence and progression.
  • Radical cystectomy can be chosen as first line treatment in patients with particularly aggressive tumours.
  • [MeSH-major] Urinary Bladder Neoplasms / diagnosis. Urinary Bladder Neoplasms / therapy
  • [MeSH-minor] Adjuvants, Immunologic / therapeutic use. BCG Vaccine / therapeutic use. Humans. Neoplasm Staging

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16709007.001).
  • [ISSN] 0003-4401
  • [Journal-full-title] Annales d'urologie
  • [ISO-abbreviation] Ann Urol (Paris)
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Adjuvants, Immunologic; 0 / BCG Vaccine
  • [Number-of-references] 58
  •  go-up   go-down


10. Gonzalo Rodríguez V, Sanz Justo L, de Miguel Santamaría I, Martínez de Iturrate J, Fernández del Busto E: [The use of NMP22 Bladder-Chek for the diagnosis and follow-up bladder cancer]. Arch Esp Urol; 2008 Apr;61(3):377-84
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [The use of NMP22 Bladder-Chek for the diagnosis and follow-up bladder cancer].
  • [Transliterated title] Empleo del NMP22 Bladder-Chek en el diagnóstico y seguimiento del cáncer de vejiga.
  • OBJECTIVES: The goal of this work is to evaluate the usefulness of NMP22 BladderChek in the diagnosis and follow-up of bladder cancer, comparing it with cystoscopy and urine cytology.
  • METHODS: Group 1: 109 asymptomatic patients on follow up for bladder cancer underwent cystoscopy, cytology and NMP22 BladderChek.
  • RESULTS: Group 1: 9 patients had tumor relapse.
  • Group 2: 12 patients had bladder cancer.
  • CONCLUSIONS: The low sensitivity of NMP22 Bladder-Chek invalidates it as alternative method to cystoscopy in the follow-up of bladder cancer.
  • But it can be recommended for screening in patients without history of bladder cancer but with an increased risk (smokers, patients with dysuria and hematuria).
  • [MeSH-major] Biomarkers, Tumor / urine. Neoplasm Recurrence, Local / diagnosis. Nuclear Proteins / urine. Urinary Bladder Neoplasms / diagnosis
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Carcinoma, Transitional Cell / pathology. Cystoscopy. Cytodiagnosis. Female. Hematuria / etiology. Hematuria / urine. Humans. Male. Middle Aged. Neoplasm Staging. Predictive Value of Tests. Reagent Strips

  • Genetic Alliance. consumer health - Bladder cancer.
  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18581675.001).
  • [ISSN] 0004-0614
  • [Journal-full-title] Archivos españoles de urología
  • [ISO-abbreviation] Arch. Esp. Urol.
  • [Language] spa
  • [Publication-type] Comparative Study; English Abstract; Evaluation Studies; Journal Article
  • [Publication-country] Spain
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Nuclear Proteins; 0 / Reagent Strips; 0 / nuclear matrix protein 22
  •  go-up   go-down


11. Aguilera Tubet C, Gutiérrez Baños JL, Antolín Juárez F, Rebollo Rodrigo MH, Portillo Martín JA, Ruiz Izquierdo F, Ballestero Diego R, Martín García B: [Comparative study between cystoscopy, urinary cytology, NMP-22 and a new method, bladder chek, in the follow-up of superficial bladder cell carcinoma]. Actas Urol Esp; 2005 Mar;29(3):252-6
MedlinePlus Health Information. consumer health - Urine and Urination.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Comparative study between cystoscopy, urinary cytology, NMP-22 and a new method, bladder chek, in the follow-up of superficial bladder cell carcinoma].
  • [Transliterated title] Estudio comparativo entre cistoscopia, citología urinaria, NMP-22 y un nuevo método, bladder chek, en el seguimiento del cáncer vesical superficial.
  • OBJECTIVE: The goal of this work tries to evaluate the utility of the qualitative determination of NMP-22 in the evaluation of the superficial bladder carcinoma in asymptomatic patients, comparing it with its quantitative determination, the cytology and the cystoscopy.
  • MATERIALS AND METHODS: A simple of urine just voided was taken in 88 asymptomatic patient follow-up for superficial bladder cell carcinoma.
  • This dose was distributed in 3 parts, for performed cytology, for determination of NMP-22, and 4 drops of the third part are added to device bladder chek.
  • Later, we performed cystoscopy and transurethral resection in patients with a suspicion of bladder cancer.
  • RESULTS: 26 patients had tumor relapse and 62 patients were free of disease.
  • The sensitivity for the bladder chek was of 28%, 34.62% for NMP-22, 34.62% for cytology and 100% for cystoscopy.
  • The sensitivity by degree was 25 in G1, 28.57 in G2 and 50 in G3 for Bladder chek; 29.41, 42.86 and 50 for NMP-22; 23.53, 71.43 and 0 for cytology.
  • The sensitivity by stages was 27.7 in Ta-1 and 50 in T2 for Bladder chek; 34.78 and 50 for NMP-22; 39.13 and 0 for the cytology.
  • CONCLUSIONS: The low sensitivity of bladder chek invalidates it like alternative method to the cystoscopy in the follow-up of the superficial asymptomatic bladder cell carcinoma.
  • [MeSH-major] Carcinoma, Transitional Cell / diagnosis. Cystoscopy. Immunologic Tests. Nuclear Proteins / analysis. Urinary Bladder Neoplasms / diagnosis. Urine / cytology

  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15945249.001).
  • [ISSN] 0210-4806
  • [Journal-full-title] Actas urologicas españolas
  • [ISO-abbreviation] Actas Urol Esp
  • [Language] spa
  • [Publication-type] Comparative Study; English Abstract; Journal Article
  • [Publication-country] Spain
  • [Chemical-registry-number] 0 / Nuclear Proteins; 0 / nuclear matrix protein 22
  •  go-up   go-down


12. Gaunez N, Larré S, Pirès C, Doré B, Wei J, Pfister C, Irani J: [French translation and linguistic validation of the questionnaire Bladder Cancer Index (BCI)]. Prog Urol; 2010 May;22(6):350-3
MedlinePlus Health Information. consumer health - Bladder Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [French translation and linguistic validation of the questionnaire Bladder Cancer Index (BCI)].
  • [Transliterated title] Traduction en langue française et validation linguistique de l'auto-questionnaire Bladder Cancer Index évaluant la qualité de vie dans les tumeurs de vessie.
  • OBJECTIVE: Translation and linguistic validation of the French version of Bladder Cancer Index (BCI).
  • MATERIAL AND METHODS: A double-back translation of the original Bladder Cancer Index was performed.
  • Finally, a pilot study followed by an interview was carried out among one woman and five men having bladder cancer.
  • The impact of various bladder cancer treatment on quality of life could hence be assessed and compared.
  • [MeSH-major] Surveys and Questionnaires. Urinary Bladder Neoplasms

  • Genetic Alliance. consumer health - Bladder cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2011 Elsevier Masson SAS. All rights reserved.
  • (PMID = 22541905.001).
  • [ISSN] 1166-7087
  • [Journal-full-title] Progrès en urologie : journal de l'Association française d'urologie et de la Société française d'urologie
  • [ISO-abbreviation] Prog. Urol.
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article; Validation Studies
  • [Publication-country] France
  •  go-up   go-down


13. Thiel DD, Williams BF, Krishna M, Leroy TJ, Igel TC: Robot-assisted laparoscopic excision of bladder wall leiomyoma. J Endourol; 2009 Apr;23(4):579-82; discussion 582
MedlinePlus Health Information. consumer health - Bladder Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Robot-assisted laparoscopic excision of bladder wall leiomyoma.
  • Leiomyoma is the most frequent nonepithelial benign tumor of the bladder, and only about 170 cases have been reported in the literature.
  • Most bladder wall leiomyomas are found incidentally and can be clinically followed if imaging and biopsy findings are consistent with the diagnosis.
  • Resection is usually performed for symptomatic or enlarging masses and is indicated if the diagnosis is in question.
  • We demonstrate imaging characteristics, port placement, operative technique, and surgical pathologic findings of the first reported case of robot-assisted laparoscopic resection of a bladder wall leiomyoma.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19335142.001).
  • [ISSN] 1557-900X
  • [Journal-full-title] Journal of endourology
  • [ISO-abbreviation] J. Endourol.
  • [Language] ENG
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


14. Wang CL, Tsai EM, Liu CM, Wu CH, Long CY: Incidental finding of a benign bladder tumor during the tension-free vaginal tape procedure. Gynecol Obstet Invest; 2007;63(1):28-30
MedlinePlus Health Information. consumer health - Pelvic Support Problems.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Incidental finding of a benign bladder tumor during the tension-free vaginal tape procedure.
  • However, concomitant resection of a bladder tumor during the TVT procedure is rare.
  • A bladder tumor located in the trigone was found incidentally during cystoscopy.
  • Concomitant resection of the bladder tumor was performed following the TVT procedure.
  • The surgical result of our patient suggests that concomitant resection of a benign intravesical pathology with TVT procedure is safe and effective.
  • [MeSH-major] Cystoscopy. Urinary Bladder Neoplasms / diagnosis. Urinary Bladder Neoplasms / surgery. Urinary Incontinence, Stress / surgery

  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16864984.001).
  • [ISSN] 0378-7346
  • [Journal-full-title] Gynecologic and obstetric investigation
  • [ISO-abbreviation] Gynecol. Obstet. Invest.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Switzerland
  • [Number-of-references] 13
  •  go-up   go-down


15. Gómez García I, Molina Burgos R, Fernández Fernández E, Palacio España A, González Chamorro F, Alvarez E, Conde Someso S: [Myofibroblastic tumor of bladder]. Actas Urol Esp; 2005 Jun;29(6):611-4
MedlinePlus Health Information. consumer health - Bladder Diseases.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Myofibroblastic tumor of bladder].
  • [Transliterated title] Tumor miofibroblástico de vejiga.
  • The myofibroblastic tumor, is a mesenchymal benign tumor of exceptional character, being its localization but habitual it is the lung; while its appearance in the bladder, is exceptional, not existing but of 100 published cases, of this tumor type in the bladder.
  • This tumor type that clinic and radiologics, behave as a wicked tumor.
  • The pathological diagnosis is complex, due to its similarity with the sarcomas, being necessary to appeal to the inmunohistochemics for a I diagnose of certainty.
  • We present a new case of this neoplasm, carrying out a wide bibliographical revision.
  • [MeSH-major] Granuloma, Plasma Cell / diagnosis. Urinary Bladder Diseases / diagnosis
  • [MeSH-minor] Diagnosis, Differential. Humans. Male. Middle Aged

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16092689.001).
  • [ISSN] 0210-4806
  • [Journal-full-title] Actas urologicas españolas
  • [ISO-abbreviation] Actas Urol Esp
  • [Language] spa
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Spain
  •  go-up   go-down


16. Tunca F, Sanli O, Demirkol K, Gulluoglu M: Inflammatory pseudotumor of urachus mimicking invasive carcinoma of bladder. Urology; 2006 Mar;67(3):623.e1-3
MedlinePlus Health Information. consumer health - Bladder Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Inflammatory pseudotumor of urachus mimicking invasive carcinoma of bladder.
  • Inflammatory pseudotumor of the bladder is a rare benign lesion of unknown etiology.
  • This benign condition mimics invasive malignant tumors of the urinary bladder, and aggressive surgery is the basic treatment modality.
  • [MeSH-major] Carcinoma, Transitional Cell / diagnosis. Granuloma, Plasma Cell / diagnosis. Urachus. Urinary Bladder Neoplasms / diagnosis
  • [MeSH-minor] Adolescent. Diagnosis, Differential. Diagnostic Errors. Humans. Male. Neoplasm Invasiveness

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16527590.001).
  • [ISSN] 1527-9995
  • [Journal-full-title] Urology
  • [ISO-abbreviation] Urology
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


17. Jalpota Y, Tewari V, Madan R: Recurrent nephrogenic adenoma of urinary bladder in a renal allograft recipient--a case report. Indian J Pathol Microbiol; 2006 Apr;49(2):261-3
MedlinePlus Health Information. consumer health - Kidney Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Recurrent nephrogenic adenoma of urinary bladder in a renal allograft recipient--a case report.
  • Nephrogenic adenoma is a rare benign tumour-like lesion within the urothelial mucosa of the urinary tract.
  • It may be an incidental finding in bladder of a patient presenting with haematuria, dysuria and bladder growth after renal allograft transplant.
  • Clinically it mimics bladder neoplasm.
  • Definite diagnosis is established by histological examination of tumor.
  • Though it attains an extensive spread in bladder mucosa and has a high tendency to recur, the clinical course is benign.
  • [MeSH-major] Adenoma / pathology. Kidney Neoplasms. Neoplasm Recurrence, Local / pathology. Urinary Bladder Neoplasms / pathology
  • [MeSH-minor] Adult. Diagnosis, Differential. Humans

  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16933732.001).
  • [ISSN] 0377-4929
  • [Journal-full-title] Indian journal of pathology & microbiology
  • [ISO-abbreviation] Indian J Pathol Microbiol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] India
  •  go-up   go-down


18. Menéndez V, Fernández-Suárez A, Galán JA, Pérez M, García-López F: Diagnosis of bladder cancer by analysis of urinary fibronectin. Urology; 2005 Feb;65(2):284-9
MedlinePlus Health Information. consumer health - Bladder Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Diagnosis of bladder cancer by analysis of urinary fibronectin.
  • OBJECTIVES: To evaluate the diagnostic efficacy of the analysis of fibronectin in the urine samples of patients with bladder cancer.
  • METHODS: The study included 123 subjects: one group of 68 patients with bladder cancer confirmed by transurethral resection; a second group of 10 patients with benign urologic disease, and a third group of 45 healthy subjects.
  • We carried out the analysis of bladder tumor fibronectin (BTF), cytology, and creatinine in urine, and calculated the BTF/creatinine (BTF/CREA) ratio.
  • The sensitivity of urinary cytology was only 55%, but the specificity was 100%.
  • The patients with bladder cancer had significantly greater levels of BTF and the BTF/CREA ratio than did the healthy subjects (P <0.001) and, in the case of BTF without correcting for creatinine, than did the patients with benign urologic disease (P <0.05).
  • We also found significant differences in the levels of BTF and the BTF/CREA ratio among tumor stages, degree of differentiation, tumor size, multifocal nature, and macroscopic appearance.
  • CONCLUSIONS: Determination of fibronectin could be a useful test in the diagnosis of bladder tumors.
  • Nevertheless, the utility of BTF needs to be studied in a wider way in the presence of other pathologic features concurrent with bladder cancer.
  • [MeSH-major] Biomarkers, Tumor / urine. Carcinoma, Transitional Cell / urine. Fibronectins / urine. Neoplasm Proteins / urine. Urinary Bladder Neoplasms / urine
  • [MeSH-minor] Creatinine / urine. Humans. Luminescent Measurements. Neoplasm Recurrence, Local / diagnosis. Neoplasm Recurrence, Local / urine. Predictive Value of Tests. Prognosis. Prospective Studies. ROC Curve. Sensitivity and Specificity. Urine / cytology. Urologic Diseases / urine

  • Genetic Alliance. consumer health - Bladder cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15708039.001).
  • [ISSN] 1527-9995
  • [Journal-full-title] Urology
  • [ISO-abbreviation] Urology
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Fibronectins; 0 / Neoplasm Proteins; AYI8EX34EU / Creatinine
  •  go-up   go-down


19. Uchikoba T, Horiuchi K, Oka F, Sato M, Tsuboi N, Ohaki Y, Nishimura T: Diagnosing the location of carcinoma in situ (CIS) of the urinary bladder using pirarubicin hydrochloride. Urol Int; 2005;74(3):235-9
Hazardous Substances Data Bank. DOXORUBICIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Diagnosing the location of carcinoma in situ (CIS) of the urinary bladder using pirarubicin hydrochloride.
  • INTRODUCTION: No established technique for locating solitary carcinoma in situ (CIS) of the urinary bladder or CIS accompanying bladder cancer has been determined.
  • Here we investigated whether the location of CIS of the urinary bladder can be macroscopically ascertained by instilling pirarubicin hydrochloride (THP) into the urinary bladder.
  • PATIENTS AND METHODS: We dissolved 50 mg of THP in 50 ml of distilled water, and instilled the resulting solution into the urinary bladder.
  • After 5 min, the urinary bladder is examined using a cystoscope.
  • RESULTS: THP uptake was seen in 19 flat (nontumorous) areas of the bladder mucosa in 13 patients.
  • THP uptake was also seen in flat malignant lesions such as bladder cancer invasion into the prostatic urethra, and in benign lesions such as chronic cystitis and urothelial hyperplasia.
  • [MeSH-major] Carcinoma in Situ / diagnosis. Doxorubicin / analogs & derivatives. Immunosuppressive Agents. Urinary Bladder Neoplasms / diagnosis
  • [MeSH-minor] Administration, Intravesical. Adult. Aged. Aged, 80 and over. Biopsy. Cystoscopy. Female. Humans. Male. Microscopy, Fluorescence. Middle Aged. Mucous Membrane / metabolism. Mucous Membrane / ultrastructure. Neoplasm Staging. Sensitivity and Specificity. Urinary Bladder / metabolism. Urinary Bladder / ultrastructure

  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2005 S. Karger AG, Basel.
  • (PMID = 15812210.001).
  • [ISSN] 0042-1138
  • [Journal-full-title] Urologia internationalis
  • [ISO-abbreviation] Urol. Int.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Immunosuppressive Agents; 80168379AG / Doxorubicin; D58G680W0G / pirarubicin
  •  go-up   go-down


20. Zani D, Simeone C, Cosciani Cunico S, da Pozzo GP: [Fluorescence endoscopy in the diagnosis and treatment of superficial bladder neoplasms]. Minerva Urol Nefrol; 2005 Dec;57(4):335-9
MedlinePlus Health Information. consumer health - Bladder Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Fluorescence endoscopy in the diagnosis and treatment of superficial bladder neoplasms].
  • [Transliterated title] L'indagine fotodinamica nella diagnosi e nel trattamento della neoplasia vseicale superficiale.
  • AIM: The results of a clinical investigation on neoplasm and bladder dysplasia detection by 5-aminolaevulinic acid (5-ALA)-induced fluorescence are reported.
  • In this paper the authors report their experience with 5-ALA in the diagnosis, treatment and follow-up of bladder neoplasms after chemotherapy and endocavitary immunotherapy.
  • METHODS: The 5-ALA was instilled in the bladder 2 h before bladder transurethral resection.
  • RESULTS: One-hundred and four benign and 92 malignant/dysplastic areas were biopsied; 46 malignant/dysplastic lesions were not detected during routine white-light cystoscopy but were identified with fluorescence cystoscopy.
  • [MeSH-major] Aminolevulinic Acid. Cystoscopy / methods. Photosensitizing Agents. Urinary Bladder Neoplasms / diagnosis. Urinary Bladder Neoplasms / therapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16247356.001).
  • [ISSN] 0393-2249
  • [Journal-full-title] Minerva urologica e nefrologica = The Italian journal of urology and nephrology
  • [ISO-abbreviation] Minerva Urol Nefrol
  • [Language] ita
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Photosensitizing Agents; 88755TAZ87 / Aminolevulinic Acid
  •  go-up   go-down


21. Mitropoulos D, Kiroudi-Voulgari A, Nikolopoulos P, Manousakas T, Zervas A: Accuracy of cystoscopy in predicting histologic features of bladder lesions. J Endourol; 2005 Sep;19(7):861-4
MedlinePlus Health Information. consumer health - Bladder Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Accuracy of cystoscopy in predicting histologic features of bladder lesions.
  • PURPOSE: To correlate individual endoscopist impressions of the nature (benign/malignant) of a urothelial lesion and, in the case of malignancy, "clinical" grade and stage of bladder lesions with the histologic findings after transurethral biopsy/resection.
  • PATIENTS AND METHODS: We considered 146 patients submitted to cystoscopy and transurethral excision of tumors or biopsy of suspect regions.
  • Both specialists and trainees had a tendency to overdiagnose bladder cancer, and they were not effective in predicting the precise stage: complete agreement with the pathologic stage was observed in 66.1% and 64.5% of cases, respectively.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16190845.001).
  • [ISSN] 0892-7790
  • [Journal-full-title] Journal of endourology
  • [ISO-abbreviation] J. Endourol.
  • [Language] ENG
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


22. Sun Y, He DL, Ma Q, Wan XY, Zhu GD, Li L, Luo Y, He H, Yang L: Comparison of seven screening methods in the diagnosis of bladder cancer. Chin Med J (Engl); 2006 Nov 5;119(21):1763-71
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Comparison of seven screening methods in the diagnosis of bladder cancer.
  • BACKGROUND: We compared the validity (evaluated by sensitivity and specificity), reliability (evaluated by reproducibility) and yield (evaluated by predictive value, examining complexity and cost) of individual and combined tests for bladder tumour antigen stat (BTAstat), nuclear matrix protein 22 (NMP22), hyaluronic acid (HA), survivin, CD44v6, vascular endothelial growth factor (VEGF), and voided urine cytology (VUC) in detecting bladder cancer.
  • And at the same time we evaluated the clinical value of these seven detecting methods in the diagnosis of bladder cancer.
  • METHODS: The six markers and VUC were detected in the urine of cancer group (151 patients with bladder cancer) and two control groups (50 patients with benign urological diseases and 50 healthy controls).
  • RESULTS: There was a significant difference between bladder cancer group and the two control groups.
  • CONCLUSIONS: All the markers have obvious clinical value in diagnosis of bladder cancer.
  • [MeSH-major] Biomarkers, Tumor / analysis. Urinary Bladder Neoplasms / diagnosis
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Antigens, CD44 / analysis. Antigens, Neoplasm / analysis. Female. Glycoproteins / analysis. Humans. Hyaluronic Acid / analysis. Inhibitor of Apoptosis Proteins. Male. Microtubule-Associated Proteins / analysis. Middle Aged. Neoplasm Proteins / analysis. Neoplasm Staging. Nuclear Proteins / analysis. Sensitivity and Specificity. Vascular Endothelial Growth Factor A / analysis

  • Genetic Alliance. consumer health - Bladder cancer.
  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • Hazardous Substances Data Bank. HYALURONIC ACID .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17097029.001).
  • [ISSN] 0366-6999
  • [Journal-full-title] Chinese medical journal
  • [ISO-abbreviation] Chin. Med. J.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Antigens, CD44; 0 / Antigens, Neoplasm; 0 / BIRC5 protein, human; 0 / Biomarkers, Tumor; 0 / CD44v6 antigen; 0 / Glycoproteins; 0 / Inhibitor of Apoptosis Proteins; 0 / Microtubule-Associated Proteins; 0 / Neoplasm Proteins; 0 / Nuclear Proteins; 0 / Vascular Endothelial Growth Factor A; 0 / nuclear matrix protein 22; 9004-61-9 / Hyaluronic Acid
  •  go-up   go-down


23. Gaisa NT, Henkel C, Knüchel R: Tumour node metastasis staging of bladder cancer: prognosis versus pitfalls. Curr Opin Urol; 2010 Sep;20(5):398-403
MedlinePlus Health Information. consumer health - Bladder Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Tumour node metastasis staging of bladder cancer: prognosis versus pitfalls.
  • PURPOSE OF REVIEW: The WHO classification of urothelial cancer in 2004 has made changes based on the insights of molecular genetics, indicating bladder cancer with entities that are genetically stable versus those that are genetically instable.
  • Clinical studies based on solid histological diagnosis are as necessary as the definition of more molecular features of bladder cancer.
  • RECENT FINDINGS: Solid histological diagnosis includes sufficient clinical information and adequate tissue processing.
  • This combined with molecular data will lead to a more clear-cut distinction between benign and malignant and possibly to another change in terminology with higher concordance to other epithelial tumours.
  • Whereas the identification of FGFR3 mutations has led to a better distinction of at least two pathways of urothelial carcinogenesis, additional multiparametric approaches may help improve the still inadequate search for urine and blood markers indicative of bladder cancer and/or its progression.
  • SUMMARY: Recent data mainly support the concept of the WHO 2004 classification of bladder cancer.
  • We are optimistic that an even more clear-cut distinction between benign recurring, nonprogressing tumours and more aggressive tumours will enable us to focus and limit chemotherapy.
  • [MeSH-major] Lymph Nodes / pathology. Neoplasm Staging. Urinary Bladder Neoplasms / pathology
  • [MeSH-minor] Humans. Lymphatic Metastasis. Molecular Diagnostic Techniques. Neoplasm Invasiveness. Predictive Value of Tests. Prognosis. Reproducibility of Results

  • Genetic Alliance. consumer health - Bladder cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20625299.001).
  • [ISSN] 1473-6586
  • [Journal-full-title] Current opinion in urology
  • [ISO-abbreviation] Curr Opin Urol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  •  go-up   go-down


24. Zachariou AG, Manoliadis IN, Kalogianni PA, Karagiannis GK, Georgantzis DJ: A rare case of bladder fibroepithelial polyp in childhood. Arch Ital Urol Androl; 2005 Jun;77(2):118-20
MedlinePlus Health Information. consumer health - Bladder Diseases.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A rare case of bladder fibroepithelial polyp in childhood.
  • OBJECTIVE: To present a rare case of a benign polyp in a child.
  • Very few cases of urinary tract fibroepithelial polyps in the bladder are reported in the international literature and they are even less common in children.
  • The patient did not report previous urinary tract disorders.
  • After a thorough laboratory investigation, which included urinalysis, urine culture, ultrasonography, intravenous pyelography and cystoscopy the presence of an exophytic papillary tumor in the bladder was identified.
  • RESULTS: The biopsy set the diagnosis of fibroepithelial polyp, which is a rare benign neoplasm and occurs in patients of nearly all ages.
  • They are rarely found in the bladder, especially in the childhood.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16146277.001).
  • [ISSN] 1124-3562
  • [Journal-full-title] Archivio italiano di urologia, andrologia : organo ufficiale [di] Societa italiana di ecografia urologica e nefrologica
  • [ISO-abbreviation] Arch Ital Urol Androl
  • [Language] ENG
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


25. Kang JU, Koo SH, Jeong TE, Kwon KC, Park JW, Jeon CH: Multitarget fluorescence in situ hybridization and melanoma antigen genes analysis in primary bladder carcinoma. Cancer Genet Cytogenet; 2006 Jan 1;164(1):32-8
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Multitarget fluorescence in situ hybridization and melanoma antigen genes analysis in primary bladder carcinoma.
  • Conventional urine cytology has a poor prognostic performance for detecting bladder cancer, particularly for low-grade tumors.
  • Fluorescence in situ hybridization (FISH) for chromosomes altered in bladder cancer and testing for antigens selectively expressed in tumors are promising alternatives.
  • This study investigated the use of FISH for detecting aneuploidy of chromosomes 3, 7, 17, and 9p21 and reverse transcriptase PCR (RT-PCR) for the expression of melanoma associated antigen (MAGE) genes for the diagnosis of bladder cancer in voided urine specimens.
  • The two techniques were compared with cystoscopic bladder biopsy results in 47 patients with urothelial cancer and 15 patients with benign prostatic hyperplasia.
  • The sensitivity of FISH increased with histologic grade and stage of the tumors, correctly identifying 77.8% of pTa and pTis, 94.1% of pT1, and 100% of Pt2-4 tumors.
  • MAGE, however, showed a decreased sensitivity in high grade advanced tumors; it was positive in 66.7% of pTa and pTis, 70.6% of pT1, and 50% of Pt2-4 tumors.
  • Combined FISH and MAGE RT-PCR testing may offer a promising alternative to conventional urine cytology in screening high-risk populations and in monitoring bladder cancer patients for recurrent tumor.
  • [MeSH-major] In Situ Hybridization, Fluorescence. Neoplasm Proteins / genetics. Urinary Bladder Neoplasms / genetics
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Antigens, Neoplasm. Female. Humans. Male. Melanoma-Specific Antigens. Middle Aged. Reverse Transcriptase Polymerase Chain Reaction

  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16364760.001).
  • [ISSN] 0165-4608
  • [Journal-full-title] Cancer genetics and cytogenetics
  • [ISO-abbreviation] Cancer Genet. Cytogenet.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / Melanoma-Specific Antigens; 0 / Neoplasm Proteins
  •  go-up   go-down


26. Eissa S, Zohny SF, Zekri AR, El-Zayat TM, Maher AM: Diagnostic value of fibronectin and mutant p53 in the urine of patients with bladder cancer: impact on clinicopathological features and disease recurrence. Med Oncol; 2010 Dec;27(4):1286-94
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Diagnostic value of fibronectin and mutant p53 in the urine of patients with bladder cancer: impact on clinicopathological features and disease recurrence.
  • Development of new methods for bladder cancer detection is required because cystoscopy is invasive, and voided urine cytology (VUC) has low sensitivity.
  • The aim of this study was to evaluate the diagnostic performance of urinary fibronectin and mutant p53 in comparison with VUC in the detection of bladder cancer.
  • This study included 100 patients diagnosed with bladder cancer, 93 patients with benign urological disorders and 47 healthy volunteers.
  • Our results indicate that fibronectin had the highest sensitivity compared to VUC and mutant p53 in bladder cancer detection; however, mutant p53 had superior specificity compared to VUC and fibronectin.
  • Mutant p53 is associated with disease recurrence and hence it has a significant prognostic role in bladder cancer.
  • [MeSH-major] Adenocarcinoma / diagnosis. Carcinoma, Squamous Cell / diagnosis. Carcinoma, Transitional Cell / diagnosis. Fibronectins / urine. Mutation / genetics. Tumor Suppressor Protein p53 / genetics. Urinary Bladder Neoplasms / diagnosis
  • [MeSH-minor] Adult. Aged. Animals. Biomarkers, Tumor / genetics. Biomarkers, Tumor / urine. Case-Control Studies. Cystoscopy. Female. Follow-Up Studies. Humans. Immunoenzyme Techniques. Lymphatic Metastasis. Male. Middle Aged. Neoplasm Recurrence, Local / diagnosis. Neoplasm Recurrence, Local / genetics. Neoplasm Recurrence, Local / urine. Neoplasm Staging. Polymerase Chain Reaction. Prognosis. ROC Curve. Schistosoma mansoni / pathogenicity. Schistosomiasis / diagnosis. Schistosomiasis / genetics. Schistosomiasis / urine. Sensitivity and Specificity. Survival Rate. Urinary Bladder / metabolism. Urinary Bladder / pathology

  • Genetic Alliance. consumer health - Bladder cancer.
  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20012564.001).
  • [ISSN] 1559-131X
  • [Journal-full-title] Medical oncology (Northwood, London, England)
  • [ISO-abbreviation] Med. Oncol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Fibronectins; 0 / TP53 protein, human; 0 / Tumor Suppressor Protein p53
  •  go-up   go-down


27. Tal R, Sivan B, Kedar D, Baniel J: Management of benign ureteral strictures following radical cystectomy and urinary diversion for bladder cancer. J Urol; 2007 Aug;178(2):538-42
Faculty of 1000. commentaries/discussion - See the articles recommended by F1000Prime's Faculty of more than 8,000 leading experts in Biology and Medicine. (subscription/membership/fee required).

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Management of benign ureteral strictures following radical cystectomy and urinary diversion for bladder cancer.
  • PURPOSE: Ureteral obstruction due to benign strictures is a significant complication of radical cystectomy and urinary diversion for bladder cancer that can lead to renal function loss and infection related morbidity.
  • We describe the 10-year experience at our department with various treatment modalities for post-cystectomy benign strictures.
  • MATERIALS AND METHODS: The study group consisted of 28 patients treated for benign ureteral strictures following radical cystectomy for bladder cancer.
  • RESULTS: The study group represented 12.7% of all 221 patients treated at our department with radical cystectomy for bladder cancer in 1994 to 2004.
  • Median time to diagnosis was 7.0 months and 75% of the patients were diagnosed within year 1 after cystectomy.
  • CONCLUSIONS: Benign ureteral strictures commonly occur during postoperative year 1 and they are usually asymptomatic.
  • Early diagnosis and prompt drainage are required to prevent consequent renal parenchymal loss and infectious complications.
  • [MeSH-major] Cystectomy. Postoperative Complications / therapy. Ureteral Obstruction / surgery. Urinary Bladder Neoplasms / surgery. Urinary Diversion
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Catheterization. Diagnostic Imaging. Female. Follow-Up Studies. Humans. Male. Middle Aged. Neoplasm Staging. Nephrostomy, Percutaneous. Recurrence. Reoperation. Retrospective Studies. Risk Factors. Stents


28. Pu XY, Wang ZP, Chen YR, Wu YL, Wang HP, Wang XH: [Clinical value of combined detection with urinary bladder cancer antigen, hyaluronic acid and cytokeratin 20 in diagnosis of bladder cancer]. Ai Zheng; 2008 Sep;27(9):970-3
Hazardous Substances Data Bank. HYALURONIC ACID .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Clinical value of combined detection with urinary bladder cancer antigen, hyaluronic acid and cytokeratin 20 in diagnosis of bladder cancer].
  • BACKGROUND & OBJECTIVE: Bladder cancer is the most common malignancy of all genitourinary tumors.
  • Urine cytology is the "gold standard" for non-invasive diagnosis of bladder cancer, but its sensitivity is low.
  • This study was to explore the clinical value of combined detection with urinary bladder cancer antigen (UBC), hyaluronic acid (HA) and cytokeratin 20 (CK20) in the diagnosis of bladder cancer.
  • METHODS: Urine samples were obtained from 64 patients with bladder cancer and 20 patients with benign urological disease.
  • RESULTS: UBC, HA and CK20 yielded significantly higher sensitivity in detecting bladder cancer compared to urinary cytology (85.9%, 89.1% and 78.1% vs. 40.6%, P<0.01).
  • The specificity of UBC, HA, CK20 and urinary cytology for the detection of bladder cancer were 85.0%, 80.0%, 80.0% and 95.0%, respectively.
  • The sensitivity of UBC, HA and CK20 were all significantly higher than that of urinary cytology in detecting different histological stages and grades of bladder cancer (P<0.01).
  • The value of UBC had no significant difference in different histological stages and grades of bladder cancer (P>0.05).
  • Combined use of UBC, HA and CK20 improved the sensitivity and specificity of detecting bladder cancer to 96.9% (62/64) and 100.0%, respectively.
  • CONCLUSIONS: Combined use of UBC, HA and CK20 can improve the sensitivity and specificity for the detection of bladder cancer in urine, thus it may replace conventional cystoscopy in the primary diagnosis.
  • [MeSH-major] Antigens, Neoplasm / urine. Carcinoma, Transitional Cell / diagnosis. Hyaluronic Acid / urine. Keratin-20 / urine. Urinary Bladder Neoplasms / diagnosis
  • [MeSH-minor] Aged. Enzyme-Linked Immunosorbent Assay. Female. Humans. Male. Middle Aged. Neoplasm Staging. Radioimmunoassay. Reverse Transcriptase Polymerase Chain Reaction. Sensitivity and Specificity

  • Genetic Alliance. consumer health - Bladder cancer.
  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18799038.001).
  • [Journal-full-title] Ai zheng = Aizheng = Chinese journal of cancer
  • [ISO-abbreviation] Ai Zheng
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / Keratin-20; 9004-61-9 / Hyaluronic Acid
  •  go-up   go-down


29. Ahmad Z, Qureshi A: Primary signet ring cell carcinoma of gall bladder: report of an extremely rare histological type of primary gall bladder carcinoma. BMJ Case Rep; 2010;2010
MedlinePlus Health Information. consumer health - Gallstones.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary signet ring cell carcinoma of gall bladder: report of an extremely rare histological type of primary gall bladder carcinoma.
  • Signet ring cell carcinoma is an extremely rare type of gall bladder carcinoma composed overwhelmingly (90%) of signet ring cells.
  • It is necessary to exclude a gastric or colonic signet ring cell carcinoma secondarily involving the gall bladder.
  • The primary aim of this case report is to describe the histopathological aspects of this tumour.
  • Primary signet ring cell carcinoma of gall bladder shows dysplastic surface gall bladder epithelium with infiltration of gall bladder wall.
  • It is also necessary to exclude benign signet ring change, which sometimes occurs in the gall bladder.
  • This case showed grossly diffuse thickening of the gall bladder wall and dysplastic surface epithelium of the gall bladder on histology, with sheets of signet ring cells infiltrating full thickness of the wall.
  • It is also necessary to exclude benign signet ring cell change, which sometimes occurs in the gall bladder.
  • [MeSH-major] Carcinoma, Signet Ring Cell / pathology. Cholelithiasis / diagnosis. Cholelithiasis / surgery. Gallbladder Neoplasms / pathology
  • [MeSH-minor] Biopsy, Needle. Cholecystectomy / methods. Diagnosis, Differential. Female. Follow-Up Studies. Humans. Immunohistochemistry. Middle Aged. Mucous Membrane / pathology. Neoplasm Invasiveness / pathology. Neoplasm Staging. Pakistan. Rare Diseases. Risk Assessment

  • Genetic Alliance. consumer health - Signet ring cell carcinoma.
  • MedlinePlus Health Information. consumer health - Gallbladder Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Surg Neurol. 1988 Apr;29(4):315-8 [2832956.001]
  • [Cites] Rom J Morphol Embryol. 1991 Jul-Dec;37(3-4):171-3 [1667605.001]
  • [Cites] Adv Ther. 2008 May;25(5):520-3 [18461291.001]
  • [Cites] Pathol Res Pract. 2001;197(11):785-8 [11770024.001]
  • [Cites] Pathol Res Pract. 1998;194(3):197-200 [9587939.001]
  • [Cites] Australas J Dermatol. 2007 Aug;48(3):187-9 [17680973.001]
  • [Cites] Semin Diagn Pathol. 1996 Nov;13(4):326-38 [8946610.001]
  • [Cites] Pathol Int. 1997 Jun;47(6):368-76 [9211524.001]
  • (PMID = 22778190.001).
  • [ISSN] 1757-790X
  • [Journal-full-title] BMJ case reports
  • [ISO-abbreviation] BMJ Case Rep
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC3028283
  •  go-up   go-down


30. Niu ZB, Yang Y, Hou Y, Chen H, Liu X, Wang CL: Lymphangioma of bladder. Urology; 2010 Oct;76(4):955-7
MedlinePlus Health Information. consumer health - Bladder Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Lymphangioma of bladder.
  • Lymphangioma in the bladder is extremely rare.
  • Ultrasonography, computed tomogram, and retrograde urethrography showed a mass that was in the wall of the bladder.
  • The tumor was red and found to be bulging into the bladder on the right lateral wall of the bladder by cystoscopy.
  • A partial cystectomy was performed and histology revealed a lymphangioma of the bladder.
  • This case, to the authors' knowledge, represents the third reported case of lymphangioma of bladder.Lymphangiomas are benign, soft-tissue tumors of lymphatic origin.
  • They rarely affect the urinary system and a location in the bladder is extremely rare.
  • Only 2 cases of lymphangioma of the bladder have been reported worldwide since 1983.
  • The present report describes a patient with a lymphangioma of the bladder and the imaging characteristics of the lesion are reported, including imagings of sonography, computed tomography, retrograde urethrography, and histologic examination.
  • [MeSH-major] Lymphangioma / pathology. Urinary Bladder Neoplasms / pathology

  • Genetic Alliance. consumer health - Lymphangioma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 Elsevier Inc. All rights reserved.
  • (PMID = 20494412.001).
  • [ISSN] 1527-9995
  • [Journal-full-title] Urology
  • [ISO-abbreviation] Urology
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  •  go-up   go-down


31. Abd El Gawad IA, Moussa HS, Nasr MI, El Gemae EH, Masooud AM, Ibrahim IK, El Hifnawy NM: Comparative study of NMP-22, telomerase, and BTA in the detection of bladder cancer. J Egypt Natl Canc Inst; 2005 Sep;17(3):193-202
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Comparative study of NMP-22, telomerase, and BTA in the detection of bladder cancer.
  • PURPOSE: The diagnostic efficacy of Nuclear Matrix Protein-22 (NMP-22), bladder tumor antigen (BTA TRAK), and telomerase activity was evaluated in urine in a trial to assess their value in the detection of bladder cancer and to compare it to that of routine urine cytology.
  • SUBJECTS AND METHODS: The study included 46 newly diagnosed bladder cancer patients, diagnosed by cystoscopy and histopathological typing, in addition to 20 patients with benign bladder lesions and 20 healthy age and sex matched volunteers as a control group.
  • The levels of the three parameters were significantly higher in the malignant group compared to either the benign group or normal controls, (p<0.001) and the positive rates were also higher in the malignant group for all 3 parameters.
  • For bilharzial cancer bladder respective sensitivities were 69.6%, 95.6%, 100% and 73.9%, while for nonbilharzial cancer bladder the respective sensitivities were 39.1%, 87%, 100% and 87%.
  • CONCLUSION: BTA showed the highest sensitivity in all the studied parameters in the bladder cancer group, bilharzial bladder cancer subgroup, and non bilharzial bladder subgroup, (100%), while the highest specificity was recorded with urine cytology (100%), followed by telomerase (95%), then BTA (92.5%), and lastly NMP- 22 (87.5%).
  • [MeSH-major] Antigens, Neoplasm / urine. Biomarkers, Tumor / urine. Nuclear Proteins / urine. Telomerase / urine. Urinary Bladder Neoplasms / diagnosis. Urinary Bladder Neoplasms / urine
  • [MeSH-minor] Adenocarcinoma / diagnosis. Adenocarcinoma / urine. Adult. Aged. Carcinoma, Squamous Cell / diagnosis. Carcinoma, Squamous Cell / urine. Carcinoma, Transitional Cell / diagnosis. Carcinoma, Transitional Cell / urine. Female. Humans. Male. Middle Aged. Schistosomiasis haematobia / complications

  • Genetic Alliance. consumer health - Bladder cancer.
  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16799657.001).
  • [ISSN] 1110-0362
  • [Journal-full-title] Journal of the Egyptian National Cancer Institute
  • [ISO-abbreviation] J Egypt Natl Canc Inst
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Egypt
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / Biomarkers, Tumor; 0 / Nuclear Proteins; 0 / bladder tumor-associated antigen; 0 / nuclear matrix protein 22; EC 2.7.7.49 / Telomerase
  •  go-up   go-down


32. Shirodkar SP, Lokeshwar VB: Bladder tumor markers: from hematuria to molecular diagnostics--where do we stand? Expert Rev Anticancer Ther; 2008 Jul;8(7):1111-23
MedlinePlus Health Information. consumer health - Bladder Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Bladder tumor markers: from hematuria to molecular diagnostics--where do we stand?
  • Bladder cancer is a common malignancy in the USA.
  • Currently, the detection of initial tumors and recurrent disease is based on evaluation of voided urinary specimens, often followed by cystoscopy.
  • As a result, intense work is being done in the field of bladder tumor markers with the goal of identifying bladder cancer earlier, both in the initial diagnosis and in recurrences of known tumor.
  • The possibility of identifying a marker that could noninvasively differentiate benign and malignant causes of hematuria, and identify recurrences prior to their pathologic progression is the objective of this area of research.
  • Currently, a large number of tumor markers exist, each scrutinized in both the laboratory and in clinical trials.
  • Some novel modalities for tumor detection are also presented.
  • [MeSH-major] Biomarkers, Tumor / genetics. Biomarkers, Tumor / urine. Hematuria / diagnosis. Urinary Bladder Neoplasms / diagnosis
  • [MeSH-minor] Antigens, Neoplasm / urine. Cystoscopy. Humans. Molecular Diagnostic Techniques / methods. Sensitivity and Specificity

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Pathol Oncol Res. 2007;13(3):187-94 [17922047.001]
  • [Cites] J Urol. 2007 Jan;177(1):80-3 [17162008.001]
  • [Cites] Urol Clin North Am. 2000 Feb;27(1):53-61 [10696245.001]
  • [Cites] Int J Oncol. 1993 Oct;3(4):559-63 [21573400.001]
  • [Cites] Urology. 2005 Dec;66(6 Suppl 1):35-63 [16399415.001]
  • [Cites] Urology. 2000 Nov 1;56(5):793-7 [11068304.001]
  • [Cites] Lancet. 1993 Aug 21;342(8869):469-71 [8102431.001]
  • [Cites] Eur Urol. 1999 Jan;35(1):52-6 [9933795.001]
  • [Cites] World J Urol. 2008 Feb;26(1):59-65 [17962949.001]
  • [Cites] Cancer. 2006 Apr 15;106(8):1701-7 [16541433.001]
  • [Cites] Cancer. 2002 Jul 1;95(1):61-72 [12115318.001]
  • [Cites] Int J Clin Oncol. 2003 Dec;8(6):369-73 [14663639.001]
  • [Cites] J Natl Cancer Inst. 1995 Jun 21;87(12):884-94 [7666477.001]
  • [Cites] Cancer Pract. 2002 Nov-Dec;10(6):311-22 [12406054.001]
  • [Cites] Int Surg. 1991 Jan-Mar;76(1):52-4 [2045253.001]
  • [Cites] JAMA. 2005 Feb 16;293(7):810-6 [15713770.001]
  • [Cites] J Urol. 2007 Apr;177(4):1277-82; discussion 1282 [17382711.001]
  • [Cites] Urol Oncol. 2006 Nov-Dec;24(6):528-37 [17138134.001]
  • [Cites] Hum Pathol. 2004 Jul;35(7):817-24 [15257544.001]
  • [Cites] J Urol. 2003 Jan;169(1):86-9 [12478110.001]
  • [Cites] J Urol. 2007 Feb;177(2):437-43 [17222605.001]
  • [Cites] Urology. 2001 Apr;57(4):680-4 [11306380.001]
  • [Cites] Br J Urol. 1996 Nov;78(5):699-703 [8976763.001]
  • [Cites] Cancer. 2006 Nov 1;107(9):2173-9 [17029275.001]
  • [Cites] Int J Cancer. 2002 Sep 20;101(3):293-7 [12209982.001]
  • [Cites] Clin Cancer Res. 1998 Oct;4(10):2511-20 [9796985.001]
  • [Cites] Cancer. 2004 Feb 1;100(3):621-30 [14745881.001]
  • [Cites] J Urol. 2001 Aug;166(2):470-5 [11458049.001]
  • [Cites] JAMA. 2006 Jan 18;295(3):299-305 [16418465.001]
  • [Cites] Urology. 2000 Aug 1;56(2):228-31 [10925083.001]
  • [Cites] Urology. 2003 Jan;61(1):243-7 [12559316.001]
  • [Cites] World J Urol. 2004 Jun;22(2):145-9 [14991320.001]
  • [Cites] J Urol. 1998 Feb;159(2):394-8 [9649246.001]
  • [Cites] Chin Med J (Engl). 2006 Nov 5;119(21):1763-71 [17097029.001]
  • [Cites] J Urol. 2006 Sep;176(3):919-26; discussion 926 [16890655.001]
  • [Cites] World J Urol. 2006 Sep;24(4):418-22 [16688457.001]
  • [Cites] J Urol. 2002 Nov;168(5):1950-4 [12394683.001]
  • [Cites] J Urol. 2000 Sep;164(3 Pt 1):634-9 [10953114.001]
  • [Cites] J Urol. 2001 Oct;166(4):1280-5 [11547058.001]
  • [Cites] J Urol. 1999 Jul;162(1):53-7 [10379739.001]
  • [Cites] Oncol Rep. 2007 Aug;18(2):405-9 [17611663.001]
  • [Cites] J Urol. 2006 Jun;175(6):2032-7; discussion 2037 [16697794.001]
  • [Cites] J Urol. 2002 Jan;167(1):80-3 [11743280.001]
  • [Cites] World J Urol. 2008 Feb;26(1):45-50 [18180926.001]
  • [Cites] Urology. 2006 Mar;67(3 Suppl 1):25-33; discussion 33-4 [16530072.001]
  • [Cites] Curr Opin Genet Dev. 1991 Dec;1(4):538-43 [1822287.001]
  • [Cites] Semin Diagn Pathol. 1997 May;14(2):123-32 [9179973.001]
  • [Cites] Can J Urol. 1997 Sep;4(3):400-405 [12735818.001]
  • [Cites] Urology. 1998 Nov;52(5):793-6 [9801101.001]
  • [Cites] Med Sci Monit. 2003 Apr;9(4):PI25-9 [12709681.001]
  • [Cites] J Clin Oncol. 2007 Dec 1;25(34):5352-8 [18048815.001]
  • [Cites] Cancer Res. 1999 Sep 1;59(17):4464-70 [10485499.001]
  • [Cites] J Cancer Res Clin Oncol. 2008 Jun;134(6):659-65 [18026991.001]
  • [Cites] Urology. 2004 Feb;63(2):392-7 [14972509.001]
  • [Cites] Urology. 2005 Dec;66(6):1256-60 [16360453.001]
  • [Cites] Cancer. 2005 Apr 1;103(7):1356-62 [15717321.001]
  • [Cites] BJU Int. 2006 Nov;98(5):1090-3 [17034609.001]
  • [Cites] BJU Int. 2005 Dec;96(9):1280-5 [16287445.001]
  • [Cites] Clin Cancer Res. 2002 Jan;8(1):171-9 [11801555.001]
  • [Cites] Int J Cancer. 2005 Aug 10;116(1):100-4 [15761870.001]
  • [Cites] J Urol. 2000 Jan;163(1):348-56 [10604388.001]
  • [Cites] J Urol. 1996 Oct;156(4):1280-5 [8808854.001]
  • [Cites] Front Biosci. 2002 Jan 01;7:e27-32 [11779714.001]
  • [Cites] Oncologist. 2007 Jan;12(1):20-37 [17227898.001]
  • [Cites] Int J Cancer. 2001 Oct 1;94(1):67-72 [11668480.001]
  • [Cites] ScientificWorldJournal. 2006 Mar 27;6:2617-25 [17619739.001]
  • [Cites] Semin Cancer Biol. 1996 Feb;7(1):15-24 [8695762.001]
  • [Cites] J Urol. 1997 Aug;158(2):338-41 [9224298.001]
  • [Cites] Ann Clin Lab Sci. 2006 Winter;36(1):31-8 [16501234.001]
  • [Cites] Am Fam Physician. 2001 Mar 15;63(6):1145-54 [11277551.001]
  • [Cites] J Natl Cancer Inst. 2003 Apr 16;95(8):588-97 [12697851.001]
  • [Cites] Asian J Androl. 2007 Sep;9(5):711-5 [17712491.001]
  • [Cites] Lab Invest. 2003 Jun;83(6):845-52 [12808119.001]
  • [Cites] BJU Int. 2008 Jan;101(1):26-9 [17850364.001]
  • [Cites] Mod Pathol. 2005 Jan;18(1):83-9 [15389253.001]
  • [Cites] Semin Oncol. 2007 Apr;34(2):75-84 [17382791.001]
  • [Cites] BJU Int. 2007 Feb;99(2):281-5 [17155984.001]
  • [Cites] Cancer Genet Cytogenet. 2007 Mar;173(2):131-5 [17321328.001]
  • [Cites] Cancer Res. 2005 Mar 15;65(6):2243-50 [15781637.001]
  • [Cites] Urology. 2003 Nov;62(5):952-7 [14624933.001]
  • [Cites] Int J Cancer. 2005 Nov 1;117(2):274-80 [15900578.001]
  • [Cites] Urol Int. 2001;66(4):185-90 [11385303.001]
  • [Cites] J Natl Cancer Inst. 1997 May 21;89(10):724-30 [9168188.001]
  • [Cites] Eur Urol. 1990;17(4):281-5 [2364965.001]
  • [Cites] Nat Med. 1997 Jun;3(6):621-4 [9176487.001]
  • [Cites] Urol Oncol. 2001 Jul;6(4):163-169 [11418323.001]
  • [Cites] JAMA. 2001 Jan 17;285(3):324-8 [11176843.001]
  • [Cites] Cancer. 2007 Mar 15;109(6):1106-13 [17311310.001]
  • [Cites] Am J Clin Pathol. 2007 Feb;127(2):295-301 [17210520.001]
  • [Cites] J Urol. 1998 Dec;160(6 Pt 1):1971-4 [9817302.001]
  • [Cites] Semin Oncol. 2002 Feb;29(1 Suppl 3):3-14 [11894002.001]
  • [Cites] J Urol. 2007 Sep;178(3 Pt 1):1068-72 [17644139.001]
  • [Cites] Urology. 2001 Sep;58(3):367-71 [11549482.001]
  • [Cites] World J Urol. 2007 Dec;25(6):563-71 [17710407.001]
  • [Cites] Cancer Lett. 2007 Apr 28;249(1):49-60 [17275177.001]
  • [Cites] World J Urol. 2000 Dec;18(6):401-5 [11204258.001]
  • [Cites] Clin Cancer Res. 2000 Jul;6(7):2618-25 [10914702.001]
  • [Cites] Clin Cancer Res. 2004 Feb 15;10(4):1384-91 [14977841.001]
  • [Cites] Cancer. 2002 Jun 1;94(11):2914-22 [12115379.001]
  • [Cites] Urology. 2007 Sep;70(3):482-6 [17905101.001]
  • [Cites] Cancer. 1998 Apr 1;82(7):1359-66 [9529029.001]
  • [Cites] Urology. 2007 Sep;70(3):449-53 [17688921.001]
  • [Cites] Oncol Rep. 2006 May;15(5):1321-6 [16596205.001]
  • [Cites] Urol Clin North Am. 1998 Nov;25(4):661-76 [10026773.001]
  • [Cites] World J Urol. 2008 Feb;26(1):31-7 [18075743.001]
  • [Cites] Blood. 1995 May 1;85(9):2315-20 [7727765.001]
  • [Cites] Int J Cancer. 2007 Jul 15;121(2):329-38 [17373664.001]
  • [Cites] Pharmacoeconomics. 2003;21(18):1315-30 [14750899.001]
  • [Cites] Urology. 2000 Feb;55(2):223-6 [10688083.001]
  • [Cites] Urol Clin North Am. 2000 Feb;27(1):25-37 [10696242.001]
  • [Cites] J Urol. 1999 May;161(5):1486-9 [10210378.001]
  • [Cites] Eur Urol. 2005 Dec;48(6):951-6; discussion 956 [16257108.001]
  • [Cites] JAMA. 2005 Oct 26;294(16):2052-6 [16249419.001]
  • [Cites] Indian J Med Sci. 2005 Jun;59(6):235-42 [15988093.001]
  • [Cites] Curr Opin Urol. 2007 Sep;17(5):352-7 [17762630.001]
  • [Cites] Eur Urol. 2007 Nov;52(5):1388-96 [17466450.001]
  • [Cites] J Clin Oncol. 2006 Dec 10;24(35):5519-27 [17158537.001]
  • [Cites] Curr Opin Urol. 2008 Jan;18(1):1-8 [18090481.001]
  • [Cites] J Urol. 2007 Jul;178(1):57-61 [17574060.001]
  • [Cites] Lancet Oncol. 2005 Sep;6(9):678-86 [16129368.001]
  • [Cites] Clin Cancer Res. 2000 Jun;6(6):2333-40 [10873084.001]
  • [Cites] Isr Med Assoc J. 2002 Mar;4(3):174-5 [11908255.001]
  • [Cites] Cancer. 1987 Oct 1;60(7):1423-7 [3304614.001]
  • [Cites] Med Clin North Am. 2004 Mar;88(2):329-43 [15049581.001]
  • [Cites] Int J Urol. 2007 Feb;14(2):108-11 [17302565.001]
  • [Cites] Br J Urol. 1991 Sep;68(3):248-53 [1717095.001]
  • [Cites] J Urol. 2004 Sep;172(3):1123-6 [15311054.001]
  • [Cites] Med Sci Monit. 2003 Aug;9 Suppl 3:25-8 [15156607.001]
  • [Cites] Urology. 2004 Dec;64(6):1121-6 [15596183.001]
  • [Cites] J Urol. 1999 Feb;161(2):443-6 [9915422.001]
  • [Cites] J Urol. 2007 Feb;177(2):481-7; discussion 487 [17222615.001]
  • [Cites] Urology. 1989 Feb;33(2):89-96 [2916296.001]
  • [Cites] Tumour Biol. 2007;28(2):57-62 [17259754.001]
  • [Cites] Eur Urol. 2004 Oct;46(4):466-71 [15363562.001]
  • (PMID = 18588456.001).
  • [ISSN] 1744-8328
  • [Journal-full-title] Expert review of anticancer therapy
  • [ISO-abbreviation] Expert Rev Anticancer Ther
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / R01 CA072821; United States / NCI NIH HHS / CA / 5R01 CA-72821-10
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / Biomarkers, Tumor
  • [Number-of-references] 136
  •  go-up   go-down


33. Haylen BT: The empty bladder. Int Urogynecol J Pelvic Floor Dysfunct; 2007 Mar;18(3):237-9

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The empty bladder.
  • The empty (near-empty) bladder can have a volume ranging from 0 to 30 ml.
  • Its diagnosis is effectively and least invasively made by ultrasound (transvaginal superior).
  • It is a key marker of normal bladder function.
  • It is necessary for the accurate assessment of uterovaginal prolapse, as increasing bladder volume has been shown to reduce the extent of the prolapse.
  • Any negative effect of prolapse on voiding is reduced at high bladder volumes compared to voiding from low bladder volumes (due to the same reduction in the extent of the prolapse).
  • An empty bladder is optimal for bimanual pelvic examination and most transvaginal ultrasound examinations including that for uterine version.
  • The woman whose bladder is empty post-voiding is at a significantly lower risk of recurrent urinary tract infections.
  • The bladder that can't be emptied is a marker of bladder dysfunction, requiring a fuller investigation.
  • From a surgical point of view, the empty bladder improves access and reduces surgical risks with laparotomy, as well as both laparoscopic and vaginal surgery.
  • [MeSH-major] Urinary Bladder / physiology
  • [MeSH-minor] Female. Gynecologic Surgical Procedures. Humans. Recurrence. Urinary Tract Infections / physiopathology. Urination / physiology. Uterine Prolapse / physiopathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Neurourol Urodyn. 2000;19(3):213-20 [10797578.001]
  • [Cites] Urology. 2003 Jan;61(1):37-49 [12559262.001]
  • [Cites] Br J Urol. 1989 Jul;64(1):30-8 [2765766.001]
  • [Cites] Br J Urol. 1989 Feb;63(2):149-51 [2649196.001]
  • [Cites] Int Urogynecol J Pelvic Floor Dysfunct. 1999;10(6):378-83 [10614974.001]
  • [Cites] Am J Obstet Gynecol. 1996 Jul;175(1):10-7 [8694033.001]
  • [Cites] Radiology. 1991 Apr;179(1):25-33 [2006286.001]
  • [Cites] Int Urogynecol J Pelvic Floor Dysfunct. 1999;10 (1):3-6 [10207759.001]
  • [Cites] Br J Urol. 1966 Apr;38(2):156-62 [5934769.001]
  • [Cites] Int Urogynecol J Pelvic Floor Dysfunct. 2005 May-Jun;16(3):236-41 [15875241.001]
  • [Cites] Int Urogynecol J Pelvic Floor Dysfunct. 2006 Nov;17 (6):555-8 [16341460.001]
  • [Cites] Br J Urol. 1989 Feb;63(2):152-4 [2702400.001]
  • [Cites] Radiol Clin North Am. 1992 Sep;30(5):955-76 [1518939.001]
  • [Cites] Br J Urol. 1989 Oct;64(4):350-2 [2684334.001]
  • [Cites] Int Urogynecol J Pelvic Floor Dysfunct. 2000;11(5):296-300 [11052565.001]
  • (PMID = 16791705.001).
  • [Journal-full-title] International urogynecology journal and pelvic floor dysfunction
  • [ISO-abbreviation] Int Urogynecol J Pelvic Floor Dysfunct
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


34. Siatelis A, Konstantinidis C, Volanis D, Leontara V, Thoma-Tsagli E, Delakas D: Pheochromocytoma of the urinary bladder: report of 2 cases and review of literature. Minerva Urol Nefrol; 2008 Jun;60(2):137-40
MedlinePlus Health Information. consumer health - Pheochromocytoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pheochromocytoma of the urinary bladder: report of 2 cases and review of literature.
  • Pheochromocytoma of the urinary bladder is a rare neoplasm of the chromaffin tissue of the sympathetic nervous system within the layers of the bladder wall.
  • It accounts for less than 0.06% of all urinary bladder tumors and less than 1% of all pheochromocytomas.
  • The diagnosis is strongly based on the clinical symptoms related to catecholamine hypersecretion.
  • In some cases however, the tumor is hormonally inactive and may go undetected for years.
  • The cytologic features of benign and malignant tumors overlap and thus there are no reliable features of malignancy.
  • Nevertheless the prognosis seems to be better for patients with superficial tumors comparing to patients with invasive tumors, found in 5-10% of cases.
  • For metastatic tumors, chemotherapy and radiotherapy seem to be effective.
  • The authors present two new cases of pheochromocytoma of the urinary bladder.
  • The authors discuss the difficulties in diagnosis and treatment and briefly review literature.
  • [MeSH-major] Pheochromocytoma. Urinary Bladder Neoplasms

  • Genetic Alliance. consumer health - Pheochromocytoma.
  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18500228.001).
  • [ISSN] 0393-2249
  • [Journal-full-title] Minerva urologica e nefrologica = The Italian journal of urology and nephrology
  • [ISO-abbreviation] Minerva Urol Nefrol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Italy
  • [Number-of-references] 12
  •  go-up   go-down


35. Lee SH, Mah SY, Chung BH: Incidentally discovered inverted papilloma of the urinary bladder in patients with lower urinary tract symptoms. J Endourol; 2010 Feb;24(2):271-5
MedlinePlus Health Information. consumer health - Bladder Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Incidentally discovered inverted papilloma of the urinary bladder in patients with lower urinary tract symptoms.
  • BACKGROUND AND PURPOSE: Inverted urothelial papilloma (IP) is an uncommon urothelial neoplasm.
  • We aimed to determine the clinicopathologic characteristics of IP of the bladder and its association with prostate volume and lower urinary tract symptoms (LUTS).
  • PATIENTS AND METHODS: From 1994 to 2008, 53 patients with urinary IP underwent transurethral resection of the bladder tumor (TURBT) at our institution.
  • We reviewed the clinicopathologic characteristics of IP of the bladder and its association with prostate volume and LUTS.
  • In IP located on the bladder neck of patients with benign prostatic hyperplasia (BPH), significantly higher obstructive symptoms and larger prostate volumes than that of other located IP with BPH were observed.
  • CONCLUSIONS: This is the largest series of cases of urinary bladder IP reported from Korea.
  • Despite the absence of agreement of its etiology, its presenting symptoms were related to LUTS and benign prostatic enlargement.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20039831.001).
  • [ISSN] 1557-900X
  • [Journal-full-title] Journal of endourology
  • [ISO-abbreviation] J. Endourol.
  • [Language] ENG
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


36. Karaguzhin SG, Merinov DS, Martov AG: [One-stage transurethral resection of the urinary bladder and the prostate in patients with superficial cancer of the urinary bladder combined with benign prostatic hyperplasia]. Urologiia; 2005 Sep-Oct;(5):17-21
MedlinePlus Health Information. consumer health - Enlarged Prostate (BPH).

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [One-stage transurethral resection of the urinary bladder and the prostate in patients with superficial cancer of the urinary bladder combined with benign prostatic hyperplasia].
  • Combination of urinary bladder cancer (UBC) with benign prostatic hyperplasia (BPH) is a prognostically unfavourable factor.
  • TUR of the urinary bladder and the prostate was made in 87 patients.
  • Stage-by-stage TUR of the urinary bladder and TUR of the prostate were made in 94 controls.
  • Reoperation (TUR of the urinary bladder) was performed in all cases of UBC recurrence.
  • The conclusion is made that in combination of superficial UBC with BPH indications appear for TUR of the urinary bladder and TUR of the prostate with adjuvant immunotherapy.
  • [MeSH-major] Cystectomy. Prostate / surgery. Prostatic Hyperplasia / surgery. Transurethral Resection of Prostate. Urinary Bladder / surgery. Urinary Bladder Neoplasms / surgery
  • [MeSH-minor] Adjuvants, Immunologic / therapeutic use. Combined Modality Therapy. Endoscopy. Humans. Immunotherapy. Male. Neoplasm Recurrence, Local / diagnosis. Neoplasm Staging. Treatment Outcome


37. Chen CS, Cheng CL: Nephrogenic adenoma of the urinary bladder: clinical experience and review of the literature. J Chin Med Assoc; 2006 Apr;69(4):166-8
MedlinePlus Health Information. consumer health - Bladder Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Nephrogenic adenoma of the urinary bladder: clinical experience and review of the literature.
  • BACKGROUND: Nephrogenic adenoma (NA) is a rare disease of the urinary tract.
  • We report our clinical experience with this disease in the urinary bladder and review the literature.
  • METHODS: Between April 1994 and July 2004, 8 patients were diagnosed with NA of the urinary bladder: 3 men and 5 women, aged 23-77 years (mean 49.6).
  • All patients had recurrent urinary tract infection.
  • Urinary tuberculosis was diagnosed in 2 patients.
  • Previous long-term urinary catheterization was noted in 3 patients.
  • Urinary frequency and microscopic hematuria were found in all patients.
  • Recurrent tumors were also treated with the endourologic method.
  • CONCLUSION: NA is an uncommon benign metaplastic lesion occurring in the urothelium.
  • Transurethral resection of NA provides a definite diagnosis and relief of symptoms.
  • [MeSH-major] Adenoma / etiology. Urinary Bladder Neoplasms / etiology
  • [MeSH-minor] Adult. Aged. Female. Humans. Male. Middle Aged. Neoplasm Recurrence, Local

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16689198.001).
  • [ISSN] 1726-4901
  • [Journal-full-title] Journal of the Chinese Medical Association : JCMA
  • [ISO-abbreviation] J Chin Med Assoc
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] China (Republic : 1949- )
  •  go-up   go-down


38. Hazzaa SM, Elashry OM, Afifi IK: Clusterin as a diagnostic and prognostic marker for transitional cell carcinoma of the bladder. Pathol Oncol Res; 2010 Mar;16(1):101-9
MedlinePlus Health Information. consumer health - Bladder Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clusterin as a diagnostic and prognostic marker for transitional cell carcinoma of the bladder.
  • We investigated the feasibility of profiling and measuring the concentration of clusterin in urine and serum for individuals with transitional cell carcinoma (TCC) of the bladder and comparing it with nontumor controls.
  • In addition, we analyzed the correlation of expression of clusterin in specimens of TCC to various clinicopathologic parameters and prognosis of bladder cancer.
  • Blood and urine samples were used from 68 patients with TCC of the bladder and from 61 patients with benign urological diseases.
  • Quantitation of clusterin mRNA was carried out in 68 bladder tumor specimens from radical cystectomy or transurethral resection and 26 normal bladder specimens from BPH patients by using RT-PCR method.
  • Serum and urine clusterin was significantly higher in individuals with bladder cancer than control (p = 0.001).
  • Sensitivity and specificity of serum and urine clusterin as a tumor marker for TCC of the bladder was found to be 80%, 91%, 87.1% and 96.7% respectively.
  • Expression of clusterin was significantly higher in patients with invasive TCC of the bladder than that in patients with superficial TCC and control (P < 0.001).
  • Overexpression of clusterin mRNA was significantly associated with tumor recurrence and overall survival (p < 0.001).
  • Clusterin may be considered as a potential diagnostic and prognostic biomarker for bladder cancer using urine, serum and/or molecular biology techniques.
  • [MeSH-major] Biomarkers, Tumor / analysis. Carcinoma, Transitional Cell / diagnosis. Clusterin / biosynthesis. Urinary Bladder Neoplasms / diagnosis
  • [MeSH-minor] Adult. Enzyme-Linked Immunosorbent Assay. Female. Humans. Male. Middle Aged. Neoplasm Staging. Prognosis. Reverse Transcriptase Polymerase Chain Reaction

  • Genetic Alliance. consumer health - Transitional cell carcinoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19757199.001).
  • [ISSN] 1532-2807
  • [Journal-full-title] Pathology oncology research : POR
  • [ISO-abbreviation] Pathol. Oncol. Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Clusterin
  •  go-up   go-down


39. Juan Escudero JU, Ramos de Campos M, Ordoño Domínguez F, Fabuel Deltoro M, Serrano de la Cruz Torrijos F, Navalón Verdejo P, López Alcina E, Zaragoza Orts J: [Inguinoscrotal bladder hernias]. Arch Esp Urol; 2007 Apr;60(3):231-6
MedlinePlus Health Information. consumer health - Bladder Diseases.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Inguinoscrotal bladder hernias].
  • In the general population, only a small percentage of them involve the bladder.
  • Bladder wall weakness and bladder outlet obstruction are involved in its pathogenesis.
  • We present our experience in the diagnosis and treatment of this rare disease.
  • METHODS: A total of eight patients have been diagnosed of inguinoscrotal bladder hernia and treated in our center over the last 18 years.
  • In most cases, retrograde and voiding cystourethrograms, prostatic and bladder ultrasound, and uroflowmetry have been performed.
  • The treatment varied depending on the characteristics of the herniated bladder tissues and bladder capacity.
  • The treatment of bladder outlet obstruction varied depending on the etiology.
  • Resection of the herniated bladder tissue was carried out in four patients due to the quality of the tissue; bladder-pexy to the abdominis rectus muscles was performed in one patient; hernia repair with bladder reintroduction was the treatment in the other four cases.
  • Bladder outlet obstruction was treated in six cases.
  • Seven patients showed clinical improvement, showing normal bladder morphology on post operative cystogram.
  • CONCLUSIONS: Bladder hernia is a rare pathology often presenting in mid age males.
  • It should be suspected in every male with lower urinary tract obstructive symptoms and associated inguinal hernia.
  • The treatment of choice is that of the hernia and bladder outlet obstruction.
  • [MeSH-major] Genital Diseases, Male / diagnosis. Genital Diseases, Male / surgery. Hernia, Inguinal / diagnosis. Hernia, Inguinal / surgery. Scrotum. Urinary Bladder Diseases / diagnosis. Urinary Bladder Diseases / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17601297.001).
  • [ISSN] 0004-0614
  • [Journal-full-title] Archivos españoles de urología
  • [ISO-abbreviation] Arch. Esp. Urol.
  • [Language] spa
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Spain
  • [Number-of-references] 16
  •  go-up   go-down


40. Moreira JM, Ohlsson G, Gromov P, Simon R, Sauter G, Celis JE, Gromova I: Bladder cancer-associated protein, a potential prognostic biomarker in human bladder cancer. Mol Cell Proteomics; 2010 Jan;9(1):161-77
MedlinePlus Health Information. consumer health - Bladder Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Bladder cancer-associated protein, a potential prognostic biomarker in human bladder cancer.
  • It is becoming increasingly clear that no single marker will have the sensitivity and specificity necessary to be used on its own for diagnosis/prognosis of tumors.
  • As a result of these studies, we have identified and reported several candidate biomarker proteins that are deregulated in bladder cancer.
  • Following the conceptual biomarker development phases proposed by the Early Detection Research Network, we have taken some of the most promising candidate proteins into postdiscovery validation studies, and here we report on the characterization of one such biomarker, the bladder cancer-associated protein (BLCAP), formerly termed Bc10.
  • To characterize BLCAP protein expression and cellular localization patterns in benign bladder urothelium and urothelial carcinomas (UCs), we used two independent sets of samples from different patient cohorts: a reference set consisting of 120 bladder specimens (formalin-fixed as well as frozen biopsies) and a validation set consisting of 2,108 retrospectively collected UCs with long term clinical follow-up.
  • We could categorize the UCs examined into four groups based on levels of expression and subcellular localization of BLCAP protein and showed that loss of BLCAP expression is associated with tumor progression.
  • [MeSH-major] Biomarkers, Tumor / analysis. Neoplasm Proteins / analysis. Proteomics / methods. Urinary Bladder Neoplasms / metabolism

  • Genetic Alliance. consumer health - Bladder cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Cell Sci. 2001 Aug;114(Pt 16):2891-3 [11686292.001]
  • [Cites] Am J Clin Pathol. 2001 Oct;116(4):495-503 [11601134.001]
  • [Cites] Int J Cancer. 2002 Apr 1;98(4):539-46 [11920613.001]
  • [Cites] Neuron. 2002 Apr 25;34(3):349-56 [11988167.001]
  • [Cites] Mol Cell Proteomics. 2002 Apr;1(4):269-79 [12096109.001]
  • [Cites] Anticancer Res. 2002 Nov-Dec;22(6B):3759-64 [12552989.001]
  • [Cites] Cancer Cell. 2003 Jan;3(1):9-15 [12559171.001]
  • [Cites] Science. 2003 Aug 8;301(5634):832-6 [12907802.001]
  • [Cites] Nature. 2004 Feb 26;427(6977):801 [14985749.001]
  • [Cites] Mol Cell Proteomics. 2004 Apr;3(4):410-9 [14736829.001]
  • [Cites] Pharmacogenomics. 2004 Jun;5(4):381-94 [15165174.001]
  • [Cites] Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi. 2003 Sep;19(5):465-6 [15169658.001]
  • [Cites] J Mol Biol. 2004 Jul 16;340(4):783-95 [15223320.001]
  • [Cites] Prostate. 2004 Nov 1;61(3):215-27 [15368473.001]
  • [Cites] Acta Chir Scand. 1965 Oct;130(4):371-8 [5842510.001]
  • [Cites] Virchows Arch A Pathol Anat Histol. 1981;391(2):217-25 [6784337.001]
  • [Cites] Cell. 1991 Oct 4;67(1):11-9 [1717158.001]
  • [Cites] Urol Clin North Am. 1992 Aug;19(3):429-33 [1636228.001]
  • [Cites] Science. 1995 Dec 8;270(5242):1677-80 [7502080.001]
  • [Cites] Cancer Res. 1996 Oct 15;56(20):4782-90 [8840999.001]
  • [Cites] Nature. 1997 May 15;387(6630):303-8 [9153397.001]
  • [Cites] Cancer Res. 1997 Sep 15;57(18):4111-7 [9307301.001]
  • [Cites] Int J Oncol. 1998 Aug;13(2):379-83 [9664136.001]
  • [Cites] Electrophoresis. 1999 Feb;20(2):241-8 [10197429.001]
  • [Cites] Electrophoresis. 1999 Feb;20(2):349-54 [10197442.001]
  • [Cites] Hybrid Hybridomics. 2004 Dec;23(6):335-42 [15684659.001]
  • [Cites] Nucleic Acids Res. 2005;33(4):1162-8 [15731336.001]
  • [Cites] Mol Cell Proteomics. 2005 Apr;4(4):570-81 [15734831.001]
  • [Cites] Bioinformatics. 2005 May 1;21(9):1853-8 [15691854.001]
  • [Cites] Bioinformatics. 2005 Jun 1;21(11):2590-5 [15797904.001]
  • [Cites] Nucleic Acids Res. 2005 Jul 1;33(Web Server issue):W226-9 [15980458.001]
  • [Cites] Tumour Biol. 2006;27(4):221-6 [16675915.001]
  • [Cites] Ai Zheng. 2006 Jul;25(7):811-7 [16831269.001]
  • [Cites] Cell. 2006 Dec 1;127(5):1071 [17129789.001]
  • [Cites] Nat Struct Mol Biol. 2007 Mar;14(3):185-93 [17310252.001]
  • [Cites] Mol Cell Biochem. 2007 Mar;297(1-2):81-92 [17031575.001]
  • [Cites] Genome Res. 2007 Nov;17(11):1586-95 [17908822.001]
  • [Cites] J Clin Epidemiol. 2007 Dec;60(12):1205-19 [17998073.001]
  • [Cites] J Biol Chem. 2008 Mar 14;283(11):7251-60 [18178553.001]
  • [Cites] RNA. 2008 Jun;14(6):1110-8 [18430892.001]
  • [Cites] Ann N Y Acad Sci. 2008;1131:1-12 [18519955.001]
  • [Cites] Cancer Cell. 2008 Jun;13(6):554-6 [18538738.001]
  • [Cites] Urology. 2008 Sep;72(3):706-10 [18342921.001]
  • [Cites] Scand J Urol Nephrol Suppl. 2008 Sep;(218):12-20 [19054893.001]
  • [Cites] Tumour Biol. 2008;29(5):311-22 [18984977.001]
  • [Cites] RNA Biol. 2008 Oct-Dec;5(4):193-7 [18971634.001]
  • [Cites] Mol Oncol. 2007 Dec;1(3):321-49 [19383306.001]
  • [Cites] Mol Oncol. 2008 Apr;1(4):384-94 [19383312.001]
  • [Cites] Mol Oncol. 2008 Apr;1(4):406-12 [19383314.001]
  • [Cites] Mol Oncol. 2008 Aug;2(2):153-60 [19383334.001]
  • [Cites] Mol Oncol. 2008 Oct;2(3):213-22 [19383342.001]
  • [Cites] Urol Oncol. 2011 Jan-Feb;29(1):21-6 [19186082.001]
  • [Cites] J Mol Biol. 1999 Dec 17;294(5):1351-62 [10600390.001]
  • [Cites] Clin Cancer Res. 1999 Dec;5(12):4079-84 [10632343.001]
  • [Cites] EXS. 2000;88:55-67 [10803371.001]
  • [Cites] Am J Pathol. 2000 Sep;157(3):787-94 [10980118.001]
  • [Cites] Int J Cancer. 2000 Dec 1;88(5):726-32 [11072240.001]
  • [Cites] J Mol Biol. 2001 Jan 19;305(3):567-80 [11152613.001]
  • [Cites] J Pathol. 2001 Jul;194(3):349-57 [11439368.001]
  • [Cites] J Natl Cancer Inst. 2001 Jul 18;93(14):1054-61 [11459866.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Dec 4;98(25):14687-92 [11717408.001]
  • (PMID = 19783793.001).
  • [ISSN] 1535-9484
  • [Journal-full-title] Molecular & cellular proteomics : MCP
  • [ISO-abbreviation] Mol. Cell Proteomics
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / BLCAP protein, human; 0 / Biomarkers, Tumor; 0 / Membrane Proteins; 0 / Neoplasm Proteins
  • [Other-IDs] NLM/ PMC2808262
  •  go-up   go-down


41. Blah M, Nouira Y, Kallel Y, Hafsia GH, Horchani A: [Bladder herniation]. Ann Chir; 2005 Dec;130(10):633-5
MedlinePlus Health Information. consumer health - Bladder Diseases.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Bladder herniation].
  • Inguinal hernia of the bladder is uncommon.
  • The diagnosis is frequently done during surgery.
  • It can be evoked before surgery when the patient presents with irritative and obstructive lower urinary tract symptoms.
  • Retrograde urethrocystography or computerized tomography confirm the diagnosis.
  • We report a case of bilateral inguinal hernia involving the bladder at the right side in a 87 years old man who had a surgical history of transvesical adenomectomy of the prostate.
  • The diagnosis was done on the retrograde urethrocystography.
  • We performed bilateral herniorrhaphy with herniated bladder reduction.
  • [MeSH-major] Hernia, Inguinal / surgery. Urinary Bladder Diseases / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16043116.001).
  • [ISSN] 0003-3944
  • [Journal-full-title] Annales de chirurgie
  • [ISO-abbreviation] Ann Chir
  • [Language] fre
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] France
  •  go-up   go-down


42. Charfi S, Moussa A, Njim L, Toffahi M, Hadhri R, Mahmoudi H, Zakhama A: [Micropapillary bladder carcinoma]. Prog Urol; 2006 Nov;16(5):607-9
MedlinePlus Health Information. consumer health - Bladder Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Micropapillary bladder carcinoma].
  • [Transliterated title] Carcinome micropapillaire de la vessie.
  • Micropapillary bladder carcinoma is a recently described, rare variant of urothelial carcinoma reputed for its poor prognosis.
  • The authors report the case of a 59-year-old man with invasive bladder tumour presenting with haematuria.
  • The authors discuss the clinicopathological and pathogenic features, treatment and clinical course of this tumour.
  • [MeSH-major] Carcinoma, Papillary / pathology. Urinary Bladder Neoplasms / pathology
  • [MeSH-minor] Hematuria / etiology. Humans. Male. Middle Aged. Neoplasm Invasiveness

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17175962.001).
  • [ISSN] 1166-7087
  • [Journal-full-title] Progrès en urologie : journal de l'Association française d'urologie et de la Société française d'urologie
  • [ISO-abbreviation] Prog. Urol.
  • [Language] fre
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] France
  •  go-up   go-down


43. Sun Y, He H, Ma Q, Wang XY, Yang L, He DL: [Clinical evaluation of BTAstat, NMP22, HA, survivin, CD44v6, vEGF and VUC in bladder cancer diagnosis]. Zhonghua Yi Xue Za Zhi; 2005 Sep 14;85(35):2507-12
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Clinical evaluation of BTAstat, NMP22, HA, survivin, CD44v6, vEGF and VUC in bladder cancer diagnosis].
  • OBJECTIVE: To evaluate the sensitivity and specificity of BTAstat, NMP22, HA, Survivin, CD44v6, VEGF, and VUC in detection of bladder cancer.
  • METHODS: We detect VUC, BTAstat, NMP22, HA, Survivin, CD44v6, VEGF in the urine of 10 normal case (healthy volunteers), 11 benign urological diseases patients and 52 bladder cancer patients.
  • The overall sensitivity and specificity of urinary tumor markers were: 42.3% and 100% for VUC; 78.8% and 90.5% for BTAstat; 76.9% and 81.0% for NMP22; 86.5% and 90.5% for HA; 67.3% and 85.7% for Survivin; 50.5% and 85.7% for CD44 and 69.2% and 95.2% for VEGF.
  • CONCLUSION: Each marker had achieved its obvious clinical value in diagnosis of bladder cancer.
  • The sensitivity of all the markers was increased with the progression of tumor grades and clinical stages, except the CD44v6.
  • [MeSH-major] Antigens, Neoplasm / urine. Biomarkers, Tumor / urine. Urinary Bladder Neoplasms / diagnosis

  • Genetic Alliance. consumer health - Bladder cancer.
  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16321281.001).
  • [ISSN] 0376-2491
  • [Journal-full-title] Zhonghua yi xue za zhi
  • [ISO-abbreviation] Zhonghua Yi Xue Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Antigens, CD44; 0 / Antigens, Neoplasm; 0 / BIRC5 protein, human; 0 / Biomarkers, Tumor; 0 / CD44v6 antigen; 0 / Inhibitor of Apoptosis Proteins; 0 / Nuclear Proteins; 0 / VEGFA protein, human; 0 / Vascular Endothelial Growth Factor A; 0 / nuclear matrix protein 22
  •  go-up   go-down


44. Grima F, Golfier F, Raudrant D: [Clinicopathological correlation in bladder endometriosis]. Prog Urol; 2005 Jun;15(3):498-500
MedlinePlus Health Information. consumer health - Endometriosis.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Clinicopathological correlation in bladder endometriosis].
  • Bladder endometriosis is a rare site of a disease with very polymorphic clinical signs.
  • The authors report the case of a 30-year-old woman operated for bladder endometriosis who presented with recent menstrual macroscopic haematuria with primary infertility and deep dyspareunia.
  • Histological examination demonstrated bladder endometriosis sparing the urothelium.
  • Comparison with our histological series of bladder endometriosis demonstrated polymorphic lesions ranging from integrity to complete loss of the bladder mucosa, with no correlation with clinical features.
  • [MeSH-major] Endometriosis / pathology. Urinary Bladder Diseases / pathology

  • Genetic Alliance. consumer health - Endometriosis.
  • MedlinePlus Health Information. consumer health - Bladder Diseases.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16097157.001).
  • [ISSN] 1166-7087
  • [Journal-full-title] Progrès en urologie : journal de l'Association française d'urologie et de la Société française d'urologie
  • [ISO-abbreviation] Prog. Urol.
  • [Language] fre
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] France
  •  go-up   go-down


45. Kavia R, Mumtaz F: Overactive bladder. J R Soc Promot Health; 2005 Jul;125(4):176-9
MedlinePlus Health Information. consumer health - Urinary Incontinence.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Overactive bladder.
  • Overactive bladder (OAB) is defined as urgency, with or without urge incontinence, usually with frequency and nocturia, in the absence of local pathological or hormonal factors.
  • ApproximateLy 70% of men with bladder outflow obstruction will have some symptoms of OAB.
  • The exact pathophysiology of OAB in bladder outflow obstruction is yet to be elucidated; evidence to date points to changes in both the efferent and afferent innervation and the detrusor.
  • More specific treatment options for OAB in bladder outflow obstruction include relief of the obstruction with surgical (e.g. transurethraL resection of prostate) or pharmaceutical (e.g. a blockers) methods.
  • [MeSH-major] Urinary Bladder Diseases / therapy. Urinary Incontinence / therapy

  • MedlinePlus Health Information. consumer health - Bladder Diseases.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16094929.001).
  • [ISSN] 1466-4240
  • [Journal-full-title] The journal of the Royal Society for the Promotion of Health
  • [ISO-abbreviation] J R Soc Promot Health
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Anti-Dyskinesia Agents; 0 / Muscarinic Antagonists; 0 / Muscle Relaxants, Central
  • [Number-of-references] 21
  •  go-up   go-down


46. Song JW, DU LL, Zhao XW, Jing JX, Han CZ, Cui Y, Liu JW, Hao HL, Wang ZG, Mi ZG: [Expression and clinical significance of nuclear matrix protein 22 and cytokeratin 18 in transitional cell carcinoma of the bladder]. Zhonghua Zhong Liu Za Zhi; 2009 Apr;31(4):274-7
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Expression and clinical significance of nuclear matrix protein 22 and cytokeratin 18 in transitional cell carcinoma of the bladder].
  • OBJECTIVE: To evaluate the expression and clinical significance of urinary nuclear matrix protein (NMP22) and cytokeratin 18 (CK18) for transitional cell carcinoma of the bladder.
  • METHODS: Urinary NMP22 and CK18 levels of 293 patients with transitional cell carcinoma of the bladder, 400 patients with non-transitional cell carcinoma of the bladder, and 105 bladder benign disease were analysed by enzyme-linked-immunosorbent assay (ELISA).
  • RESULTS: The levels of urinary NMP22 and CK18 in the patients with transitional cell carcinoma of the bladder (M = 17.3 U/ml, M(CK18) = 484.2 U/L) were significantly higher than those in the non-transitional cell carcinoma of the bladder (M = 6.8 U/ml, M(CK18) = 156.0 U/L) and the benign disease group (M(NMP22) = 2.3 U/ml, M(CK18) = 66.6 U/L) (P < 0.001).
  • The sensitivity and specificity of urinary NMP22 and CK18 were 79.2%, 88.6% and 78.2%, 82.9%, respectively, for transitional cell carcinoma of the bladder before any treatment.
  • The levels of urinary nmp22 and CK18 were significantly different among pathological grade G1, G2, G3, and stage Ta, T1, T2, T3 (P < 0.01).
  • CONCLUSION: NMP22 and CK18 are useful tumor marker for diagnosis of transitional cell carcinoma of the bladder and for monitoring the state of illness.
  • NMP22 and CK18 may become a new class of tumor markers, and to be the basis for development of a new assay with an increased efficacy for the detection and treatment of bladder cancer.
  • [MeSH-major] Carcinoma, Transitional Cell / urine. Keratin-18 / urine. Nuclear Proteins / urine. Urinary Bladder Neoplasms / urine
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Biomarkers, Tumor / urine. Carcinoma, Renal Cell / urine. Child. Female. Follow-Up Studies. Humans. Male. Middle Aged. Neoplasm Metastasis. Neoplasm Recurrence, Local / urine. Neoplasm Staging. Prognosis. Sensitivity and Specificity. Young Adult

  • Genetic Alliance. consumer health - Transitional cell carcinoma.
  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19615282.001).
  • [ISSN] 0253-3766
  • [Journal-full-title] Zhonghua zhong liu za zhi [Chinese journal of oncology]
  • [ISO-abbreviation] Zhonghua Zhong Liu Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Keratin-18; 0 / Nuclear Proteins; 0 / nuclear matrix protein 22
  •  go-up   go-down


47. Daniely M, Rona R, Kaplan T, Olsfanger S, Elboim L, Freiberger A, Lew S, Leibovitch I: Combined morphologic and fluorescence in situ hybridization analysis of voided urine samples for the detection and follow-up of bladder cancer in patients with benign urine cytology. Cancer; 2007 Dec 25;111(6):517-24
MedlinePlus Health Information. consumer health - Urine and Urination.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Combined morphologic and fluorescence in situ hybridization analysis of voided urine samples for the detection and follow-up of bladder cancer in patients with benign urine cytology.
  • BACKGROUND: Bladder cancer is among the 5 most common malignancies worldwide.
  • Patients with bladder cancer are closely followed with periodic cystoscopies and urine cytology analyses due to the significant risk of tumor recurrence.
  • The UroVysion fluorescence in situ hybridization (FISH) test demonstrated higher sensitivity over urine cytology in detecting bladder cancer by most comparative studies.
  • METHODS: In the current study, the diagnostic usefulness of a combined cytology and FISH analysis approach was tested using the Duet automatic scanning system in patients with benign urine cytology who were being monitored for recurrent urothelial carcinoma or being assessed for various urologic symptoms.
  • RESULTS: By combining the benefits of conventional cytology with molecular diagnostics, a more sensitive detection of bladder cancer was attained.
  • CONCLUSIONS: Given the absolute sensitivity and NPV of the combined analysis test, the management of patients with a negative combined analysis result might be revised and allow for more flexible assessment and management of bladder cancer patients relying more on urine bound tests.
  • [MeSH-major] Urinary Bladder Neoplasms / pathology. Urinary Bladder Neoplasms / urine. Urine / cytology
  • [MeSH-minor] Cytodiagnosis. Female. Follow-Up Studies. Humans. In Situ Hybridization, Fluorescence. Male. Neoplasm Recurrence, Local / diagnosis. Sensitivity and Specificity

  • Genetic Alliance. consumer health - Bladder cancer.
  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17963263.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


48. Hillard T: The postmenopausal bladder. Menopause Int; 2010 Jun;16(2):74-80
MedlinePlus Health Information. consumer health - Urinary Incontinence.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The postmenopausal bladder.
  • The bladder and its surrounding structures are rich in estrogen receptors and there are demonstrable physiological and anatomical changes that occur around and immediately after the menopause.
  • The prevalence of many bladder symptoms, such as frequency, urgency and incontinence, does seem to increase around the menopause, but there is continuing debate over whether these effects are due to ageing, menopause or a combination of the two.
  • The impact of the menopause varies with individual symptoms; stress urinary incontinence being associated more with estrogen deficiency than urge incontinence which seems to be more age-related.
  • Based on these effects, it could be anticipated that estrogen replacement would have a positive effect on bladder symptoms.
  • It seems that topical estrogens do have some positive effects, particularly on symptoms of urgency, frequency and urge incontinence, the prevention of urogenital atrophy and in the prevention of recurrent urinary tract infections.
  • The possible explanations for this apparent contradiction are explored, but based on current evidence, it would appear preferable to use vaginal estrogens rather than systemic as part of the management of menopause-related bladder problems.
  • [MeSH-major] Estrogen Replacement Therapy. Postmenopause / physiology. Urinary Bladder / physiopathology. Urinary Incontinence / etiology. Urinary Incontinence / physiopathology
  • [MeSH-minor] Administration, Intravaginal. Age Factors. Female. Humans. Receptors, Estrogen / physiology. Receptors, Progesterone / physiology. Urinary Tract Infections / prevention & control

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20729499.001).
  • [ISSN] 1754-0461
  • [Journal-full-title] Menopause international
  • [ISO-abbreviation] Menopause Int
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Receptors, Estrogen; 0 / Receptors, Progesterone
  •  go-up   go-down


49. Lebret T: [Infiltrating bladder tumours]. Rev Prat; 2007 Mar 31;57(6):630-40
MedlinePlus Health Information. consumer health - Bladder Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Infiltrating bladder tumours].
  • [Transliterated title] Tumeurs infiltrantes de la vessie.
  • Invasive bladder tumours are defined as carcinomas infiltrating the muscular fibbers of the bladder wall.
  • The assessment of tumour extension includes a clinical examination and an abdominopelvic computed tomography.
  • In patients with in situ bladder cancers, this treatment results in a five-year specific survival of 90 percent.
  • After bladder resection, several types of urinary diversion may be considered.
  • The efficiency of the neobladder should be monitored regularly to ensure a satisfactory urinary voiding as well as continence acquisition, which can be achieved through auto-rehabilitation.
  • [MeSH-major] Urinary Bladder Neoplasms / pathology. Urinary Bladder Neoplasms / surgery
  • [MeSH-minor] Cystectomy. Diagnostic Imaging. Humans. Neoplasm Invasiveness. Urinary Diversion

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17593787.001).
  • [ISSN] 0035-2640
  • [Journal-full-title] La Revue du praticien
  • [ISO-abbreviation] Rev Prat
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] France
  • [Number-of-references] 10
  •  go-up   go-down


50. Zhang X, Gupta R, Nicastri AD: Bladder adenocarcinoma following gastrocystoplasty. J Pediatr Urol; 2010 Oct;6(5):525-7
MedlinePlus Health Information. consumer health - Bladder Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Bladder adenocarcinoma following gastrocystoplasty.
  • Bladder augmentation with segments of small bowel (ileocystoplasty), large intestine (colocystoplasty) or stomach (gastrocystoplasty) has been used to treat patients with small or noncompliant bladders by increasing the capacity or compliance.
  • Carcinomas following gastrocystoplasty have been observed in the segments of stomach; however, to our knowledge, carcinoma arising in the residual native bladder has not been reported.
  • We report the first case of adenocarcinoma arising in the residual native bladder in association with intestinal metaplasia and dysplasia of bladder mucosa 17 years following gastrocystoplasty.
  • Intestinal metaplasia secondary to recurrent urinary infection, chronic inflammation, and some form of irritation may potentiate the development of native bladder adenocarcinoma.
  • Patients with gastrocystoplasty are at an increased risk for carcinoma in stomach segments and require close long-term follow up; however, the risk of carcinoma in native bladder is still unclear.
  • [MeSH-major] Adenocarcinoma / etiology. Urinary Bladder / surgery. Urinary Bladder Neoplasms / etiology. Urologic Surgical Procedures / adverse effects

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 Journal of Pediatric Urology Company. Published by Elsevier Ltd. All rights reserved.
  • (PMID = 20392671.001).
  • [ISSN] 1873-4898
  • [Journal-full-title] Journal of pediatric urology
  • [ISO-abbreviation] J Pediatr Urol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  •  go-up   go-down


51. Morsi MI, Youssef AI, Hassouna ME, El-Sedafi AS, Ghazal AA, Zaher ER: Telomerase activity, cytokeratin 20 and cytokeratin 19 in urine cells of bladder cancer patients. J Egypt Natl Canc Inst; 2006 Mar;18(1):82-92
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Telomerase activity, cytokeratin 20 and cytokeratin 19 in urine cells of bladder cancer patients.
  • AIM OF THE STUDY: This work aims to search for markers suitable for the screening of bladder cancer, which should be specific, sensitive, reproducible, non-invasive and at acceptable cost.
  • PATIENTS AND METHODS: The study included 50 patients diagnosed as bladder cancer (35 TCC, 15 SCC) of different stages and grades, 30 patients with various urothelial diseases, besides 20 apparently healthy subjects of matched age and sex to the malignant group.
  • RESULTS: For all parameters (telomerase, K19, K20 and cytology) the malignant group was significantly different from both the benign and the control groups.
  • CONCLUSION: K 19 may be used as a biological marker for the diagnosis of bladder cancer.
  • K19 could not be used for differential diagnosis of different types of bladder cancer, meanwhile it could be a marker for differentiation that decreases in less differentiated tumors.
  • As a tumor marker, K20 reflects inability to differentiate tumor type or grade in TCC, while in SCC of the bladder it is correlated with the grade.
  • As a method, RT-PCR is superior to immunostaining for the detection of bladder cancer, meanwhile K20 immunohistochemistry (IHC) results were much better than urine cytology as a bladder cancer screening test.
  • Haematuria and inflammation reduced the specificity of telomerase assay, which reduced its validity as a tumor marker of bladder cancer.
  • K19 and K20 are the best candidates as screening tests for the diagnosis of bladder cancer, representing the highest sensitivity and specificity, beside the radiological and histopathology.
  • [MeSH-major] Biomarkers, Tumor / urine. Keratin-18 / urine. Keratin-20 / urine. Telomerase / urine. Urinary Bladder Neoplasms / urine
  • [MeSH-minor] False Positive Reactions. Female. Humans. Immunohistochemistry. Male. Mass Screening / methods. Middle Aged. Neoplasm Staging. ROC Curve. Reverse Transcriptase Polymerase Chain Reaction. Sensitivity and Specificity

  • Genetic Alliance. consumer health - Bladder cancer.
  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17237854.001).
  • [ISSN] 1110-0362
  • [Journal-full-title] Journal of the Egyptian National Cancer Institute
  • [ISO-abbreviation] J Egypt Natl Canc Inst
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Egypt
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Keratin-18; 0 / Keratin-20; EC 2.7.7.49 / Telomerase
  •  go-up   go-down


52. Engholm G, Hakulinen T, Gislum M, Tryggvadóttir L, Klint A, Bray F, Storm HH: Trends in the survival of patients diagnosed with kidney or urinary bladder cancer in the Nordic countries 1964-2003 followed up to the end of 2006. Acta Oncol; 2010 Jun;49(5):655-64
MedlinePlus Health Information. consumer health - Kidney Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Trends in the survival of patients diagnosed with kidney or urinary bladder cancer in the Nordic countries 1964-2003 followed up to the end of 2006.
  • BACKGROUND: Previous studies have shown systematic differences between the Nordic Countries in population-based relative survival following a kidney or urinary bladder cancer diagnosis.
  • Comparison of bladder cancer over time and between Nordic registries is complicated by variable coding practices with respect to the inclusion of in situ cases with invasive tumours.
  • MATERIAL AND METHODS: Five-year relative survival of patients with urinary cancer diagnosed in the Nordic countries 1964-2003 and followed up for death through 2006 was studied and contrasted with developments in incidence and mortality.
  • RESULTS: The survival following bladder cancer was higher than for kidney cancer and highest for men.
  • Survival increased over the years in all countries, more for kidney cancer than bladder cancer.
  • Danish bladder cancer patient survival was in the last period 4% points lower among men and 10% points lower among women than in the other Nordic countries.
  • The differences were mainly found in the first year following diagnosis, where a higher excess mortality in Denmark was observed.
  • Survival decreased with higher age at diagnosis.
  • CONCLUSION: The increasing 5-year relative survival in all the Nordic countries for both kidney and bladder cancer are promising, but for kidney cancer a higher percentage detected coincidentally during an imaging investigation for other diseases could play a role.
  • Denmark had the lowest survival, despite their known practice of including benign conditions with invasive bladder cancers.
  • The lower Danish survival after kidney and bladder cancer in the first year after diagnosis could be due to later diagnosis on average, a higher co-morbidity from smoking-related diseases, and perhaps, less adequate cancer treatment and management in Denmark.
  • [MeSH-major] Kidney Neoplasms / mortality. Urinary Bladder Neoplasms / mortality
  • [MeSH-minor] Adult. Age Distribution. Aged. Aged, 80 and over. Denmark / epidemiology. Female. Finland / epidemiology. Follow-Up Studies. Humans. Iceland / epidemiology. Incidence. Male. Mass Screening. Middle Aged. Mortality / trends. Neoplasm Staging. Norway / epidemiology. Registries. Risk Factors. Survival Analysis. Survival Rate / trends. Sweden / epidemiology

  • Genetic Alliance. consumer health - Kidney cancer.
  • Genetic Alliance. consumer health - Bladder cancer.
  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20156116.001).
  • [ISSN] 1651-226X
  • [Journal-full-title] Acta oncologica (Stockholm, Sweden)
  • [ISO-abbreviation] Acta Oncol
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down


53. Hautmann RE: [Ileal bladder substitute]. Urologe A; 2008 Jan;47(1):33-4, 36-40

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Ileal bladder substitute].
  • The history of urinary diversion in general began in 1852 and started right away with continent diversion, i.e., ureterosigmoidostomy.
  • They replaced the bladder by an isoperistaltic ileal segment which was interposed between ureters and urethra in a female dog.
  • In 1951 Couvelaire reactivated this idea of an ileal bladder substitute.
  • Retrospectively many disappointing results of urinary diversion were often not caused by insufficient competence of the outlet mechanism, but because the intestinal reservoir maintained its peristaltic properties causing high pressure peaks.
  • Transsection of the circular intestinal musculature when performing bladder augmentation had already been published by Rutkowski in 1899, Tasker in 1953, and Giertz in 1957.
  • Reflux prevention in neobladders is even less important than in a normal bladder.
  • In these patients life is similar to that in individuals with a native lower urinary tract.
  • Until a better solution is devised orthotopic bladder reconstruction remains the best option for patients requiring cystectomy.
  • [MeSH-major] Urinary Diversion / history. Urinary Reservoirs, Continent / history

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Br J Urol. 1996 Dec;78(6):840-6 [9014706.001]
  • [Cites] J Urol. 2006 Jan;175(1):185-9; discussion 189 [16406905.001]
  • [Cites] J Urol. 1987 Nov;138(5):1150-4 [3312639.001]
  • [Cites] Ann R Coll Surg Engl. 1970 Jun;46(6):320-37 [5420581.001]
  • [Cites] Br J Urol. 1953 Dec;25(4):349-57 [13115674.001]
  • [Cites] Urol Res. 1985;13(5):243-7 [4060368.001]
  • [Cites] J Urol. 1953 Oct;70(4):600-4 [13097637.001]
  • [Cites] Ann Surg. 1943 Jan;117(1):106-9 [17858159.001]
  • [Cites] Arch Surg. 1969 Aug;99(2):223-31 [5794896.001]
  • [Cites] Urol Clin North Am. 1986 May;13(2):321-31 [3515728.001]
  • [Cites] Urologe A. 1987 Mar;26(2):67-73 [3296394.001]
  • [Cites] Eur Urol. 1976;2(1):8-12 [971687.001]
  • [Cites] J Urol. 2005 Jan;173(1):144-7 [15592057.001]
  • [Cites] J Urol. 1957 Dec;78(6):683-720 [13482070.001]
  • [Cites] Acta Chir Scand. 1957 Oct 4;113(3):218-28 [13478409.001]
  • [Cites] Eur Urol. 1988;14 Suppl 1:36-40 [3181240.001]
  • [Cites] J Urol. 2005 Feb;173(2):482-4 [15643221.001]
  • [Cites] J Urol. 2003 Mar;169(3):834-42 [12576795.001]
  • [Cites] J Urol Medicale Chir. 1951;57(6):408-17 [14889638.001]
  • [Cites] J Urol. 1996 Dec;156(6):1913-7 [8911354.001]
  • [Cites] World J Urol. 2006 Aug;24(3):305-14 [16830152.001]
  • (PMID = 18210063.001).
  • [ISSN] 1433-0563
  • [Journal-full-title] Der Urologe. Ausg. A
  • [ISO-abbreviation] Urologe A
  • [Language] ger
  • [Publication-type] English Abstract; Historical Article; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


54. Waine E, Stott M: Changing treatments for overactive bladder. Nurs Times; 2008 Oct 14-20;104(41):45-8
MedlinePlus Health Information. consumer health - Overactive Bladder.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Changing treatments for overactive bladder.
  • Overactive bladder is a common urological diagnosis which is often untreated as patients fail to seek help for this embarrassing problem.
  • Elizabeth Waine and Mark Stott summarise the symptoms and investigations for overactive bladder and provide an overview of the treatments available.
  • [MeSH-major] Urinary Bladder, Overactive / drug therapy. Urinary Incontinence, Urge / drug therapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18979960.001).
  • [ISSN] 0954-7762
  • [Journal-full-title] Nursing times
  • [ISO-abbreviation] Nurs Times
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Muscarinic Antagonists; 0 / Neuromuscular Agents; 0 / Parasympatholytics; EC 3.4.24.69 / Botulinum Toxins, Type A
  • [Number-of-references] 20
  •  go-up   go-down


55. Carballo Alvarez M, Martínez Vilariño M, Llaga Rodríguez M: [Bladder cleansing]. Rev Enferm; 2008 Jan;31(1):27-30
MedlinePlus Health Information. consumer health - Bladder Diseases.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Bladder cleansing].
  • [Transliterated title] Lavado vesical.
  • Bladder cleansings are administered in order to maintain the permeability of a probe and/or to eliminate an obstruction, be it a clot, urinary sand or detritus, by means of an infusion of intravenous fluid using sterile procedures through a bladder catheter.
  • This is a technique frequently used with patients undergoing genital-urinary surgery; it is not recommended for routine usage due to its high risk of associated infection.
  • Bladder cleansing can be continuous by means of a permanent bladder cleansing method or intermittent by means of an open or closed system.
  • [MeSH-major] Therapeutic Irrigation. Urinary Bladder Diseases / therapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18497003.001).
  • [ISSN] 0210-5020
  • [Journal-full-title] Revista de enfermería (Barcelona, Spain)
  • [ISO-abbreviation] Rev Enferm
  • [Language] spa
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Spain
  •  go-up   go-down


56. Fatela-Cantillo D, Fernández-Suárez A, Menéndez V, Galán JA, Filella X: Low utility of CYFRA 21-1 serum levels for diagnosis and follow-up in bladder cancer patients. J Clin Lab Anal; 2005;19(4):167-71
MedlinePlus Health Information. consumer health - Bladder Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Low utility of CYFRA 21-1 serum levels for diagnosis and follow-up in bladder cancer patients.
  • We evaluated serum levels of soluble fragments of cytokeratin 19 (CYFRA 21-1) by immunoassay (ES-700; Roche Diagnostics, Mannheim, Germany) to assess its usefulness in the diagnosis and follow-up of bladder cancer.
  • The study included 39 patients with a diagnosis of transitional cell carcinoma (group 1) and 190 patients (group 2) with no evidence of tumor.
  • In group 2, 180 patients had a history of bladder cancer, and 10 had benign prostatic hyperplasia.
  • However, CYFRA 21-1 levels did not significantly differ between the patients with benign prostatic hyperplasia and those with bladder cancer (P=0.274).
  • CYFRA 21-1 values were higher in invasive bladder cancer compared to that detected in superficial stages (P=0.011).
  • CYFRA 21-1 serum levels do not provide enough sensitivity to justify its application in routine protocols for the detection and follow-up of bladder cancer.
  • [MeSH-major] Antigens, Neoplasm / blood. Keratins / blood. Urinary Bladder Neoplasms / blood. Urinary Bladder Neoplasms / diagnosis
  • [MeSH-minor] Adult. Aged. Biomarkers, Tumor / blood. Female. Follow-Up Studies. Humans. Keratin-19. Male. Middle Aged

  • Genetic Alliance. consumer health - Bladder cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16025482.001).
  • [ISSN] 0887-8013
  • [Journal-full-title] Journal of clinical laboratory analysis
  • [ISO-abbreviation] J. Clin. Lab. Anal.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / Biomarkers, Tumor; 0 / Keratin-19; 0 / antigen CYFRA21.1; 68238-35-7 / Keratins
  •  go-up   go-down


57. Behzatoğlu K, Durak H, Canberk S, Aydin O, Huq GE, Oznur M, Ozyalvaçli G, Yildiz P: Giant cell tumor-like lesion of the urinary bladder: a report of two cases and literature review; giant cell tumor or undifferentiated carcinoma? Diagn Pathol; 2009;4:48

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Giant cell tumor-like lesion of the urinary bladder: a report of two cases and literature review; giant cell tumor or undifferentiated carcinoma?
  • Giant cell tumor, excluding its prototype in bone, is usually a benign but local aggressive neoplasm originating from tendon sheath or soft tissue.
  • Visceral organ involvement including urinary bladder is rare.
  • Giant cell tumors in visceral organs usually accompany epithelial tumors and the clinical behavior of giant cell tumor in urinary bladder is similar to its bone counterpart.
  • Here, we report two cases of giant cell tumor located in urinary bladder in comparison with nine reported cases in the English literature.
  • One of the two cases we present had no concurrent urothelial tumor at the time of diagnosis but had a history of a low grade noninvasive urothelial carcinoma with three recurrences.
  • The histology of these two cases was similar to the giant cell tumor of bone and composed of oval to spindle mononuclear cells with evenly spaced osteoclast-like giant cells.
  • The histologic and immunohistochemical properties in our cases as well as their clinical courses were consistent with a giant cell tumor.
  • Consequently, tumors in urinary bladder showing features of giant cell tumor of bone may also be considered and termed "giant cell tumor".

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer. 1998 Apr 1;82(7):1279-87 [9529019.001]
  • [Cites] J Urol. 2002 Apr;167(4):1784 [11912413.001]
  • [Cites] J Orthop Sci. 2005 Nov;10(6):581-8 [16307183.001]
  • [Cites] Mod Pathol. 2006 Feb;19(2):161-71 [16322750.001]
  • [Cites] Am J Surg Pathol. 2006 Apr;30(4):495-500 [16625096.001]
  • [Cites] Eur Arch Otorhinolaryngol. 2007 Feb;264(2):205-8 [16977452.001]
  • [Cites] Mod Pathol. 2001 Dec;14(12):1209-15 [11743042.001]
  • [Cites] Am J Surg Pathol. 2002 Nov;26(11):1467-76 [12409723.001]
  • [Cites] Pathol Int. 2003 Jul;53(7):450-6 [12828610.001]
  • [Cites] Arch Pathol Lab Med. 2004 Apr;128(4):440-3 [15043462.001]
  • [Cites] BMC Urol. 2004 Jun 18;4:7 [15207006.001]
  • [Cites] Am J Surg Pathol. 2004 Jul;28(7):953-61 [15223968.001]
  • [Cites] Cancer. 1973 Mar;31(3):621-5 [4693590.001]
  • [Cites] Am J Clin Pathol. 1984 May;81(5):666-75 [6326564.001]
  • [Cites] J Urol. 1985 Mar;133(3):472-5 [3974000.001]
  • [Cites] J Urol. 1989 Jul;142(1):120-2 [2733086.001]
  • [Cites] Arch Pathol Lab Med. 1987 Jan;111(1):43-8 [2432851.001]
  • [Cites] Am J Surg Pathol. 1991 Feb;15(2):160-8 [1989464.001]
  • [Cites] Histopathology. 1990 Nov;17(5):413-8 [1706298.001]
  • [Cites] J Oral Pathol Med. 1999 Feb;28(2):54-8 [9950250.001]
  • (PMID = 20043822.001).
  • [ISSN] 1746-1596
  • [Journal-full-title] Diagnostic pathology
  • [ISO-abbreviation] Diagn Pathol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2811699
  •  go-up   go-down


58. Nerli RB, Kamat GV, Alur SS, Koura A, Prabha V, Amarkhed SS: Bladder exstrophy in adulthood. Indian J Urol; 2008 Apr;24(2):164-8

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Bladder exstrophy in adulthood.
  • BACKGROUND: We report our experience with the treatment of classic exstrophy of the bladder in a small series of seven adult males.
  • There are very few documented cases of adults presenting with exstrophy of bladder in literature.
  • MATERIALS AND METHODS: Adult males presenting with classic exstrophy of the bladder and complete epispadias underwent detailed evaluation including psychological assessment and counseling.
  • Prior to 2002 all patients underwent cystectomy of the existing bladder plate, with creation of catheterizable modified Mainz pouch.
  • Since 2002 patients were assessed for bladder reconstruction with augmentation ileocystoplasty, bladder neck reconstruction, and abdominal wall closure.
  • RESULTS: Seven adult males with classic exstrophy of the bladder and complete epispadias who had not received any previous treatment presented to us during the period 1991-2006.
  • Five of these underwent cystectomy with continent pouch and the remaining two underwent bladder reconstruction.
  • CONCLUSIONS: Surgical correction in adults with exstrophy of the bladder greatly improves self-esteem, confidence, and social relationship.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Urol Clin North Am. 1983 Aug;10(3):473-81 [6623735.001]
  • [Cites] Urology. 1973 Jul;2(1):20-4 [4148867.001]
  • [Cites] J Urol. 1966 Mar;95(3):356-9 [5906001.001]
  • [Cites] BJU Int. 2004 May;93(7):1037-42 [15142160.001]
  • [Cites] Urology. 2001 May;57(5):906-10 [11337291.001]
  • [Cites] J Urol. 2005 May;173(5):1728-31 [15821570.001]
  • [Cites] J Urol. 1999 Jun;161(6):1934-41 [10332476.001]
  • [Cites] J Urol. 1997 Mar;157(3):947-8 [9072609.001]
  • [Cites] Int Urol Nephrol. 1996;28(6):747-50 [9089040.001]
  • [Cites] J Urol. 1996 Dec;156(6):2037-40 [8911384.001]
  • [Cites] J Urol (Paris). 1992;98(1):64-5 [1527404.001]
  • [Cites] Teratology. 1987 Oct;36(2):221-7 [3424208.001]
  • [Cites] Urol Int. 1987;42(1):74-6 [3590408.001]
  • (PMID = 19468391.001).
  • [ISSN] 0970-1591
  • [Journal-full-title] Indian journal of urology : IJU : journal of the Urological Society of India
  • [ISO-abbreviation] Indian J Urol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] India
  • [Other-IDs] NLM/ PMC2684262
  • [Keywords] NOTNLM ; Adult / augmentation ileocystoplasty / bladder reconstruction / epispadias / exstrophy bladder
  •  go-up   go-down


59. Mori Y, Maruyama T, Kondoh N, Nojima M, Yamamoto S, Shima H: [Orthotopic bladder substitution]. Hinyokika Kiyo; 2006 Jun;52(6):427-30

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Orthotopic bladder substitution].
  • Orthotopic bladder substitution is the most desired form of urinary diversion because the patient can restore normal voiding after cystectomy.
  • Each method of bladder substitution has merits and demerits.
  • We compared the Mainz method and the Studer method of orthotopic bladder substitution we performed on 8 and 11 patients, respectively since 1992.
  • The Studer orthotopic ileal bladder substitution has given better results with better voiding pattern and less complication rates.
  • We consider the Studer ileal bladder substitution as a good technique to restore normal voiding after cystectomy.
  • [MeSH-major] Ileum / surgery. Urinary Diversion / methods. Urinary Reservoirs, Continent

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16848355.001).
  • [ISSN] 0018-1994
  • [Journal-full-title] Hinyokika kiyo. Acta urologica Japonica
  • [ISO-abbreviation] Hinyokika Kiyo
  • [Language] jpn
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


60. Srivastava S, Roy R, Singh S, Kumar P, Dalela D, Sankhwar SN, Goel A, Sonkar AA: Taurine - a possible fingerprint biomarker in non-muscle invasive bladder cancer: A pilot study by 1H NMR spectroscopy. Cancer Biomark; 2010;6(1):11-20
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Taurine - a possible fingerprint biomarker in non-muscle invasive bladder cancer: A pilot study by 1H NMR spectroscopy.
  • Urinary bladder cancer is a major epidemiological problem that continues to grow each year.
  • In this pilot study, utility of non-invasive (1)H NMR spectroscopy has been evaluated for probing the metabolic perturbations occurring in non-muscle invasive urinary bladder cancer. (1)H NMR spectra of urine of bladder cancer patients and controls (healthy and urinary tract infection/bladder stone) (n = 103) were acquired at 400MHz.
  • The cancer patients showed significant (p < 0.05) variations in concentration of hippurate and citrate as compared with healthy controls and benign controls.
  • The significant elevation in concentration of taurine was observed in urine of bladder cancer patients, which was below the sensitivity limit of 400MHz in control cases.
  • [MeSH-major] Biomarkers, Tumor / urine. Early Detection of Cancer / methods. Magnetic Resonance Spectroscopy / methods. Taurine / urine. Urinary Bladder Neoplasms / diagnosis
  • [MeSH-minor] Adult. Aged. Carcinoma in Situ / diagnosis. Carcinoma in Situ / metabolism. Humans. Male. Middle Aged. Neoplasm Staging. Pilot Projects. Protons. Sensitivity and Specificity. Young Adult

  • Genetic Alliance. consumer health - Bladder cancer.
  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • Hazardous Substances Data Bank. Taurine .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20164538.001).
  • [ISSN] 1875-8592
  • [Journal-full-title] Cancer biomarkers : section A of Disease markers
  • [ISO-abbreviation] Cancer Biomark
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Protons; 1EQV5MLY3D / Taurine
  •  go-up   go-down


61. Matsushima M, Asakura H, Sakamoto H, Horinaga M, Nakahira Y, Yanaihara H: Leiomyoma of the bladder presenting as acute urinary retention in a female patient: urodynamic analysis of lower urinary tract symptom; a case report. BMC Urol; 2010;10:13
MedlinePlus Health Information. consumer health - Bladder Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Leiomyoma of the bladder presenting as acute urinary retention in a female patient: urodynamic analysis of lower urinary tract symptom; a case report.
  • BACKGROUND: Most bladder tumors are derived from the urothelium.
  • Benign mesenchymal tumors are rare.
  • Leiomyoma of the bladder is the most common benign neoplasm.
  • We present a case of leiomyoma of the bladder presenting with acute urinary retention in a female patient and report on the post-operative change in urodynamic findings.
  • CASE PRESENTATION: A 56-year-old woman presented with acute urinary retention.
  • Evaluations including ultrasound, magnetic resonance imaging, cystoscopy, and urodynamics contributed to a diagnosis of leiomyoma of the bladder.
  • Various medications were ineffective for solving her lower urinary tract symptoms; therefore, a transurethral resection was performed.
  • CONCLUSIONS: Leiomyoma of the bladder can cause female outlet obstruction.
  • [MeSH-major] Leiomyoma / complications. Leiomyoma / physiopathology. Urinary Bladder Neoplasms / complications. Urinary Bladder Neoplasms / physiopathology. Urinary Retention / etiology. Urodynamics
  • [MeSH-minor] Female. Humans. Magnetic Resonance Imaging. Manometry. Middle Aged. Treatment Outcome. Urinary Bladder Neck Obstruction / etiology. Urologic Surgical Procedures / methods

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Neurourol Urodyn. 2000;19(3):213-20 [10797578.001]
  • [Cites] Arch Esp Urol. 1991 Sep;44(7):795-8 [1953060.001]
  • [Cites] Urology. 1994 Feb;43(2):238-41 [8116123.001]
  • [Cites] Arch Esp Urol. 1995 Dec;48(10):987-90 [8588732.001]
  • [Cites] AJR Am J Roentgenol. 1997 Feb;168(2):399-403 [9016215.001]
  • [Cites] Urology. 1998 Mar;51(3):408-11 [9510344.001]
  • [Cites] Urology. 1998 Dec;52(6):1142-3 [9836573.001]
  • [Cites] Urology. 2007 Oct;70(4):807-8 [17991566.001]
  • [Cites] Saudi J Kidney Dis Transpl. 2008 Mar;19(2):232-5 [18310873.001]
  • [Cites] Can J Urol. 2009 Aug;16(4):4762-4 [19671234.001]
  • (PMID = 20684762.001).
  • [ISSN] 1471-2490
  • [Journal-full-title] BMC urology
  • [ISO-abbreviation] BMC Urol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2924335
  •  go-up   go-down


62. Burks FN, Bui DT, Peters KM: Neuromodulation and the neurogenic bladder. Urol Clin North Am; 2010 Nov;37(4):559-65
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Neuromodulation and the neurogenic bladder.
  • Neurogenic bladder resulting from spinal cord injury and spina bifida has a profound impact on voiding function.
  • This article reviews the current literature with regards to electrical stimulation for neurogenic bladder and the clinical outcomes associated with sacral neuromodulation, pudendal neuromodulation, posterior tibial nerve stimulation, and the Finetech-Brindley posterior/anterior stimulator.
  • Neuromodulation, both electrical and physical, play an important role in the management of neurogenic bladder.
  • [MeSH-major] Electric Stimulation Therapy. Urinary Bladder, Neurogenic / therapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 Elsevier Inc. All rights reserved.
  • (PMID = 20955907.001).
  • [ISSN] 1558-318X
  • [Journal-full-title] The Urologic clinics of North America
  • [ISO-abbreviation] Urol. Clin. North Am.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  •  go-up   go-down


63. Otto W, Fritsche HM, Dirmeyer M, Burger M, Straub M, Rössler W, Wieland WF, Denzinger S: [Analysis of Clinical, Histopathological and Follow-Up Data on Transurethral Resections of the Bladder Performed during One Year at a University Centre]. Aktuelle Urol; 2010 Sep;41(5):316-9
MedlinePlus Health Information. consumer health - Bladder Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Analysis of Clinical, Histopathological and Follow-Up Data on Transurethral Resections of the Bladder Performed during One Year at a University Centre].
  • [Transliterated title] Untersuchung klinischer und histopathologischer Parameter sowie von Verlaufsdaten zur transurethralen Resektion der Harnblase an einem universitären Einzelzentrum.
  • INTRODUCTION: Transurethral resection of the bladder (TURB) is one of the most common surgical treatments in urology.
  • We examined the TURBs that had been carried out during one year for suspected bladder cancer (first findings and recurrence) and then analysed the further clinical courses of these patients within the first twelve months after TURB.
  • All initial and recurrence TURB were carried out with photodynamic diagnosis; the histological evaluation was performed at a university centre.
  • RESULTS: 71 % of the 118 initial resections performed during the observation period showed urothelial cell carcinoma of the bladder - pTa (61 %), pT1 (20 %), pT2-4 (17 %), Cis (2 %) while 60 re-TURBs in the whole period detected 17 % residual tumours.
  • Two patients (7 %) with initially benign findings developed bladder cancer in the follow-up period.
  • When bladder cancer is diagnosed in 7 % within one year after urocystitis has been detected in the initial TURB findings, regular follow-up examination of these patients, especially with certain risk profiles, has to be discussed.
  • [MeSH-major] Cystoscopy. Urinary Bladder Neoplasms / pathology. Urinary Bladder Neoplasms / surgery
  • [MeSH-minor] Administration, Intravesical. Adult. Aged. Aged, 80 and over. Chemotherapy, Adjuvant. Combined Modality Therapy. Cystectomy. Female. Humans. Male. Middle Aged. Neoplasm Recurrence, Local / diagnosis. Neoplasm Recurrence, Local / pathology. Neoplasm Recurrence, Local / surgery. Neoplasm Staging. Neoplasm, Residual / diagnosis. Neoplasm, Residual / drug therapy. Neoplasm, Residual / pathology. Neoplasm, Residual / surgery. Retrospective Studies. Urinary Bladder / pathology. Urinary Bladder / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Georg Thieme Verlag Stuttgart * New York.
  • (PMID = 20669097.001).
  • [ISSN] 1438-8820
  • [Journal-full-title] Aktuelle Urologie
  • [ISO-abbreviation] Aktuelle Urol
  • [Language] ger
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


64. Henderson E, Drake M: Overactive bladder. Maturitas; 2010 Jul;66(3):257-62
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Overactive bladder.
  • Overactive bladder is a condition whose prevalence increases with ageing, and which can substantially impair quality of life.
  • It is defined by presence of urinary urgency, in the absence of other causes of similar problems.
  • The underlying mechanisms are incompletely understood, but may include increased excitability of smooth muscle, abnormal spread of excitation through the bladder wall, increased sensory nerve activity, and altered processing of information in the central nervous system.
  • Initial treatment comprises fluid advice and bladder training, followed by drug prescription.
  • Neuromodulatory techniques (sacral or tibial nerve stimulation) and reconstructive surgery (augmentation cystoplasty, detrusor myectomy or urinary diversion) can be offered in severe cases, but can have inadequate outcomes and significant implications.
  • [MeSH-major] Urinary Bladder / physiopathology. Urinary Bladder, Overactive / therapy. Urinary Incontinence, Urge / therapy

  • MedlinePlus Health Information. consumer health - Overactive Bladder.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 Elsevier Ireland Ltd. All rights reserved.
  • (PMID = 20399043.001).
  • [ISSN] 1873-4111
  • [Journal-full-title] Maturitas
  • [ISO-abbreviation] Maturitas
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Ireland
  • [Number-of-references] 54
  •  go-up   go-down


65. Drake MJ: The integrative physiology of the bladder. Ann R Coll Surg Engl; 2007 Sep;89(6):580-5
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The integrative physiology of the bladder.
  • Normal bladder function is complex, resulting from the co-operative interaction of numerous regulatory cell types, of which the interstitial cells and the peripheral neurones are particularly interesting.
  • Collectively, these comprise the myovesical plexus, which appears to confer structural and functional characteristics on the bladder loosely akin to those of the gut.
  • These include functional modularity, which gives rise to the potential for localised and propagating peristalsis-like movements in the bladder wall according to the prevailing physiological conditions.
  • Localised modular activity during filling may contribute to normal generation of sensation and exaggerated modular activity may give rise to urinary urgency.
  • Enhanced co-ordination of modular activity occurs in various models of detrusor overactivity; it leads to surges of contraction over a large part of the bladder wall, generating phasic changes in intravesical pressure.
  • During voiding, the myovesical plexus sustains detrusor contraction at the behest of the brainstem, monitoring state of bladder fullness as it does so, as a guide to the required duration for which it has to keep up the effort.
  • Accordingly, the bladder wall itself may house structures which render the bladder the effector level in a hierarchy of lower urinary tract regulation.
  • Dysfunction in these vital regulatory structures is an underestimated factor in the pathophysiology of clinical bladder problems.
  • [MeSH-major] Urinary Bladder / physiology. Urinary Bladder Diseases / physiopathology

  • MedlinePlus Health Information. consumer health - Bladder Diseases.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Lab Invest. 2000 Oct;80(10):1491-9 [11045565.001]
  • [Cites] BJU Int. 2006 Sep;98(3):643-50 [16925766.001]
  • [Cites] J Urol. 2002 Aug;168(2):832-6 [12131376.001]
  • [Cites] Exp Physiol. 2003 Jan;88(1):19-30 [12525852.001]
  • [Cites] J Urol. 2003 Apr;169(4):1573-6 [12629418.001]
  • [Cites] BJU Int. 2003 May;91(7):702-10 [12699489.001]
  • [Cites] Exp Physiol. 2003 May;88(3):343-57 [12719759.001]
  • [Cites] J Urol. 2003 Jul;170(1):276-9 [12796704.001]
  • [Cites] J Physiol. 2004 Sep 1;559(Pt 2):567-81 [15235094.001]
  • [Cites] Neurourol Urodyn. 1993;12(5):463-71 [8252050.001]
  • [Cites] J Anat. 1997 Jan;190 ( Pt 1):125-34 [9034888.001]
  • [Cites] BJU Int. 2005 May;95(7):1002-5 [15839921.001]
  • [Cites] J Urol. 2006 Feb;175(2):771-6 [16407048.001]
  • [Cites] BJU Int. 2006 Mar;97(3):612-6 [16469036.001]
  • [Cites] BJU Int. 2006 Jun;97(6):1332-7 [16686734.001]
  • [Cites] Auton Autacoid Pharmacol. 2006 Jul;26(3):253-60 [16879490.001]
  • [Cites] Auton Autacoid Pharmacol. 2006 Jul;26(3):261-6 [16879491.001]
  • [Cites] Lancet. 2001 Aug 4;358(9279):401-3 [11502339.001]
  • (PMID = 18201471.001).
  • [ISSN] 1478-7083
  • [Journal-full-title] Annals of the Royal College of Surgeons of England
  • [ISO-abbreviation] Ann R Coll Surg Engl
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Number-of-references] 19
  • [Other-IDs] NLM/ PMC2121225
  •  go-up   go-down


66. Nicola M, De Luca F: Bladder hernia. Arch Ital Urol Androl; 2006 Jun;78(2):77-8
MedlinePlus Health Information. consumer health - Bladder Diseases.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Bladder hernia.
  • Bladder hernia is a rare condition, but crural herniation of the bladder into the scrotum is very rare.
  • A case of bladder hernia presenting with urological symptoms is described.
  • A 71-year-old man presented to the urological ward complaining for persistent frequency and nocturia associated with loss offorce and decrease of caliber of the urinary stream and the presence of a large mass of the right scrotum.
  • An IVP (intra venous pyelography) showed a large herniation of the bladder through the right inguinal canal into the scrotum.
  • The hernia sac, containing bowel and bladder, was dissectedfreefrom the spermatic cord and the testis and the hernia defect was repaired.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16929610.001).
  • [ISSN] 1124-3562
  • [Journal-full-title] Archivio italiano di urologia, andrologia : organo ufficiale [di] Societa italiana di ecografia urologica e nefrologica
  • [ISO-abbreviation] Arch Ital Urol Androl
  • [Language] ENG
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


67. Freeman RM, Adekanmi OA: Overactive bladder. Best Pract Res Clin Obstet Gynaecol; 2005 Dec;19(6):829-41
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Overactive bladder.
  • The overactive bladder is a common condition, which has significant effects on quality of life.
  • Management includes excluding pathology and implementing behavioural changes such as caffeine reduction, bladder and pelvic floor training, as well as antimuscarinic drug therapy.
  • [MeSH-major] Urinary Bladder Diseases / physiopathology
  • [MeSH-minor] Behavior Therapy / methods. Cholinergic Antagonists / therapeutic use. Electric Stimulation Therapy / methods. Estrogens / therapeutic use. Female. Humans. Muscle Contraction. Patient Compliance. Pelvic Floor / physiopathology. Prevalence. Quality of Life. Risk Factors. Terminology as Topic. Urinary Incontinence / etiology. Urinary Incontinence / surgery

  • MedlinePlus Health Information. consumer health - Bladder Diseases.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16176887.001).
  • [ISSN] 1521-6934
  • [Journal-full-title] Best practice & research. Clinical obstetrics & gynaecology
  • [ISO-abbreviation] Best Pract Res Clin Obstet Gynaecol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Cholinergic Antagonists; 0 / Estrogens
  • [Number-of-references] 83
  •  go-up   go-down


68. Radosavljević R, Hadzi Djokić J, Aćimović M, Pejcić T, Tulić C, Dzamić Z: [Morphologic characteristics of the urothelial bladder tumors]. Acta Chir Iugosl; 2007;54(4):101-4
MedlinePlus Health Information. consumer health - Bladder Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Morphologic characteristics of the urothelial bladder tumors].
  • Cancer of the urinary bladder is the fourth most common cancer in men and the ninth in women.
  • Approximately 67,000 people (50,000 males and 17,000 females) develop bladder cancer each year in the United States, and 13,750 individuals (9,630 males and 4,120 females) are expected to die from it.
  • In the showing of the morphologic characteristics of the tumors, authors underlining the increasing of the incidence, pathogenesis, premalignant lesions and the risk factors of disease.
  • [MeSH-major] Carcinoma, Transitional Cell / pathology. Urinary Bladder Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18595239.001).
  • [ISSN] 0354-950X
  • [Journal-full-title] Acta chirurgica Iugoslavica
  • [ISO-abbreviation] Acta Chir Iugosl
  • [Language] hrv
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Serbia
  •  go-up   go-down


69. Yoshimura R, Adachi T, Funao K, Kobayakawa H, Matsuyama M, Tsuchida K, Takemoto Y, Nakatani T: Treatment of bladder tumors and benign prostatic hyperplasia with a new TUR system using physiological saline as perfusate. World J Surg; 2006 Mar;30(3):473-7
Hazardous Substances Data Bank. SODIUM CHLORIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treatment of bladder tumors and benign prostatic hyperplasia with a new TUR system using physiological saline as perfusate.
  • We have treated both bladder tumor and benign prostatic hyperplasia cases with this new system.
  • When physiological saline is used as the perfusate, blood electrolyte levels are not greatly changed, even after extensive resection of the bladder wall; as a result, this new system is also cost effective because physiological saline is less expensive than non-electroconductive solutions and requires no counter-electrode.
  • [MeSH-major] Prostatic Hyperplasia / surgery. Sodium Chloride / administration & dosage. Transurethral Resection of Prostate / methods. Urinary Bladder Neoplasms / surgery


70. Tilki D, Singer BB, Shariat SF, Behrend A, Fernando M, Irmak S, Buchner A, Hooper AT, Stief CG, Reich O, Ergün S: CEACAM1: a novel urinary marker for bladder cancer detection. Eur Urol; 2010 Apr;57(4):648-54
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] CEACAM1: a novel urinary marker for bladder cancer detection.
  • BACKGROUND: Carcinoembryonic antigen-related cell adhesion molecule 1 (biliary glycoprotein; CEACAM1) is expressed in normal bladder urothelium and in angiogenically activated endothelial cells, where it exhibits proangiogenic properties.
  • OBJECTIVE: The aim of this study was to evaluate the value of urinary CEACAM1 for detection of urothelial carcinoma of the bladder (UCB).
  • Enzyme-linked immunosorbent assay (ELISA) for CEACAM1 was performed on urine specimens of healthy volunteers (n=30), patients with benign prostatic hyperplasia (BPH; n=5), severe cystitis (n=5), non-muscle-invasive UCB (n=72), muscle-invasive UCB (n=21), or past history of UCB without evidence of disease (n=42).
  • ELISA analysis confirmed that urinary CEACAM1 levels were significantly higher in UCB patients compared with control subjects (median: 207 ng/ml vs 0 ng/ml; p<0.001).
  • CONCLUSIONS: Urinary CEACAM1 levels discriminate UCB patients from non-UCB subjects.
  • Moreover, urinary levels of CEACAM1 increased with advancing stage and grade.
  • [MeSH-major] Antigens, CD / urine. Biomarkers, Tumor / urine. Carcinoma / diagnosis. Cell Adhesion Molecules / urine. Urinary Bladder / chemistry. Urinary Bladder Neoplasms / diagnosis
  • [MeSH-minor] Blotting, Western. Case-Control Studies. Chi-Square Distribution. Endothelial Cells / chemistry. Enzyme-Linked Immunosorbent Assay. Germany. Humans. Immunohistochemistry. Logistic Models. Neoplasm Invasiveness. Neoplasm Staging. Odds Ratio. Predictive Value of Tests. Prognosis. Prospective Studies. Risk Assessment. Risk Factors. Sensitivity and Specificity. Up-Regulation. Urothelium / chemistry


71. Kanematsu A, Yamamoto S, Ogawa O: Changing concepts of bladder regeneration. Int J Urol; 2007 Aug;14(8):673-8
MedlinePlus Health Information. consumer health - Bladder Diseases.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Changing concepts of bladder regeneration.
  • During the last decade, there has been a dramatic increase in studies aimed at regeneration of the urinary bladder.
  • Many studies employed animal-derived or synthetic materials as grafts for experimental bladder augmentation models, with or without additional measures to promote regeneration, such as autologous cell transplantation or growth factor loading.
  • One major problem in these studies is the lack of a clear distinction between native and regenerated bladder in total bladder function after augmentation.
  • In contrast, researchers have recently attempted to establish alternative regenerative strategies for treating bladder diseases, and have employed far more diverse approaches according to the various pathological conditions to be treated.
  • For total replacement of the bladder after cystectomy for invasive bladder cancer, urothelium-covered neobladder with non-urinary tract backbone remains a viable choice.
  • In addition, functional bladder diseases such as urinary incontinence, weak detrusor, or non-compliant fibrotic bladder have also been major targets for many leading research groups in this field.
  • Such altered research direction would inevitably lead to less surgically based basic biological research, and also would include a far wider spectrum of adult and pediatric bladder diseases, from overactive bladder to dysfunctional voiding.
  • [MeSH-major] Regeneration. Urinary Bladder / physiology. Urinary Bladder Diseases / physiopathology. Urinary Bladder Diseases / therapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17681053.001).
  • [ISSN] 0919-8172
  • [Journal-full-title] International journal of urology : official journal of the Japanese Urological Association
  • [ISO-abbreviation] Int. J. Urol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Australia
  • [Number-of-references] 65
  •  go-up   go-down


72. Pascual Mateo C, Nieto Gallego MA, Rodríguez García N, Luján Galán M, Berenguer Sánchez A: [Idiopathic local bladder amyloidosis]. Arch Esp Urol; 2005 Apr;58(3):253-5
MedlinePlus Health Information. consumer health - Bladder Diseases.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Idiopathic local bladder amyloidosis].
  • [Transliterated title] Amiloidosis vesical primaria localizada idiopática.
  • OBJECTIVE: To report one case of primary bladder amyloidosis.
  • RESULTS: Pathologic features were consistent with amyloidosis of the bladder wall.
  • CONCLUSIONS: Local idiopathic bladder amyloidosis is a very rare disease and the most common presenting symptom is painless hematuria.
  • It may be difficult to differentiate between this disease and a urothelial bladder neoplasia.
  • [MeSH-major] Amyloidosis / pathology. Urinary Bladder Diseases / pathology

  • Genetic Alliance. consumer health - Amyloidosis.
  • MedlinePlus Health Information. consumer health - Amyloidosis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15906621.001).
  • [ISSN] 0004-0614
  • [Journal-full-title] Archivos españoles de urología
  • [ISO-abbreviation] Arch. Esp. Urol.
  • [Language] spa
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Spain
  •  go-up   go-down


73. Eloubeidi MA, Varadarajulu S, El-Galley R, Bueschen AJ, Eltoum I: EUS-guided FNA for the diagnosis of recurrent bladder cancer through the ileal conduit: a novel approach. Gastrointest Endosc; 2006 Sep;64(3):450-3
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] EUS-guided FNA for the diagnosis of recurrent bladder cancer through the ileal conduit: a novel approach.
  • BACKGROUND: Diagnosing local recurrence of tumor after cystectomy and ileal conduit construction for urinary bladder cancer remains a diagnostic challenge.
  • Also, distinction of benign stricture from recurrent tumor at the site of ureteral anastomosis in the ileal conduit is difficult.
  • OBJECTIVE: A new method is described for performing EUS-guided FNA through the ileal conduit in patients suspected of having local tumor recurrence after complete cystectomy for bladder cancer.
  • PATIENTS: Three patients who had undergone total cystectomy and ileal conduit construction for bladder cancer underwent EUS-guided FNA through the ileal conduit for evaluation of suspected tumor recurrence at the site of anastomosis of the distal ureter and the ileal conduit.
  • A diagnosis of recurrent transitional cell cancer was made in 2 patients and anastomotic stricture was found in 1 patient.
  • Both patients with tumor recurrence received palliative chemotherapy, and the patient with an anastomotic stricture was managed by placement of a nephrostomy stent.
  • CONCLUSIONS: EUS-guided FNA through the ileal conduit is technically feasible, safe, and establishes diagnosis in patients suspected of tumor recurrence after complete cystectomy for bladder cancer.
  • [MeSH-major] Biopsy, Fine-Needle / methods. Endosonography / methods. Neoplasm Recurrence, Local / ultrasonography. Urinary Bladder Neoplasms / ultrasonography
  • [MeSH-minor] Aged. Aged, 80 and over. Anastomosis, Surgical. Feasibility Studies. Humans. Male. Middle Aged. Prospective Studies. Ultrasonography, Interventional. Urinary Diversion

  • Genetic Alliance. consumer health - Bladder cancer.
  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16923503.001).
  • [ISSN] 0016-5107
  • [Journal-full-title] Gastrointestinal endoscopy
  • [ISO-abbreviation] Gastrointest. Endosc.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


74. Boyle H, Fléchon A, Droz JP: [Uncommon bladder tumours]. Bull Cancer; 2010;97 Suppl Cancer de la vessie:51-7
MedlinePlus Health Information. consumer health - Bladder Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Uncommon bladder tumours].
  • [Transliterated title] Tumeurs rares de la vessie.
  • Bladder tumours are frequent with around 10,000 new cases each year in France.
  • These tumours are possibly secondary to alkylating drug metabolites or pelvic radiotherapy and they have often a poor prognostic outcome.
  • This is also the case of spindle cell carcinoma, an endocrine variant of rare bladder cancers.
  • Other tumours have a more locally invasive pattern, as have urachal adenocarcinomas, sarcomas.
  • The treatment is based on aggressive surgical exeresis of the tumour and surrounding structures.
  • [MeSH-major] Urinary Bladder Neoplasms

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20534390.001).
  • [ISSN] 1769-6917
  • [Journal-full-title] Bulletin du cancer
  • [ISO-abbreviation] Bull Cancer
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] France
  •  go-up   go-down


75. Birder LA: TRPs in bladder diseases. Biochim Biophys Acta; 2007 Aug;1772(8):879-84
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] TRPs in bladder diseases.
  • This review attempts to provide an overview of the current knowledge of TRP proteins and their possible role in bladder function and disease.
  • Of those belonging to the group 1 subfamily, a number of TRPV, TRPM and TRPA proteins associated with osmoregulation, thermal, chemical and mechanical signaling mechanisms have been shown to be expressed within the lower urinary tract.
  • Though the biological role of many of these channels in urinary bladder function still remains elusive, TRPV1 is by far the best characterized and is thought to be involved in a number of bladder disorders [A.

  • MedlinePlus Health Information. consumer health - Bladder Diseases.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Nature. 1997 Oct 23;389(6653):816-24 [9349813.001]
  • [Cites] Urology. 1997 Dec;50(6A Suppl):36-52; discussion 53-6 [9426749.001]
  • [Cites] Pharmacol Ther. 2005 May;106(2):179-208 [15866319.001]
  • [Cites] Neurosci Lett. 2005 Jun 10-17;381(1-2):42-6 [15882787.001]
  • [Cites] J Urol. 1999 Dec;162(6):1890-6 [10569531.001]
  • [Cites] Proc Natl Acad Sci U S A. 2000 May 23;97(11):6155-60 [10823958.001]
  • [Cites] Am J Physiol Renal Physiol. 2000 Jun;278(6):F867-74 [10836974.001]
  • [Cites] Proc Natl Acad Sci U S A. 2000 Jul 5;97(14):8134-9 [10859346.001]
  • [Cites] J Urol. 2000 Sep;164(3 Pt 1):676-9 [10953124.001]
  • [Cites] Nature. 2000 Dec 21-28;408(6815):985-90 [11140687.001]
  • [Cites] Regul Pept. 2001 Sep 15;101(1-3):1-18 [11495674.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Nov 6;98(23):13396-401 [11606761.001]
  • [Cites] Cell. 2002 Mar 8;108(5):705-15 [11893340.001]
  • [Cites] Neuroscience. 2002;109(4):787-98 [11927161.001]
  • [Cites] J Urol. 2002 Jul;168(1):293-7 [12050559.001]
  • [Cites] Science. 2002 Jun 14;296(5575):2046-9 [12016205.001]
  • [Cites] J Physiol. 2002 Aug 15;543(Pt 1):211-20 [12181293.001]
  • [Cites] Nat Neurosci. 2002 Sep;5(9):856-60 [12161756.001]
  • [Cites] Urology. 2003 Nov;62(5):909-13 [14624918.001]
  • [Cites] J Urol. 2004 Feb;171(2 Pt 1):938-43 [14713858.001]
  • [Cites] Urol Int. 2004;72(2):145-9 [14963356.001]
  • [Cites] J Biol Chem. 2004 Feb 20;279(8):7048-54 [14630912.001]
  • [Cites] BJU Int. 2004 Apr;93(6):770-6 [15049988.001]
  • [Cites] J Urol. 2004 Jun;171(6 Pt 1):2492-6 [15126883.001]
  • [Cites] Eur Urol. 2004 Jul;46(1):88-93; discussion 93-4 [15183552.001]
  • [Cites] J Urol. 2005 Sep;174(3):818 [16093961.001]
  • [Cites] J Urol. 2005 Sep;174(3):977-82; discussion 982-3 [16094018.001]
  • [Cites] J Physiol. 2005 Aug 15;567(Pt 1):53-8 [15961428.001]
  • [Cites] Eur J Neurosci. 2005 Aug;22(4):825-34 [16115206.001]
  • [Cites] Br J Urol. 1997 Dec;80(6):845-52 [9439395.001]
  • [Cites] J Urol. 1998 Jul;160(1):34-8 [9628600.001]
  • [Cites] Neurourol Urodyn. 1998;17(5):513-23 [9776014.001]
  • [Cites] World J Urol. 1999 Apr;17(2):126-30 [10367373.001]
  • [Cites] J Urol. 1999 Jul;162(1):3-11 [10379728.001]
  • [Cites] Am J Physiol. 1999 Sep;277(3 Pt 2):R786-94 [10484496.001]
  • [Cites] Urology. 2005 Feb;65(2):400-5 [15708075.001]
  • [Cites] J Cell Sci. 2005 Mar 1;118(Pt 5):917-28 [15713749.001]
  • [Cites] J Urol. 2005 May;173(5):1590-4 [15821499.001]
  • [Cites] Pflugers Arch. 2005 Oct;451(1):160-7 [15952037.001]
  • [Cites] Nat Clin Pract Urol. 2004 Dec;1(2):85-9 [16474520.001]
  • [Cites] Nat Clin Pract Urol. 2005 Oct;2(10):492-501 [16474623.001]
  • [Cites] Nat Clin Pract Urol. 2005 Nov;2(11):546-54 [16474598.001]
  • [Cites] J Neurosci. 2006 Apr 5;26(14):3864-74 [16597741.001]
  • [Cites] Endocr Relat Cancer. 2006 Mar;13(1):27-38 [16601277.001]
  • [Cites] J Urol. 2006 Jun;175(6):2341-4 [16697870.001]
  • [Cites] Biochem Pharmacol. 2006 Jun 28;72(1):104-14 [16725114.001]
  • [Cites] J Urol. 2006 Aug;176(2):797-801 [16813950.001]
  • [Cites] Naunyn Schmiedebergs Arch Pharmacol. 2006 Jul;373(4):287-99 [16721555.001]
  • [Cites] Mol Cell Neurosci. 2006 Aug;32(4):335-43 [16829128.001]
  • [Cites] Neurogastroenterol Motil. 2006 Aug;18(8):590-4 [16918723.001]
  • [Cites] Trends Mol Med. 2006 Nov;12(11):545-54 [16996800.001]
  • [Cites] Eur Urol. 2006 Dec;50(6):1299-305 [16697519.001]
  • [Cites] Nat Clin Pract Urol. 2007 Jan;4(1):46-54 [17211425.001]
  • [Cites] Cell Calcium. 2007 Mar;41(3):285-94 [16949669.001]
  • [Cites] Biochim Biophys Acta. 2007 Aug;1772(8):989-1003 [17321113.001]
  • [Cites] J Urol. 2004 Sep;172(3):1175-8 [15311065.001]
  • [Cites] Eur J Pharmacol. 2004 Oct 1;500(1-3):351-69 [15464045.001]
  • [Cites] J Urol. 1989 Jul;142(1):150-4 [2733095.001]
  • [Cites] J Auton Nerv Syst. 1990 Jul;30 Suppl:S71-7 [2212495.001]
  • [Cites] Ciba Found Symp. 1990;151:77-83; discussion 83-90 [2226067.001]
  • [Cites] Lancet. 1992 May 16;339(8803):1239 [1349978.001]
  • [Cites] Life Sci. 1993;52(20):PL221-6 [8483387.001]
  • [Cites] Brain Res. 1995 Apr 24;678(1-2):40-8 [7620897.001]
  • [Cites] J Urol. 1995 Nov;154(5):1825-9 [7563356.001]
  • [Cites] J Urol. 1997 Feb;157(2):585-9 [8996364.001]
  • [Cites] Am J Physiol. 1997 Apr;272(4 Pt 2):R1271-82 [9140030.001]
  • (PMID = 17560087.001).
  • [ISSN] 0006-3002
  • [Journal-full-title] Biochimica et biophysica acta
  • [ISO-abbreviation] Biochim. Biophys. Acta
  • [Language] ENG
  • [Grant] United States / NIDDK NIH HHS / DK / R01 DK57284; United States / NIDDK NIH HHS / DK / R01 DK54824; United States / NIDDK NIH HHS / DK / R01 DK057284-10; United States / NIDDK NIH HHS / DK / R37 DK054824-13; United States / NIDDK NIH HHS / DK / R01 DK057284; United States / NIDDK NIH HHS / DK / R37 DK054824-12; United States / NIDDK NIH HHS / DK / R01 DK057284-11; United States / NIDDK NIH HHS / DK / R37 DK054824; United States / NIDDK NIH HHS / DK / R56 DK057284; United States / NIDDK NIH HHS / DK / R01 DK054824
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Review
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Transient Receptor Potential Channels
  • [Number-of-references] 74
  • [Other-IDs] NLM/ NIHMS243025; NLM/ PMC3713460
  •  go-up   go-down


76. Carr LK: Overactive bladder. Can J Urol; 2008 Aug;15 Suppl 1:32-6; discussion 36
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Overactive bladder.
  • Overactive bladder (OAB) is a common condition (prevalence 14%-18% of Canadians) and has a significant negative impact on quality of life.
  • OAB may be idiopathic or may occur with other common conditions such as bladder outlet obstruction, neurological disease, or stress incontinence.
  • [MeSH-major] Urinary Bladder, Overactive
  • [MeSH-minor] Behavior Therapy / methods. Canada / epidemiology. Diagnosis, Differential. Humans. Muscarinic Antagonists / therapeutic use. Neuromuscular Agents / therapeutic use. Prevalence. Prognosis. Urodynamics

  • MedlinePlus Health Information. consumer health - Overactive Bladder.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18700063.001).
  • [ISSN] 1195-9479
  • [Journal-full-title] The Canadian journal of urology
  • [ISO-abbreviation] Can J Urol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Canada
  • [Chemical-registry-number] 0 / Muscarinic Antagonists; 0 / Neuromuscular Agents
  • [Number-of-references] 21
  •  go-up   go-down


77. O'Hanlan KA: Cystosufflation to prevent bladder injury. J Minim Invasive Gynecol; 2009 Mar-Apr;16(2):195-7
Hazardous Substances Data Bank. Carbon dioxide .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cystosufflation to prevent bladder injury.
  • STUDY OBJECTIVE: This brief report will share information about the use and safety of inflating the bladder with carbon dioxide to delineate the margins during laparoscopic dissections near the bladder in patients who have scarring, adhesions, or challenging anatomy.
  • Indications included finding of adhesions from earlier cesarean section or massive myomas obscuring bladder margins, or planned anterior colpopexy or vaginal sacrocolpopexy.
  • INTERVENTIONS: Cystosufflation uniformly entailed the following: clamping of the bladder catheter with a Kelly clamp; connection of the laparoscopic carbon-dioxide insufflation tubing to the catheter; then under direct laparoscopic observation, release of the Kelly clamp with immediate bladder inflation revealing the cystic margins.
  • MEASUREMENTS AND MAIN RESULTS: Cystosufflation safely facilitated the dissection of the bladder off the anterior cervix and vagina, or off the anterior abdominal wall.
  • Distention of the bladder elevated and rounded up the bladder margins so that the muscularis could be clearly identified, preventing bladder injury in all patients.
  • [MeSH-major] Carbon Dioxide. Hysterectomy / methods. Insufflation / methods. Intraoperative Complications / prevention & control. Laparoscopy / methods. Urinary Bladder / injuries

  • MedlinePlus Health Information. consumer health - Hysterectomy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19138575.001).
  • [ISSN] 1553-4650
  • [Journal-full-title] Journal of minimally invasive gynecology
  • [ISO-abbreviation] J Minim Invasive Gynecol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 142M471B3J / Carbon Dioxide
  •  go-up   go-down


78. Mann S, Johnson MP, Wilson RD: Fetal thoracic and bladder shunts. Semin Fetal Neonatal Med; 2010 Feb;15(1):28-33
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Fetal thoracic and bladder shunts.
  • Congenital obstructive lesions involving the bladder and the lung can lead to serious complications for the newborn.
  • The in-utero placement of a diverting shunt in the fetal bladder or thoracic cavity can decrease the morbidity and mortality associated with these obstructive conditions.
  • This review focuses on the indications for prenatal evaluation, technique, and outcomes for those fetuses with a lower urinary tract obstruction, congenital pleural effusion or macrocystic congenital cystic adenomatoid malformation after placement of a vesicoamniotic or thoracoamniotic shunt.

  • MedlinePlus Health Information. consumer health - Fetal Health and Development.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2009. Published by Elsevier Ltd.
  • (PMID = 19596218.001).
  • [ISSN] 1878-0946
  • [Journal-full-title] Seminars in fetal & neonatal medicine
  • [ISO-abbreviation] Semin Fetal Neonatal Med
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Netherlands
  • [Number-of-references] 38
  •  go-up   go-down


79. Griffiths D: Imaging bladder sensations. Neurourol Urodyn; 2007 Oct;26(6 Suppl):899-903
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Imaging bladder sensations.
  • Normal bladder sensations progress in a continuum of gradually increasing intensity and unpleasantness, from first sensation of bladder filling, through first desire to void, to strong desire to void.
  • The abnormal sensation of urgency is not part of this continuum and is one of the defining symptoms of the overactive bladder (OAB) syndrome.
  • We have imaged these cerebral responses in female volunteers, either with normal bladder control or with urge incontinence (poor control).
  • Normal bladder filling sensations are mapped mainly in the insula, shifting anteriorly as sensation becomes stronger and more unpleasant.
  • In subjects with poor bladder control, sensations and brain responses are different from normal.
  • Responses are relatively small at low bladder volumes (with mild sensation), but become exaggerated (with strong sensation) above a certain volume threshold, even when there is no actual detrusor overactivity.
  • Based on these results, it is unlikely that abnormal (OAB) responses to bladder filling can be accounted for simply by increased bladder afferent activity, that is, bladder hypersensitivity.
  • [MeSH-major] Brain / physiology. Magnetic Resonance Imaging. Sensation / physiology. Urinary Bladder / innervation. Urinary Incontinence, Urge / physiopathology

  • MedlinePlus Health Information. consumer health - MRI Scans.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2007 Wiley-Liss, Inc.
  • (PMID = 17654564.001).
  • [ISSN] 0733-2467
  • [Journal-full-title] Neurourology and urodynamics
  • [ISO-abbreviation] Neurourol. Urodyn.
  • [Language] eng
  • [Grant] United States / NIA NIH HHS / AG / R01-AG020629; United States / NIA NIH HHS / AG / R03-AG25166
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  • [Number-of-references] 7
  •  go-up   go-down


80. Allen D, Glass J: Transvaginal contraception--avoid the bladder. Int J Clin Pract Suppl; 2005 Apr;(147):87-8
MedlinePlus Health Information. consumer health - Foreign Bodies.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Transvaginal contraception--avoid the bladder.
  • We report two cases of female contraceptive methods, resulting in urological presentation, with bladder foreign bodies.
  • History, mode of diagnosis and surgical extraction technique differed in both patients.
  • A second patient, with recurrent urinary tract infections, was found to have an intrauterine contraceptive device (IUCD) in her bladder on ultrasound.
  • Attempts to remove it endoscopically failed, and an, open procedure was required to free the IUCD from the bladder sidewall.
  • [MeSH-major] Foreign Bodies / etiology. Intrauterine Devices / adverse effects. Natural Family Planning Methods / adverse effects. Urinary Bladder
  • [MeSH-minor] Adult. Female. Humans. Thermometers. Urinary Tract Infections / etiology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15875635.001).
  • [ISSN] 1368-504X
  • [Journal-full-title] International journal of clinical practice. Supplement
  • [ISO-abbreviation] Int J Clin Pract Suppl
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  •  go-up   go-down


81. Solifenacin and darifenacin for overactive bladder. Med Lett Drugs Ther; 2005 Mar 14;47(1204):23-4
MedlinePlus Health Information. consumer health - Urinary Incontinence.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Solifenacin and darifenacin for overactive bladder.
  • Darifenacin (Enablex) and solifenacin (VESIcare) are 2 new oral anticholinergics available for once-daily symptomatic treatment of overactive bladder.
  • Overactive bladder is a common condition in older patients.
  • In some experimental studies, the new drugs particularly target bladder receptors, but the clinical significance of these findings is unknown.
  • [MeSH-major] Benzofurans / therapeutic use. Pyrrolidines / therapeutic use. Quinuclidines / therapeutic use. Tetrahydroisoquinolines / therapeutic use. Urinary Incontinence / drug therapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15767976.001).
  • [ISSN] 0025-732X
  • [Journal-full-title] The Medical letter on drugs and therapeutics
  • [ISO-abbreviation] Med Lett Drugs Ther
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Benzofurans; 0 / Pyrrolidines; 0 / Quinuclidines; 0 / Tetrahydroisoquinolines; APG9819VLM / darifenacin; KKA5DLD701 / Solifenacin Succinate
  •  go-up   go-down


82. Spahn M, Bader P, Westermann D, Echtle D, Frohneberg D: Bladder carcinoma during pregnancy. Urol Int; 2005;74(2):153-9
MedlinePlus Health Information. consumer health - Tumors and Pregnancy.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Bladder carcinoma during pregnancy.
  • INTRODUCTION: We report 3 cases of bladder cancer during pregnancy and give a review of the literature in an attempt to evaluate tumor at presentation, characteristics, maternal and fetal outcome.
  • MATERIALS AND METHODS: The case history of 3 pregnant women treated for bladder cancer in 2001 together with the results of a MEDLINE search from 1966 to 2003.
  • RESULTS: Out of 27 cases of nonbilharzial bladder carcinoma, 74% presented with transitional cell carcinoma.
  • Five patients had muscle-invasive tumors.
  • Only half of the tumors were identified by ultrasonography.
  • Although superficial bladder carcinoma was transurethrally resected alone, outcome and prognosis are good.
  • But the prognosis of locally advanced bladder carcinoma is poor.
  • CONCLUSION: Any doubtful genital bleeding during pregnancy without definite proof of vaginal/cervical origin should be investigated by both ultrasonography of the upper urinary tract and urethrocystoscopy.
  • Superficial bladder tumors can be most effectively treated by transurethral resection followed by cystoscopy, whereas the prognosis of muscle-invasive bladder carcinoma is poor and demands more radical treatment, depending on the stage of pregnancy.
  • [MeSH-major] Carcinoma, Transitional Cell. Pregnancy Complications, Neoplastic. Urinary Bladder Neoplasms

  • Genetic Alliance. consumer health - Pregnancy.
  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15756068.001).
  • [ISSN] 0042-1138
  • [Journal-full-title] Urologia internationalis
  • [ISO-abbreviation] Urol. Int.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Switzerland
  • [Number-of-references] 34
  •  go-up   go-down


83. Rioja Zuazu J, Toutziaris V, Laguna Pes MP, de Reijke TM, de la Rosette JJ: [Laser and bladder tumors]. Arch Esp Urol; 2008 Nov;61(9):994-1003
MedlinePlus Health Information. consumer health - Bladder Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Laser and bladder tumors].
  • Bladder cancer is one of the most frequents pathologies in urology.
  • We perform a review and try to assess the actual indications for its employment in the treatment of bladder cancer, as well as future applications.
  • [MeSH-major] Laser Therapy. Urinary Bladder Neoplasms / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19140580.001).
  • [ISSN] 0004-0614
  • [Journal-full-title] Archivos españoles de urología
  • [ISO-abbreviation] Arch. Esp. Urol.
  • [Language] spa
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Spain
  • [Number-of-references] 44
  •  go-up   go-down


84. Karam JA, Kabbani W, Sagalowsky AI: Pseudosarcomatous fibromyxoid tumor of the bladder. Urol Oncol; 2008 May-Jun;26(3):291-4
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pseudosarcomatous fibromyxoid tumor of the bladder.
  • Pseudosarcomatous fibromyxoid tumors are uncommon lesions with uncertain pathogenesis.
  • Work-up revealed a bladder mass that was initially treated with transurethral resection that showed pseudosarcomatous fibromyxoid tumors.
  • Partial cystectomy is a viable option in the treatment of recurrent symptomatic pseudosarcomatous fibromyxoid tumors of the bladder, when performed selectively.
  • [MeSH-major] Fibroma / pathology. Sarcoma / pathology. Urinary Bladder Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18452822.001).
  • [ISSN] 1078-1439
  • [Journal-full-title] Urologic oncology
  • [ISO-abbreviation] Urol. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


85. Lopes EJ, dos Santos TC, Martins V: [Schistosomiasis mansoni simulating bladder neoplasia]. Rev Soc Bras Med Trop; 2006 May-Jun;39(3):287-8
Hazardous Substances Data Bank. OXAMNIQUINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Schistosomiasis mansoni simulating bladder neoplasia].
  • [Transliterated title] Esquistossomose mansônica simulando neoplasia da bexiga.
  • Cytoscopy showed a protuberant tumor in the bladder anterior wall, suggestive of cancer.
  • Transurethral resection confirmed the diagnosis.
  • The case presented in this work emphasizes that not all the tumors of bladder with microscopic hematuria are bladder cancers.
  • [MeSH-major] Oxamniquine / therapeutic use. Schistosoma mansoni / isolation & purification. Schistosomiasis mansoni / diagnosis. Schistosomicides / therapeutic use. Urinary Bladder Diseases / parasitology
  • [MeSH-minor] Adult. Animals. Biopsy. Diagnosis, Differential. Humans. Male. Treatment Outcome. Urinary Bladder Neoplasms / diagnosis

  • Genetic Alliance. consumer health - Schistosomiasis.
  • MedlinePlus Health Information. consumer health - Bladder Diseases.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16906256.001).
  • [ISSN] 0037-8682
  • [Journal-full-title] Revista da Sociedade Brasileira de Medicina Tropical
  • [ISO-abbreviation] Rev. Soc. Bras. Med. Trop.
  • [Language] por
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Brazil
  • [Chemical-registry-number] 0 / Schistosomicides; 0O977R722D / Oxamniquine
  •  go-up   go-down


86. Gargollo PC, Borer JG: Contemporary outcomes in bladder exstrophy. Curr Opin Urol; 2007 Jul;17(4):272-80
MedlinePlus Health Information. consumer health - Urinary Incontinence.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Contemporary outcomes in bladder exstrophy.
  • PURPOSE OF REVIEW: The patient with bladder exstrophy presents complex surgical and clinical management challenges to the pediatric urologist.
  • RECENT FINDINGS: Most of the early literature pertaining to bladder exstrophy has focused on surgical techniques and management.
  • Psychosexual development, sexual function and social adaptation have received as much attention as urinary continence status, bladder, and renal function.
  • SUMMARY: Despite the complex nature of bladder exstrophy, there are no well designed, prospective trials examining clinical outcomes in these patients.
  • Until better trials are planned, executed and published, much of what we know about patients with bladder exstrophy will be based on retrospective observations with significant biases.
  • [MeSH-major] Bladder Exstrophy / psychology. Bladder Exstrophy / surgery. Urinary Incontinence / psychology. Urinary Incontinence / surgery. Urologic Surgical Procedures / methods

  • Genetic Alliance. consumer health - Exstrophy of the Bladder.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17558272.001).
  • [ISSN] 0963-0643
  • [Journal-full-title] Current opinion in urology
  • [ISO-abbreviation] Curr Opin Urol
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 63
  •  go-up   go-down


87. Sithasanan N, Kihne M, Naidu RR, Ramanujam TM: Twisted fate of bladder catheters. Med J Malaysia; 2006 Aug;61(3):369-70

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Twisted fate of bladder catheters.
  • Catheter knotting is a rare complication of bladder catheterisation.
  • We report a case of a vesical calculus formed over a broken and retained supra-pubic catheter which to the best of our knowledge has yet to be reported, along with three other cases of bladder catheter knotting.
  • [MeSH-major] Urinary Catheterization / instrumentation
  • [MeSH-minor] Adolescent. Child. Equipment Failure. Humans. Infant, Newborn. Male. Urinary Calculi / etiology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17240594.001).
  • [ISSN] 0300-5283
  • [Journal-full-title] The Medical journal of Malaysia
  • [ISO-abbreviation] Med. J. Malaysia
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Malaysia
  •  go-up   go-down


88. Fumadó Ciutat L, Rodríguez Tolrà J, Pastor López S, Riera Canals L, Franco Miranda E: [Massive bladder hernia]. Arch Esp Urol; 2005 Dec;58(10):1078-80
MedlinePlus Health Information. consumer health - Bladder Diseases.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Massive bladder hernia].
  • [Transliterated title] Hernia vesical masiva.
  • OBJECTIVES: We report a case of a huge bladder hernia conditioning the migration of almost all the bladder into the scrotum.
  • METHODS AND RESULTS: 65-year-old male being studied for BPH who presents a scrotal tumor, which turned out to be a huge inguinal bladder hernia in scrotum, paraperitoneal, accompanied by an inguinal hernia.
  • The treatment consisted in bladder resection and repair of the inguinal hernia with a marlex mesh.
  • CONCLUSIONS: Bladder hernia is an uncommon pathology, and in most of the cases it is an incidental finding during the repair of an inguinal hernia.
  • The diagnosis is clinical, but comfirmation can be done by retrograde cystoghraphy, ultrasonography or CT The treatment is surgical, repairing the herniation or adding the resection of the bladder herniation.
  • [MeSH-major] Hernia, Inguinal / etiology. Urinary Bladder Diseases / complications

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16482863.001).
  • [ISSN] 0004-0614
  • [Journal-full-title] Archivos españoles de urología
  • [ISO-abbreviation] Arch. Esp. Urol.
  • [Language] spa
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Spain
  •  go-up   go-down


89. Han J, Lin T, Xu K, Jiang C, Huang H, Yin X, Xie W, Yao Y, Zhang C, Huang J: Improved detection of nonmuscle invasive urothelial carcinoma of the bladder using pirarubicin endoscopy: a prospective, single-center preliminary study. J Endourol; 2010 Nov;24(11):1801-6
Hazardous Substances Data Bank. DOXORUBICIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Improved detection of nonmuscle invasive urothelial carcinoma of the bladder using pirarubicin endoscopy: a prospective, single-center preliminary study.
  • The aim of the present study was to determine whether the use of the fluorescent dye pirarubicin [(2"R)-4'-O-tetrahydropyranyl doxorubicin] (THP) in endoscopy can improve detection of nonmuscle invasive urothelial carcinoma of the bladder.
  • PATIENTS AND METHODS: Forty-eight patients with known or suspected bladder urothelial carcinoma were enrolled in this prospective study between January 2008 and April 2009.
  • Among 238 biopsies evaluated (84 malignant, 20 dysplasia, and 134 benign), sensitivity of overall tumors, carcinoma in situ (CIS), and dysplasia detection using FC was 96% (81/84), 100% (6/6), and 90% (18/20), respectively.
  • CONCLUSION: THP endoscopy may improve the detection of nonmuscle invasive urothelial carcinoma of the bladder, especially CIS and flat lesions.
  • Results indicate that THP is a promising fluorescent dye for diagnosis and follow-up of nonmuscle invasive bladder carcinoma.

  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20932082.001).
  • [ISSN] 1557-900X
  • [Journal-full-title] Journal of endourology
  • [ISO-abbreviation] J. Endourol.
  • [Language] ENG
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 80168379AG / Doxorubicin; D58G680W0G / pirarubicin
  •  go-up   go-down


90. Katz DJ, Sengupta S, Snow RM: Isolated vasculitis of the bladder. Urology; 2005 Apr;65(4):797
MedlinePlus Health Information. consumer health - Vasculitis.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Isolated vasculitis of the bladder.
  • We describe a case of isolated vasculitis involving the bladder that presented with severe irritative voiding and hematuria.
  • It is important to differentiate this rare pathologic entity from the much more frequent tumors of the bladder because the treatment is medical rather than surgical.
  • [MeSH-major] Urinary Bladder / blood supply. Urinary Bladder Diseases / diagnosis. Vasculitis / diagnosis

  • Genetic Alliance. consumer health - Vasculitis.
  • MedlinePlus Health Information. consumer health - Bladder Diseases.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15833535.001).
  • [ISSN] 1527-9995
  • [Journal-full-title] Urology
  • [ISO-abbreviation] Urology
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


91. Foon R, Drake MJ: The overactive bladder. Ther Adv Urol; 2010 Aug;2(4):147-55

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The overactive bladder.
  • Urinary urgency and the associated symptoms which comprise overactive bladder are prevalent amongst the general population and adversely affect quality of life.
  • Disease management consists of a sequential series of options starting with behavioural and lifestyle techniques, pharmacological management (antimuscarinics) and, in severe cases, surgical treatment (urinary diversion, neuromodulation, augmentation cystoplasty and detrusor myectomy).
  • The hierarchy of the central nervous system control adds additional complexity to understanding the oflower urinary tract function.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Urol Int. 2004;72(2):145-9 [14963356.001]
  • [Cites] J Physiol. 2004 Sep 1;559(Pt 2):567-81 [15235094.001]
  • [Cites] J Urol. 2004 Aug;172(2):748-52 [15247775.001]
  • [Cites] Neurochem Int. 2004 Dec;45(7):987-93 [15337297.001]
  • [Cites] J Urol. 2005 Sep;174(3):977-82; discussion 982-3 [16094018.001]
  • [Cites] J Physiol. 2006 Jan 1;570(Pt 1):13-22 [16210349.001]
  • [Cites] BJU Int. 2006 Jan;97(1):29-32 [16336323.001]
  • [Cites] Br J Pharmacol. 2006 Feb;147 Suppl 2:S25-40 [16465182.001]
  • [Cites] BMC Urol. 2006;6:6 [16519806.001]
  • [Cites] Eur Urol. 2006 Nov;50(5):1050-7 [16753252.001]
  • [Cites] J Urol. 2006 Jul;176(1):177-85 [16753396.001]
  • [Cites] Eur Urol. 2006 Dec;50(6):1306-14; discussion 1314-5 [17049716.001]
  • [Cites] Eur Urol. 2007 May;51(5):1350-5; discussion 1355-6 [17070984.001]
  • [Cites] N Engl J Med. 2000 Mar 2;342(9):665 [10702067.001]
  • [Cites] Lab Invest. 2000 Oct;80(10):1491-9 [11045565.001]
  • [Cites] Am J Manag Care. 2000 Jul;6(11 Suppl):S599-606 [11183903.001]
  • [Cites] Lancet. 2001 Aug 4;358(9279):401-3 [11502339.001]
  • [Cites] Neurourol Urodyn. 2002;21(2):167-78 [11857671.001]
  • [Cites] BJU Int. 2000 May;85 Suppl 3:1-6; discussion 8-9 [11954191.001]
  • [Cites] Urology. 2004 Mar;63(3 Suppl 1):24-31 [15013649.001]
  • [Cites] Urol Clin North Am. 2005 Feb;32(1):113-5, viii [15698884.001]
  • [Cites] BJU Int. 2005 Aug;96(3):341-4 [16042727.001]
  • [Cites] J Urol. 2006 Jan;175(1):191-4; discussion 194-5 [16406907.001]
  • [Cites] BJU Int. 2006 Mar;97(3):547-50 [16469023.001]
  • [Cites] J Urol. 2006 Mar;175(3 Pt 1):999-1004; discussion 1004 [16469601.001]
  • [Cites] BJU Int. 2006 Sep;98(3):643-50 [16925766.001]
  • [Cites] Br J Urol. 1991 Nov;68(5):483-6 [1747722.001]
  • [Cites] BJU Int. 2007 Jun;99 Suppl 3:1-7 [17488366.001]
  • [Cites] Urology. 2008 May;71(5):839-43 [18342923.001]
  • [Cites] Br J Urol. 1978 Jun;50(4):243-5 [753469.001]
  • [Cites] Br J Urol. 1995 May;75(5):592-6 [7613795.001]
  • [Cites] Br J Urol. 1994 Jan;73(1):3-8 [8298896.001]
  • [Cites] Br J Urol. 1996 Mar;77(3):333-8 [8814833.001]
  • [Cites] J Urol. 1996 Nov;156(5):1744-7 [8863585.001]
  • [Cites] Scand J Urol Nephrol Suppl. 1996;179:47-53 [8908664.001]
  • [Cites] J Urol. 1997 Dec;158(6):2087-92 [9366318.001]
  • [Cites] Br J Urol. 1998 Jan;81(1):68-72 [9467479.001]
  • [Cites] J Urol. 2000 Feb;163(2):646-51 [10647702.001]
  • [Cites] Br J Pharmacol. 2002 Dec;137(7):1001-10 [12429572.001]
  • [Cites] World J Urol. 2003 May;20(6):327-36 [12811491.001]
  • [Cites] J Urol. 2003 Dec;170(6 Pt 1):2503-7 [14634460.001]
  • [Cites] Eur J Pharmacol. 2004 Jan 12;483(2-3):133-8 [14729100.001]
  • [Cites] Pharmacoeconomics. 2007;25(2):129-42 [17249855.001]
  • [Cites] J Pharmacol Exp Ther. 2007 May;321(2):642-7 [17293563.001]
  • [Cites] BJU Int. 2007 Aug;100(2):419-29 [17617145.001]
  • [Cites] J Pharmacol Exp Ther. 2007 Oct;323(1):202-9 [17626794.001]
  • [Cites] Cochrane Database Syst Rev. 2007;(3):CD005493 [17636801.001]
  • [Cites] Int J Urol. 2007 Jul;14(7):595-7 [17645600.001]
  • [Cites] Neurourol Urodyn. 2008;27(1):13-21 [17671973.001]
  • [Cites] Neurourol Urodyn. 2007 Oct;26(6 Suppl):914-9 [17763395.001]
  • [Cites] Neurourol Urodyn. 2007 Oct;26(6 Suppl):928-33 [17806124.001]
  • [Cites] J Urol. 2007 Nov;178(5):2029-34 [17869298.001]
  • [Cites] J Clin Invest. 2007 Nov;117(11):3453-62 [17948126.001]
  • [Cites] Eur Urol. 2008 Feb;53(2):391-9 [18031925.001]
  • [Cites] Naunyn Schmiedebergs Arch Pharmacol. 2008 Jun;377(4-6):449-62 [18060543.001]
  • [Cites] BJU Int. 2008 Mar;101(5):615-20 [18070178.001]
  • [Cites] Curr Med Res Opin. 2008 Feb;24(2):343-7 [18073008.001]
  • [Cites] Ann R Coll Surg Engl. 2007 Sep;89(6):580-5 [18201471.001]
  • [Cites] Am J Physiol Renal Physiol. 2008 Apr;294(4):F821-9 [18216148.001]
  • [Cites] Eur Urol. 2008 May;53(5):1029-37 [18243515.001]
  • [Cites] Naunyn Schmiedebergs Arch Pharmacol. 2008 Jun;377(4-6):473-81 [18311486.001]
  • [Cites] Eur Urol. 2008 Jun;53(6):1245-53 [18343564.001]
  • [Cites] Pflugers Arch. 2008 Oct;457(1):61-6 [18421472.001]
  • [Cites] BJU Int. 2008 Jun;101(11):1388-95 [18454794.001]
  • [Cites] Nat Clin Pract Urol. 2008 Jun;5(6):319-28 [18461049.001]
  • [Cites] Int J Urol. 2008 Aug;15(8):681-7 [18462357.001]
  • [Cites] Urology. 2008 Nov;72(5):1174-8 [18468662.001]
  • [Cites] J Urol. 2008 Jul;180(1):217-22 [18499184.001]
  • [Cites] Eur Urol. 2009 Jan;55(1):100-19 [18823697.001]
  • [Cites] Curr Urol Rep. 2008 Nov;9(6):445-51 [18947508.001]
  • [Cites] Clin Ther. 2008 Oct;30(10):1766-81 [19014833.001]
  • [Cites] Eur Urol. 2009 Jun;55(6):1440-8 [19054608.001]
  • [Cites] J Urol. 2009 Apr;181(4):1764-72 [19233423.001]
  • [Cites] BJU Int. 2009 Aug;104(3):352-60 [19281467.001]
  • [Cites] Neurourol Urodyn. 2010;29(1):49-55 [19412958.001]
  • [Cites] Neurourol Urodyn. 2010;29(1):82-7 [20025023.001]
  • [Cites] Neurourol Urodyn. 2010;29(1):119-27 [20025025.001]
  • [Cites] Br J Urol. 1995 Nov;76(5):551-7 [8535671.001]
  • [Cites] Cytokine. 1997 Sep;9(9):696-701 [9325019.001]
  • [Cites] Urology. 1997 Dec;50(6A Suppl):36-52; discussion 53-6 [9426749.001]
  • [Cites] Urology. 1997 Dec;50(6A Suppl):57-67; discussion 68-73 [9426752.001]
  • [Cites] World J Urol. 1998;16(4):268-73 [9775426.001]
  • [Cites] Drugs Aging. 2003;20(11):857-64 [12964892.001]
  • (PMID = 21789091.001).
  • [ISSN] 1756-2880
  • [Journal-full-title] Therapeutic advances in urology
  • [ISO-abbreviation] Ther Adv Urol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC3126078
  • [Keywords] NOTNLM ; detrusor overactivity / overactive bladder / urge incontinence / urgency
  •  go-up   go-down


92. Thwaini A, McLeod A, Nambirajan T: Laparoscopic bladder diverticulectomy. J Laparoendosc Adv Surg Tech A; 2008 Dec;18(6):849-51
MedlinePlus Health Information. consumer health - Bladder Diseases.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Laparoscopic bladder diverticulectomy.
  • Acquired bladder diverticulae are herniations of the bladder mucosa through detrusor muscle.
  • Due to the ineffective emptying of the bladder diverticulum, urine accumulation may lead to urinary tract infection, stone disease, and lower urinary tract malignancy in the diverticulum.
  • We report a case of laparoscopic bladder diverticulectomy for transitional cell carcinoma in an acquired bladder diverticulum.
  • To our knowledge, this is the third case of laparoscopic diverticulectomy for a tumor.
  • [MeSH-major] Carcinoma, Transitional Cell / surgery. Diverticulum / surgery. Laparoscopy / methods. Urinary Bladder Diseases / surgery. Urinary Bladder Neoplasms / surgery

  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19105670.001).
  • [ISSN] 1092-6429
  • [Journal-full-title] Journal of laparoendoscopic & advanced surgical techniques. Part A
  • [ISO-abbreviation] J Laparoendosc Adv Surg Tech A
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


93. Nordling J: Sensory bladder disorders. Int J Clin Pract Suppl; 2006 Dec;(151):38-42
MedlinePlus Health Information. consumer health - Interstitial Cystitis.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Sensory bladder disorders.
  • Sensory bladder disorders include disorders involving abnormal sensations resulting from many diseases of the urinary bladder.
  • In a proportion of patients no cause can be found and if pain or pelvic pressure is a part of the symptomatology, they are labelled as having painful bladder syndrome (PBS).
  • In a subgroup of these patients abnormal findings can be demonstrated at cystoscopy and/or by histological examination of bladder biopsies.
  • This paper looks into the differential diagnosis, evaluation and treatment of patients with PBS.
  • [MeSH-major] Cystitis, Interstitial / diagnosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17169010.001).
  • [ISSN] 1368-504X
  • [Journal-full-title] International journal of clinical practice. Supplement
  • [ISO-abbreviation] Int J Clin Pract Suppl
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Number-of-references] 43
  •  go-up   go-down


94. Yiee J, Wilcox D: Abnormalities of the fetal bladder. Semin Fetal Neonatal Med; 2008 Jun;13(3):164-70

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Abnormalities of the fetal bladder.
  • This review aims to outline the management of a fetus in whom a distended bladder or an absent bladder has been identified during prenatal fetal screening.
  • [MeSH-major] Fetus / abnormalities. Ureterocele / therapy. Urethra / abnormalities. Urinary Bladder / abnormalities
  • [MeSH-minor] Bladder Exstrophy. Cloaca / abnormalities. Female. Humans. Pregnancy. Prune Belly Syndrome / diagnosis. Syndrome. Ultrasonography, Prenatal

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18053783.001).
  • [ISSN] 1744-165X
  • [Journal-full-title] Seminars in fetal & neonatal medicine
  • [ISO-abbreviation] Semin Fetal Neonatal Med
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Netherlands
  • [Number-of-references] 46
  •  go-up   go-down


95. Oliveira PA, Colaco A, De la Cruz P LF, Lopes C: Experimental bladder carcinogenesis-rodent models. Exp Oncol; 2006 Mar;28(1):2-11
MedlinePlus Health Information. consumer health - Bladder Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Experimental bladder carcinogenesis-rodent models.
  • Several rodent models of bladder cancer development have been established.
  • The aim of this review article is to provide a critical assessment of different animal models available for the study of bladder carcinogenesis, its chemoprevention and therapy.
  • Spontaneous bladder tumor models are extremely rare.
  • We describe chemical carcinogens most commonly used to induce bladder cancer, pellet implantation and urinary calculi, agents that promote bladder cancer, and irradiation.
  • We also evaluated other tools such as cell cultures, tumor implantation and transgenic models for bladder cancer, that have been developed to study the process.
  • The review considers how several imaging techniques can be applied to study rodent bladder carcinogenesis.
  • [MeSH-major] Neoplasms, Experimental. Urinary Bladder Neoplasms / pathology
  • [MeSH-minor] Animals. Animals, Genetically Modified. Carcinogens. Disease Models, Animal. Genetic Engineering. Humans. Neoplasm Transplantation / methods. Rodentia

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16614700.001).
  • [ISSN] 1812-9269
  • [Journal-full-title] Experimental oncology
  • [ISO-abbreviation] Exp. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] Ukraine
  • [Chemical-registry-number] 0 / Carcinogens
  • [Number-of-references] 99
  •  go-up   go-down


96. Tran H, Nguyen N, Nguyen T: Neonatal bladder rupture. Indian J Pediatr; 2009 Apr;76(4):427-9
MedlinePlus Health Information. consumer health - Bladder Diseases.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Neonatal bladder rupture.
  • Neonatal bladder rupture is rare as a complication of bladder obstruction due to abnormal anatomy or iatrogenic cause such as umbilical catheterization.
  • The present study describes the case of a 27-day old infant with ascites due to bladder perforation secondary to bladder wall necrosis as a result of severe urinary tract infection.
  • [MeSH-major] Urinary Bladder Diseases / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19205633.001).
  • [ISSN] 0973-7693
  • [Journal-full-title] Indian journal of pediatrics
  • [ISO-abbreviation] Indian J Pediatr
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] India
  •  go-up   go-down


97. Wilkinson K: Supplementary prescribing for overactive bladder. Nurs Stand; 2005 Jan 19-25;19(19):38-42
MedlinePlus Health Information. consumer health - Urinary Incontinence.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Supplementary prescribing for overactive bladder.
  • Overactive bladder is a common condition that can be treated effectively in primary care by nurses.
  • Supplementary nurse prescribing enables nurses with the appropriate qualification to provide holistic programmes of care for individuals with an overactive bladder.
  • [MeSH-major] Community Health Nursing / organization & administration. Drug Prescriptions. Nurse Clinicians / organization & administration. Primary Health Care / organization & administration. Professional Autonomy. Urinary Incontinence / drug therapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15700865.001).
  • [ISSN] 0029-6570
  • [Journal-full-title] Nursing standard (Royal College of Nursing (Great Britain) : 1987)
  • [ISO-abbreviation] Nurs Stand
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Number-of-references] 27
  •  go-up   go-down


98. Rigby D: Underactive bladder syndrome. Nurs Stand; 2005 May 11-17;19(35):57-64; quiz 66-7
MedlinePlus Health Information. consumer health - Bladder Diseases.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Underactive bladder syndrome.
  • Underactive bladder syndrome causes difficulty in voiding, resulting in incomplete bladder emptying.
  • [MeSH-major] Urinary Bladder Diseases / diagnosis. Urinary Bladder Diseases / therapy
  • [MeSH-minor] Clinical Protocols. Diagnosis, Differential. Female. Humans. Male. Quality of Life. Urinary Bladder / physiopathology. Urinary Catheterization / instrumentation. Urinary Catheterization / methods. Urinary Catheterization / nursing. Urine

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15915959.001).
  • [ISSN] 0029-6570
  • [Journal-full-title] Nursing standard (Royal College of Nursing (Great Britain) : 1987)
  • [ISO-abbreviation] Nurs Stand
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Number-of-references] 38
  •  go-up   go-down


99. Spiess PE, Tuziak T, Tibbs RF, Bassett R, Tamboli P, Brown GA, Grossman HB, Ayala AG, Czerniak B: Pseudosarcomatous and sarcomatous proliferations of the bladder. Hum Pathol; 2007 May;38(5):753-61
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pseudosarcomatous and sarcomatous proliferations of the bladder.
  • Pseudosarcomatous fibromyxoid tumor (PFT), postoperative spindle cell nodule (PSN), sarcoma, and sarcomatoid carcinoma of the bladder are frequently difficult to distinguish histopathologically with significant differences in disease-related outcomes.
  • A retrospective review of our pathology registry over the last 25 years identified 7 PFT, 10 PSN, 18 primary bladder sarcomas, and 17 sarcomatoid carcinomas.
  • A previous history of urological instrumentation and bladder cancer was present in all patients with PSN but none of the patients with PFT.
  • Pseudosarcomatous fibromyxoid tumors were characterized by a tissue culture-like proliferation of myofibroblastic cells with focal atypia and overall cytoarchitectural features mimicking nodular fasciitis.
  • Pseudosarcomatous fibromyxoid tumor and PSN have unique clinical and pathologic features that allow their distinction from primary bladder sarcoma and sarcomatoid carcinoma.
  • [MeSH-major] Sarcoma / pathology. Urinary Bladder Neoplasms / pathology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Carcinoma / pathology. Female. Fibroma / pathology. Humans. Male. Middle Aged. Neoplasm Metastasis. Retrospective Studies

  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17306332.001).
  • [ISSN] 0046-8177
  • [Journal-full-title] Human pathology
  • [ISO-abbreviation] Hum. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


100. Castillo O, Hoyos J, Vitagliano G, Arellano L: [Inverted papilloma of the bladder]. Arch Esp Urol; 2006 Sep;59(7):691-5
MedlinePlus Health Information. consumer health - Bladder Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Inverted papilloma of the bladder].
  • [Transliterated title] Papiloma invertido vesical.
  • OBJECTIVES: To report a series of patients with bladder inverted papilloma, pointing out the clinical features, presentations, treatment options and outcomes.
  • METHODS: We reviewed the medical charts of all patients with the diagnosis of bladder inverted papilloma treated by our group between July 1996 and June 2003.
  • RESULTS: 16 cases of inverted papilloma of the bladder were diagnosed in ten males and six females, with a mean age of 53.1 yr. (range 31-72).
  • In 14/16 patients the lesion was localized in the bladder trigone.
  • [MeSH-major] Papilloma, Inverted. Urinary Bladder Neoplasms

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17078392.001).
  • [ISSN] 0004-0614
  • [Journal-full-title] Archivos españoles de urología
  • [ISO-abbreviation] Arch. Esp. Urol.
  • [Language] spa
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Spain
  • [Number-of-references] 12
  •  go-up   go-down






Advertisement